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The continued risk of death due to heart failure has spurred the advancement of biomaterials-
based treatments for cardiac repair, two of which are the application of a cardiac patch or 
intramyocardial material injection. The inclusion of signaling molecules in these materials can 
improve the treatment results; however, appropriate molecule delivery is not trivial. This 
research presents the broad application of therapeutics from both a patch and injectable system to 
demonstrate how system properties influence drug delivery and how these systems may be 
engineered to provide added benefit in the desired application.  
We demonstrated the ability to release a gene-inducing molecule, Rheoswitch ligand 1 
(RSL1), from a biodegradable elastomer that has been used as a cardiac patch. Not only was 
bioactive RSL1 released over an extended period, the ability to differentially load scaffolds with 
RSL1 allowed for spatial patterning of gene expression in cells cultured on the scaffold surface, 
which has implications for creating complex 3D tissues in vitro. This same elastomeric material 
was able to release bioactive insulin-like growth factor 1 (IGF1) and hepatocyte growth factor 
(HGF) in vitro. The complex release behavior of IGF1 into saline was replaced by a much 
simpler release profile during simulated in vivo degradation, demonstrating that the implant 
environment must be considered when studying drug delivery behavior.  
A strong, thermoresponsive and degradable hydrogel was developed for intramyocardial 
injection. We showed the release rates of a model protein from this gel, or from protein-loaded 
microparticles inside the gel, could be controlled by changing the material composition. The 
combination of hydrogel with microparticles delivered two proteins in a sequential manner. We 
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further used this system to release bioactive basic fibroblast growth factor (bFGF) followed by 
IGF1 in vitro. Injection of the unloaded polymer into infarcted rat hearts was able to improve the 
remodeling process for at least 16 weeks. While increased tissue bFGF and IGF1 were 
demonstrated following injection of growth factor-loaded gels, there were no clear benefits seen 
from protein inclusion. This points to the primary ability of the hydrogel alone to benefit cardiac 
function and cellular environment and warrants further investigation.   
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1.0 INTRODUCTION 
1.1 SIGNIFICANCE 
 
(Note: A majority of this chapter was previously published as: Nelson, D.M., Z. Ma, K.L. 
Fujimoto, R. Hashizume, and W.R. Wagner. Intra-myocardial biomaterial injection therapy in 
the treatment of heart failure: materials, outcomes and challenges. Acta Biomaterialia 
2011;7(1):1-15) 
It is estimated that a new coronary attack will be experienced by 785,000 Americans annually, 
while 470,000 will have a recurrent attack.[1] This number of myocardial infarctions (MIs) 
increases by 20% when one adds silent occlusive events, unrecognized by the individual and 
often asymptomatic until more extensive tissue damage is incurred.[1, 2] Coronary artery disease 
and MI provide the underlying etiology in 2 out of 3 cases of heart failure, the widespread, end 
stage condition that draws heavily on health care resources. Currently 5 million Americans have 
been diagnosed with heart failure and 670,000 more patients are identified each year, which 
leads to $33.7 billion in annual direct costs.[1, 3]  
The deterioration of patients with ischemic cardiomyopathy is driven by the progressive 
remodeling in left ventricular (LV) architecture occurring after MI. This is the result of stages of 
necrosis and fibrosis that lead to cell death, breakdown of extracellular matrix, and scar 
formation following ischemia. Initially, this remodeling is required for maintenance of cardiac 
output in the face of decreased pumping capacity but ultimately it leads to LV dysfunction and 
heart failure, even in the absence of a recurrent ischemic event.[4, 5] Even with current optimal 
therapy, mortality in end-stage heart failure amounts to 20–50% per year and it is arguable that 
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there has been little to no improvement in the prognosis for patients with heart failure over the 
past several decades.[6, 7] 
A diverse array of treatment methods and technologies has been developed in an attempt to 
alleviate the morbidity and mortality associated with cardiac failure.[8] Interventional procedures 
that seek to revascularize the myocardium through coronary artery bypass grafting and coronary 
stent placement have become both common and effective when performed early following an MI 
– though the benefits of such interventions are not as clear in late presenting patients.[9-11] 
Cardiac pacing in appropriate patients has been shown to increase the energy efficiency of the 
heart.[12] Pharmacological regimens are useful to improve systolic performance and decrease 
workload.[13, 14] The gold standard for those with end-stage heart failure remains cardiac 
transplantation, but donor hearts far outstrip the number of people who could benefit from 
transplantation.[15] To address this need, ventricular assist device implantation can take over the 
pumping function of the ventricle by independently circulating blood in late stage heart failure 
patients. [16, 17] Biomaterials development has played a critical role in the creation of medical 
devices for advanced heart failure treatment, from membrane oxygenator microporous hollow 
fibers, to stents and stent coatings, prosthetic heart valves, pacing leads, and many other devices. 
Important areas of cardiovascular biomaterials research and development for treating heart 
failure that have grown during the past decade include delivery of materials to the epicardium in 
the form of a cardiac patch and direct biomaterial injection into the myocardium.[18] Results in 
these areas demonstrate that the mechanical effects that may be achieved with appropriate 
biomaterial application may be beneficial independent of any cellular components.  
1.2 MECHANICAL APPROACHES TO HEART DISEASE 
Myocardial infarction sets off a series of complicated processes that alter the cellular, structural 
and mechanical properties of the heart.[4, 19, 20] Not only does the heart lose systolic capacity 
due to a decrease in the amount of functional myocardium after MI, simple geometric changes 
that take place in remodeling also play a role in heart failure progression. As pumping efficiency 
decreases, blood backs up in the LV leading to increased intraventricular pressures contributing 
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to LV dilation – Figure 1. While the initial dilation following infarction is believed to be a 
coping mechanism by which cardiac output can be maintained through the Frank-Starling 
mechanism, it has been shown that over time the cardiomyocytes lose the ability to respond with 
increased contractility when stretched, resulting in a dilated, underperforming ventricle.[21] 
Ventricular dilation in terms of LV sphericity, and particularly LV volume is strongly linked to 
poor outcomes following MI.[22, 23] This remodeling involves a host of biomechanical 
processes which alter the local mechanical environment and cellular milieu leading to changes in 
cardiac performance. 
 
.  
Figure 1. Ventricular dilation associated with progressive heart failure. After the initial 
insult, infarct expansion and ventricular wall thinning contribute to further ventricular 
remodeling, ultimately causing increased intraventricular pressure and decreased cardiac 
output (from [8]) 
 
Pathological LV dilation is propagated through a positive feedback loop with LV wall 
stress.[4, 24] This stress is the preload against which the cardiomyocytes must contract during 
systole. As this stress increases their strain to high levels, the cardiomyocytes lose the capacity to 
shorten effectively, leading to further stretching and continued decreases in cardiac pumping 
efficiency, quantified as the ejection fraction (EF). The physics behind this unfortunate positive 
feedback system can be explained in part by the Law of Laplace, where the stress in the wall of a 
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round chamber (T) is directly related to the pressure in the chamber (P), the radius of curvature 
(R), and the thickness of the wall (h), as shown in Equation 1. During the ventricular 
remodeling process following an MI, changes in the local and global mechanical environments 
causes pressure and radius to increase and the LV free wall to thin. This increases the cardiac 
wall stress, which ultimately leads to more dilation, thinning, and stress. The heart can proceed 
down a pathway towards end-stage heart failure where transplantation, hospice care, or 
ventricular assist device implantation are the only options.  
h
PRT =      (1) 
Many treatments exist that use mechanical approaches to discourage cardiac dilation, 
restore geometry, and reduce ventricular wall stress and thinning.[25] Cardiac restraint devices 
such as the CorCap (Acorn Cardiovascular Inc) and HeartNet (Paracor Medical Inc) employ 
Dacron and nitinol wraps, respectively, to provide physical support for the failing ventricular 
wall – Figure 2.[26-29] Experimental devices such as the Myosplint (Myocor Inc) and 
CardioClasp (CardioClasp Inc) force a dilated ventricle into two smaller lobes to reduce the 
intraventricular radius and thereby decrease wall stress.[30, 31] Advanced surgical procedures 
such as endoventricular patch plasty (the Dor procedure) and partial left ventriculectomy (the 
Batista procedure) physically restructure a spherical, dilated ventricle into a more natural 
elongated shape.[32, 33] These methods have demonstrated limited clinical efficacy in both 
acute and chronic heart failure patients. One reason for the lack of complete success of these 
devices may include their inability to address the underlying damage to the native tissue. Even 
when a restraint device is able to prevent dilation, the myocardium can continue to thin and 
cardiomyocyte death and tissue fibrosis will not be completely halted.  
As the limitations to cardiac restraint devices have been recognized in recent years, other 
approaches wherein biomaterials interact more actively with the native myocardium and 
encourage tissue repair have been investigated. The two treatments that have been shown to be of 
most value for this approach are the implantation of a cardiac patch on the epicardium or 
injection of a material directly into the myocardial wall. Both of these approaches are under 
active investigation with many types of materials being applied in an effort to elucidate the 
material parameters that will provide the most benefit when employed. Understanding what has 
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been done in both the patch and material injection literature is critical to moving forward in this 
relatively nascent field of research.  
 
 
Figure 2. Cardiac restraint devices are used as a means to limit ventricular dilation 
following MI. The CorCap device (A) uses a Dacron woven mesh to maintain ventricular 
dimensions whereas the HeartNet (B) surrounds the ventricle in an elastic nitinol metal 
wrap. (A from [29] and B from [27]). 
1.3 CARDIAC PATCH IMPLANTATION 
1.3.1 Biological Materials 
An important subset of commonly utilized biomaterials is derivatives of natural materials 
produced by biological systems. Examples of biological materials that are commonly employed 
for implants include collagen, fibrin and extracellular matrix (ECM) derivatives. These materials 
have been applied in a variety of physiological environments because they often have acceptable 
levels of biocompatibility without significant processing, and are readily accessible to clinicians 
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and researchers. Thus, it is not surprising that early studies evaluating biomaterials as a cardiac 
patch have employed these materials.  
While various biological materials have been used as a cardiac patch following 
myocardial infarction, few of these materials are used individually for the purpose of providing 
mechanical support and aiding in regeneration. The primary material that has been explored as a 
patch is collagen, though usually in conjunction with cellular delivery which will be discussed 
later. Porous collagen scaffolds without cells were implanted immediately after cryoinjury in rats 
– Figure 3.[34] The scaffolds were all but degraded 60 days after implantation and demonstrated 
significant angiogenesis and arteriogenesis in the scaffold region. While patches were heavily 
infiltrated with macrophages, no cardiomyoblasts or cardiomyocytes, and few cells staining 
positive for cardiac stem cell markers, were observed. The functional role that the observed 
angiogenesis had on cardiac function remains to be explored in this model. In a similar study 
however, there was no detectable benefit to collagen patch implantation immediately after left 
anterior descending artery (LAD) ligation in rats.[35] While angiogenesis was mildly spurred by 
patch implantation there was no benefit in terms of contractile behavior or remodeling. Besides a 
mild improvement in intraventricular pressures, a similar lack of benefit was seen when gelatin, a 
derivative of collagen, was used as a patch material.[36] These results suggest collagen to be an 
inadequate material for this application.  
 
 
Figure 3. Optical (a) and SEM (b,c) images of an acellular cardiac patch (cp) made from 
collagen. The high porousity and fiber structure of the collagen are apparent. (From [34]). 
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A similar lack of effect was seen when fibrin patches were applied to the heart in a 
porcine ischemia reperfusion injury. There was no significant benefit to functional performance 
or histological assessment compared to control infarcted animals.[37] When a fibrin material 
bound to poly(ethylene glycol) (PEG) was used it showed a mild ability to prevent infarct 
expansion though this did not translate to functional improvements.[38] The reason for the lack 
of effect may be related to many factors including mechanical environment or lack of biological 
activity. 
A sheet of decellularized ECM of porcine small intestinal submucosa (SIS) was used by 
Tan et al as a patch on 4 week old infarcts in rabbits.[39] The material was shown to have good 
integration into the host myocardium, be infiltrated with macrophages and fibroblasts, and show 
new collagen deposition after 4 weeks. This may have contributed to the increased angiogenesis 
and wall thickness shown after patch implantation compared to control animals. Importantly, the 
function of hearts receiving the SIS patch was also significantly better than controls. This was 
demonstrated by an improved EF, decreased dilation, and lower LV end diastolic pressure 
(LVEDP).  
Krupnick et al investigated the application of a scaffold combining both biological and 
synthetic components to make a patch for full-thickness myocardial replacement following 
ventriculectomy.[40] The patch consisted of a solution of type I rat tail collagen, Dulbecco’s 
Modified Eagle’s Medium (DMEM), horse serum, and Matrigel which is poured into a 
poly(lactic acid) (PLA) porous, non-woven mesh and allowed to gel. This scaffold is then 
attached to a poly(tetrafluoroethylene) (PTFE) sheet which facilitates the patch attachment to the 
myocardium. It was demonstrated that this construct could be successfully implanted with good 
proximity between native myocardium and the patch. The presence of the patch was able to 
increase ventricular volumes as desired. The behavior of this scaffold as a long-term substitute 
for the myocardium following ventriculectomy is yet to be explored though the increased 
biological activity from collagen and Matrigel, as well as the degradation of the scaffold 
components, may make this a more appealing option than PTFE alone – the current material of 
choice for this procedure. 
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1.3.2 Synthetic Materials 
Materials that can be designed and synthesized in the laboratory from primary building blocks 
offer some advantages over those adapted from biological systems. In particular, every stage of 
material synthesis is under control of the engineer, allowing for material generation to meet 
specific design objectives, such as degradation, mechanical, and biocompatibility properties. A 
trade-off for this control is that synthetic materials are generally more likely to trigger 
inflammatory and foreign body responses that can be avoided for some minimally processed 
natural materials. Introducing biomolecules into the design process and utilizing labile synthetic 
materials that degrade into non-toxic components can potentially minimize the undesired effects 
associated with permanent foreign body implantation.  
Many synthetic materials have been approved for use in various surgical applications and 
devices. For example, materials such as PTFE and PET have been employed in vascular grafts 
for many years with significant success. Degradable materials such as PLA have revolutionized 
suture technology. While usually employed with a cellular component, these kinds of established 
synthetic materials represent the majority of materials that have been used for cardiac patches.  
The use of a slow degrading, highly porous polyurethane patch has been explored both in 
short-term and long-term implants.[41, 42] Rats were implanted two weeks after infarction by 
permanent ligation of the LAD. Following patch application it was found that results for patched 
animals were nearly identical to sham animals who received no treatment, when looking at EF, 
dilation, and LV pressure generation. Whereas sham animals had significantly worse function 6 
months after sham treatment, patch animals had regressed to the same deteriorated state by 9 
months. Over the course of a one-year follow-up there was some angiogenesis in the patch but 
no evidence of patch degradation.  
In contrast, Fujimoto et al showed that a quicker degrading poly(ester urethane)urea 
(PEUU) patch with greater elasticity was shown to halt LV functional deterioration when sutured 
onto the epicardium 2 weeks after infarction – Figure 4.[43] This material prevented further 
dilation and was associated with the formation of a new smooth muscular layer in the infarct 
zone, possibly due to the stress shielding provided by the patch. Additionally the global 
mechanics of the LV stress-strain relationship was closer to native myocardium after patch 
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implantation than infarct control animals. Further investigation of the new smooth muscle cells 
in the infarct zone showed they co-expressed proteins α-SMA, α-actinin, cardiac troponin T, 
connexin 43, and genes Nkx-2.5 and GATA-4.[44] This expression was shown to be similar to 
cells in the embryonic rat heart during development and designate these cells to be on a 
myocardial lineage. While the benefit of material implantation was also manifest by increased 
reserve in dobutamine stress testing, there was no evidence that the smooth muscle cells take on 
an adult cardiomyocyte contractile phenotype. This same material was also applied as a full 
thickness patch for reconstruction of a right ventricular outflow graft defect.[45] This patch 
material allowed significant cellular infiltration and was completed degraded at the 3 month 
endpoint leaving behind only native tissue in the sealed defect. By comparison, non-degradable 
PTFE patch controls showed no cellular infiltration and had increased inflammation throughout 
the study. Taken together, these results suggest that material properties of degradation time and 
mechanics may play important roles in the success or failure of a particular patch material.  
Polyester patch materials have also been employed as cardiac patches with mixed results. 
For example, poly(glycolide-co-ε-caprolactone) was implanted as a cardiac patch 1 week after an 
ischemia reperfusion injury in rats.[46] At the 4 week echocardiography assessment these 
patches showed significantly better fractional shortening (FS), left ventricular end diastolic 
diameter (LVEDD), LV end systolic diameter (LVESD), and LVEDP than saline control groups. 
Importantly, the results were the same as patches that had been loaded with stem cells. On the 
contrary, poly(lactic-co-ε-caprolactone) (PLCL) patches showed no improvements over saline 
control animals 4 weeks after implantation in a rat cryoinjury model.[47] While functional and 
geometric parameters were not improved by placement of the patch there was evidence of 
increased expression of cardiomyocyte proteins myosin heavy chain (MHC) and troponin I (TnI) 
in the infarct zone. It is interesting to note the differences in these two studies considering the 
general similarity between materials used. This highlights the need for further investigation into 
what material properties and deployment techniques may provide the greatest benefit in this 
therapy.  
Overall it appears that the material that is used in a cardiac patch can influence the 
outcomes seen after treatment. While biological materials may have inherent biocompatibility, 
they seem generally unable to provide much benefit when used alone as a cardiac patch. The 
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highly variable results that can be seen when similar materials are applied points to the need for 
further research in this field. Synthetic materials have been able to show some good 
improvements to cardiac function after implantation. It may the mechanical properties of some of 
these materials or it may the inflammatory response that comes with their use that provides cell 
infiltration and support to the failing ventricle. As will be shown presently, the combination of a 
patch with signaling molecules may augment the results shown with patch alone for some 
materials. 
 
Figure 4. Electron micrograph of a porous polyester urethane urea material used as a 
cardiac patch (A). Macroscopic image of patch before implantation (B). Representative 
images, 8 weeks after implantation, of the anterior view of infarction control (C) and 
patched (D) hearts. The cross-sectional view of both groups is shown in E and F, 
respectively. Black arrows point to the implanted patch, and white arrows indicate the 
infarcted anterior wall. Scale bar: 500 µm in A, 1 mm in B, 55 mm in C to F. P = the patch 
implanted area; S = the infarcted scar. (From [43]) 
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1.3.3 Cardiac Patch Materials Including Drug Delivery 
There has been significant research into direct injection of growth factor solutions into the heart 
for therapeutic angiogenesis, including in human clinical trials.[48-50] However, the controlled 
release of signaling molecules from scaffolds for the cardiac patch application has received 
notably less attention. What reports do exist suggest that inclusion of signaling molecules in the 
cardiac patch can be beneficial and warrants further investigation. In one report, the release of 
1.5 µg of basic fibroblast growth factor (bFGF) from alginate patches was studied. The left 
coronary artery of rabbits was permanently ligated followed by immediate application of an 
alginate epicardial patch. This patch was mostly degraded at the 4 week endpoint suggesting 
nearly all of the growth factor would have been delivered by that time. While the data on cardiac 
function under rest conditions was not better for patches with bFGF compared to those without, 
staining of CD31 positive cells did show increased angiogenesis when bFGF was present. The 
presence of growth factor also trended towards smaller infarcts. When hearts were stressed by 
norepinephrine those that received the patch or the patch with bFGF had better pressure 
responses in the LV than control animals. 
 In the case of stromal cell derived factor 1 (SDF1), which has been shown to be 
upregulated after infarction in the heart and is responsible for stem cell recruitment, controlled 
release may be beneficial following MI.[51, 52] Zhang et al. used a PEGylated fibrin that bound 
SDF1 as a cardiac patch immediately following infarction in a mouse model.[38] In vitro 
characterization showed that the SDF1 was completely released within 10 days and was 
equivalently bioactive to unbound SDF1. In vivo it was shown that the number of ckit+ cells was 
higher at 2 and 4 weeks after implantation in the SDF1 patch group compared to direct injection 
of SDF1. It is notable that there were more ckit + cells after one week in the SDF1 injection 
group, followed by a steep decline in later weeks. This shows the longer term benefits of the 
controlled release mechanism compared to direct injection of growth factor. The SDF1 patch 
groups also had an improved EF after 4 weeks compared to controls and patch without the 
growth factor, demonstrating the functional benefits of this approach.  
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1.4 BIOMATERIAL INJECTION 
The use of biomaterials for cardiac repair has primarily focused on applications where the 
material is anchored to and interacts with the outer edges of the myocardium to provide support. 
Incorporating the material completely within the heart wall is an alternative approach where 
direct contact with cardiac cells occurs as the material acts as a bulking agent for the heart wall. 
Generally, materials are delivered through direct epicardial injection at distinct locations in and 
around the infarct leading to focal points of biomaterial presence – Figure 5. Current methods 
for direct injection have required sternotomy or thoractomy, though thorascopic or intravascular 
procedures could be feasible to decrease procedure-related morbidity. Not only may the injected 
material alter the mechanical environment upon injection, but appropriate biomaterials can have 
biological functions that encourage cardiac repair. Functions such as angiogenesis, 
cardiomyocyte protection, and stem cell recruitment may be another primary means to improve 
the efficacy of material injections for treating heart disease.  
In 2006, a report by Wall et al. utilized a finite element model to evaluate the theoretical 
effect on cardiac wall stress of injecting a noncontractile biomaterial into the LV wall.[53] The 
injected volume changes the LV geometry by increasing the wall thickness, thus lowering local 
wall stress. The simulation showed that injection of a volume 4.5% of the total LV wall volume 
and with a stiffness 20% of the natural LV tissue into the infarct border zone could decrease the 
wall fiber stress in the border zone by 20% compared to a control simulation in which there was 
no injection – Figure 6. The mechanical simulation also showed that this attenuating effect on 
LV wall stress increased with the injection volume and modulus of the injected material.  
Importantly, while this model demonstrated a slight increase in EF following material 
injection, a more precise measure of global cardiac function, namely stroke volume divided by 
LV end-diastolic pressure, was unchanged. This disparity results from the fact that EF is 
computed from geometric factors and thus changes in ventricular geometry from the presence of 
material can cause higher EF calculations without real functional improvement. Because EF is a 
common clinical metric of heart performance it is advisable to confirm perceived improvements 
to EF with other measures of function. Reductions in cardiac wall stress computed after material 
injection have been corroborated by recent finite element modeling where mean myofiber stress 
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for the entire LV can be reduced by 15% and 5% at end-diastole and end-systole, respectively, 
depending on number and configuration of injection sites. [54] These finite element models, in 
conjunction with an understanding of the Law of Laplace, provide the theoretical basis for 
growing interest in injectable biomaterials to treat cardiac failure.  
 
 
Figure 5. Direct epicardial injection of a fibrin–alginate composite into porcine 
myocardium. (A) Using a grid template, material was injected from a double-barreled 
syringe to distinct points across the infarcted area. (B) A myocardial cross section reveals 
the material present as amorphous compartments at the injection sites. (From [55]). 
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Figure 6. Representation of mid-wall ventricular fiber stress as a function of position in the 
heart. (A) Wall stress with an apical infarct (red is higher stress localized near the infarct). 
(B) Wall stress with injection of a theoretical gel material at four different numbered 
locations peripheral to the infarct region. (C) The difference in the previous two images. A 
marked reduction in wall stress is seen due to injection therapy (cooler colors representing 
reduced stress). (From [53]). 
1.4.1 Biological Materials 
Inherent in the application of materials to intramyocardial injection therapy is the ability to pass 
the material through a small needle. Examples of biological materials that are amenable to 
injection delivery include collagen, gelatin, fibrin and alginate. These materials have been 
investigated extensively and thus the processing parameters needed to change material properties 
is well understood. This provides a framework to change the injectability and mechanical 
properties of these materials for this application.  
1.4.1.1 Alginate 
Alginate, a linear block copolymer of (1-4)-linked β-D-mannuronate and α-L-guluronate 
residues, is bioinert and does not support cell attachment.[56] However, modifications to 
alginate, such as introduction of the cell binding sequence arginine-glycine-aspartate (RGD), can 
significantly improve attachment.[56, 57] The material properties of alginate, especially 
mechanical strength and degradation rate have been extensively studied leading to a good 
understanding of methods to adjust these properties[58]. Increasing alginate concentration in 
solution increases mechanical strength but also increases solution viscosity, which may be 
undesirable when material injection is desired. However, it has been demonstrated that a mixture 
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of high and low molecular weight (MW) chains can lead to a relatively high elastic shear 
modulus of 10-24 kPa while still maintaining a low viscosity of less than 2 Pa s.[59] Variations 
in alginate composition and ionic makeup can vary the elastic modulus of the gel widely from 5 
to 55 kPa.[60, 61] The same characteristics of alginate that influence mechanical properties, such 
as molecular weight, also influence the degradation time of the gel. To further tailor degradation 
time alginate polymer chains can be partially oxidized by reaction with sodium periodate, which 
ultimately provides hydrolysable bonds to speed degradation.[62] Alginate has been used in both 
drug delivery and tissue engineering applications with marked success.[56-58, 63, 64]  
Landa et al. aimed to study the ability of alginate to improve LV remodeling and function 
when injected as a bulking agent into the myocardium. [65] They compared the results of 
injecting 150 μL of alginate (MW 30 kD) solution into both recent (7 days after) and old (8 
weeks after) infarcts. Eight weeks after material injection into recent infarcts LV geometry was 
improved in the biomaterial group in the form of increased LV wall thickness and attenuated LV 
dilation compared to control hearts that received a saline injection. The improvements in old 
infarcts were less pronounced demonstrating the greater difficulty in rescuing a chronically 
infarcted heart. Using a biotin-labeled alginate, histological sections were able to accurately track 
material degradation in vivo. One hour after injection alginate occupied 45% of the infarct area, 
but this decreased to 6% after six weeks. Of particular note, material injection was compared to 
injection of 1x106 neonatal cardiomyoctyes in saline with similar or better results in all measures 
for material injection alone. In other reports alginate was able to show significantly improved 
cardiac function in terms of fractional area change (FAC) or fractional shortening compared to 
saline injection controls. The improvements in FAC and FS associated with alginate injection 
were demonstrated for as many as 5 to 8 weeks after injection, and even in a chronic infarct 
model where injections occur several weeks after infarction. [66, 67]  
A mixture of alginate polymers with molecular weights of 125 kD and 5 kD at a ratio of 
75:25 High MW: Low MW was injected in the peri-infarct region of rat hearts 7 days after 
coronary ligation.[68] The histological evaluation showed the inert properties of alginate, as the 
material was unable to increase capillary density or α-actin positive smooth muscle cell (SMC) 
density 28 days after injection. In this material 1% of the alginate sugar residues were oxidized 
by incubation with sodium periodate, to increase the material degradation rate. In vivo only a 
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third of all hearts showed any material left at the 28 day endpoint – and then only in small 
fragments. The lack of angiogenesis in this study after alginate injection has not been universally 
observed. Other studies have reported that plain alginate injection into the myocardium can cause 
mild increases in capillary and arteriole density and myofibroblast infiltration. [55, 65, 66, 69, 
70] The direct cause of the increased cell population is not completely understood but may be 
related to the alginate creating a healthier microenvironment through stress shielding. 
Alternatively, the inflammatory response to the foreign body injection may similarly have 
triggered increases in local cellular content. For cardiac biomaterials injection studies in general 
it is difficult to separate the underlying cause of the observed effects. While mechanical effects 
are most commonly hypothesized, the material-related inflammatory response is potentially 
contributing in concert or independently.  
In order to improve upon results from cardiac injection of alginate alone by facilitating 
greater cellular infiltration into the material, the cell adhesion peptides RGD and tyrosine-
isoleucine- glycine-serine-arginine (YIGSR) have been introduced into the polymer 
backbone.[66, 70] While in vitro studies confirmed that these peptide sequences allowed for 
improved cell attachment, functional and histological results with peptide-modified alginate have 
been mixed. For example, Yu et al. reported that 2 days after injection, both unmodified alginate 
and RGD-alginate showed mild improvements in FS and wall thickness but after 5 weeks no 
functional difference was seen between peptide-modified and plain alginate. However, there was 
a significant increase in arteriole density after 5 weeks in the RGD-alginate compared to plain 
alginate and saline injected control animals, indicating some local biological effect. While these 
results would suggest that the cell adhesion sequence may be beneficial for angiogenesis, a 
report by Tsur-Gang et al. showed that injection of alginate modified with both RGD and YIGSR 
peptides was not able to cause improved function or increase angiogenesis compared to 
unmodified alginate or alginate with a nonsense arginine-glycine-glutamate (RGE) peptide 
attached. Even though RGD/YIGSR-modified alginate showed the lowest blood vessel density 
compared to plain and RGE alginate, it was still able to maintain scar thickness. It is unknown 
why there was not a stronger cellular response in the RGD/YIGSR alginate group but the authors 
speculate that the modification, which involved 0.2% of uronic acid monomers, may have been 
inadequate or that the peptides were not well exposed to surrounding cells.  
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Another interesting approach to encourage cell infiltration into alginate was the blending 
of polypyrrole with alginate.[69] Polypyrrole, though mechanically brittle, may be particularly 
advantageous for cardiac injection because of its ability to conduct electrical signals and 
encourage endothelial cell growth.[71] Injection of 0.025% w/v polypyrrole with alginate led to 
significantly higher arteriole density than injection of alginate alone. The authors reasoned that 
increased cell attachment to polypyrrole, as was demonstrated in vitro, as well as improved 
electrical conductivity through the infarct region may have encouraged cell growth and arteriole 
formation.  
While the most common delivery site for injectable biomaterials is through an epicardial 
approach, a recent report demonstrates that intracoronary injection of appropriate materials may 
be possible without detrimental side effects. An alginate-calcium solution was injected 
intravascularly into the left anterior descending artery of pigs post-MI through a coronary 
catheter.[72] The vasculature in the injured myocardium becomes leaky after infarction, allowing 
the alginate polymer to diffuse across the permeable endothelium into the extravascular space. 
While the alginate solution is unable to gel in the vasculature due to inadequate calcium ion 
concentration, within the myocardium the calcium concentration is adequate to allow ionic 
crosslinking and gel formation throughout the myocardial wall – Figure 7. Different volumes of 
alginate solution were injected and results studied for 60 days. It was demonstrated that the 
volume injected was related to the measured benefit, as injection of 2 ml had better outcomes 
than 1 or 4 ml. It is not clear what volume is optimal for cardiac injection therapy but this report 
suggests that an optimal range may be desired wherein there is enough material to provide 
mechanical benefit but without impinging on diastolic expansion. In this study, even though the 
material was completely removed by the 2 month endpoint, improvements to FS and wall 
thickness remained. This method allows for diffuse delivery noninvasively but may lead to other 
concerns. For example many patients with heart failure also have co-morbidities such as diabetes 
and peripheral vascular disease.[73] Damaged blood vessels from these conditions may allow for 
alginate deposition and gelation in undesired locations, the effects of which are not known. It 
will be necessary for appropriate controls to prove efficacy, or appropriate patient selection to 
make this a clinically feasible approach.  
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Figure 7. Two hours after intracoronary injection of alginate the material had migrated 
from the vascular space and was found throughout the myocardial wall in a porcine model. 
The presence of this material led to increased wall thickness, which persisted after the 
material had degraded 6 weeks later. (From [72]). 
1.4.1.2 Fibrin 
Fibrin, which has been used as a biomaterial in a broad array of applications for decades, has 
been reviewed extensively.[74-76] A fibrin “glue” or fibrin “sealant” aims to reproduce the final 
steps of the coagulation cascade which forms a three dimensional cross-linked fibrin network. 
This occurs when fibrinogen is cleaved by thrombin into fibrin monomers that self-assemble and 
are subsequently cross-linked by factor XIIIa. In commercially available fibrin sealants such as 
Tisseel (Baxter Healthcare) or Crosseal (Ethicon Inc) the reactive components that form the 
fibrin clot come in contact only upon injection through a double-barreled syringe. One of the 
solutions consists of fibrinogen mixed with anti-fibrinolytic agent aprotinin, while the other 
solution contains thrombin, factor XIIIa and calcium ions. The deposited fibrin, which is 
digested by the enzyme plasmin, is usually completely degraded within days to weeks depending 
on implant location and the concentration of aprotinin. The material properties of these sealants 
depend on the starting solution compositions. For example, increasing the thrombin 
concentration increases clotting speed and also leads to stronger networks. A high fibrinogen 
concentration (70 mg/ml) can provide an elastic modulus up to 40 kPa compared to 10 kPa for a 
low concentration (30 mg/ml).[77] Importantly, fibrin sealants have been FDA approved in 
certain applications as a sealant or to aid hemostasis, allowing ready access in most operating 
rooms.  
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Fibrin injected into rat hearts following creation of an infarct by ischemia-reperfusion 
injury has been shown to yield positive results.[67, 78-81] Injection of 50 μL of fibrin into one 
site in week-old infarcts prevented wall thinning and maintained FS over 5 weeks after injection, 
even though the material is resorbed within 2 weeks.[78, 82] In contrast, injection into 5 week-
old infarcts did not improve FS 5 weeks after fibrin injection.[67] After injection of fibrin infarct 
size, as measured by the ratio of infarcted LV area to total LV area, is consistently reduced 
compared to negative control studies. Arteriole density, but not capillary density, was increased 
after fibrin injection compared to bovine serum albumin injection, and importantly it was proven 
that the new arterioles formed were found within the infarct zone, were functional, and were 
connected to the existing vasculature. [80, 81] Since arteriole formation was consistently 
associated with fibrin injection, but functional improvement was not, improvements to the 
vasculature alone do not appear to be sufficient for improving long-term function.  
A report of myocardial injection in a large animal model involved fibrin injection into 
infarcted porcine hearts.[55] Researchers injected 200 μL of a composite of fibrin with gelatin-
grafted alginate into each of 25 points on a grid across the infarct area. While the report did not 
demonstrate functional improvement the researchers did show increased posterior wall thickness 
for one week following injection and infarct expansion was prevented for two weeks after 
injection. Likely due to the presence of alginate in the fibrin clot, material was still detected at 
three weeks. While limited conclusions can be drawn from this study, it is notable as one of the 
first reports of biomaterial injection therapy applied to a large animal model.  
1.4.1.3 Chitosan 
Chitosan, a cationic polymer derivative of chitin, has been used in biomedical, tissue 
engineering, and drug delivery applications because of its general biocompatibility, capacity to 
form porous structures and gels, and tunable degradation rate.[83, 84] While being soluble in 
acidic aqueous solutions through protonation of its many amine groups, neutralization of 
chitosan aqueous solutions to a pH exceeding 6.2 systematically leads to the formation of a 
hydrated gel-like precipitate.[85] Chitosan aqueous solutions can be transformed from purely 
pH-dependent solutions into temperature-controlled pH-dependent chitosan solutions by mixing 
with polyol salts bearing a single anionic head, such as glycerol-, sorbitol-, fructose- or glucose-
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phosphate. Conjugation of hydrophobic groups such as hydroxybutyl to the hydroxyl and amino 
reactive sites of chitosan can also confer temperature-responsive properties. [86] Thermal 
responsiveness allows chitosan to be optimized for injection, with achievable elastic moduli over 
5 kPa reported after gelation.[85] 
A thermally responsive chitosan formed by mixing chitosan with β-glycerol phosphate 
and hydoxyethyl cellulose has been injected into infarcted rat hearts one week after an ischemia-
reperfusion injury. Injection of the material, which was almost completely degraded by 4 weeks, 
was shown to improve FS and decrease dilation to the same extent as injection of stem cells 
alone, and better than saline injections alone.[87] A new material developed by Yeo et al. 
combined an azidobenzoic acid-modified chitosan with an acryloyl-PEG-RGDS to make a 
photocrosslinkable gel for use in injection therapy.[88] The material was able to form a gel in 
situ after two minutes of UV irradiation and had a shear modulus up to 370 Pa. This material was 
shown to support cell growth at a level comparable to tissue culture polystyrene and was able to 
release VEGF in vitro for more than 24 days. While not yet studied in vivo, this material does 
represent the growing interest in enhanced material properties through improved material design 
for the field of cardiac injection. 
1.4.1.4 Extracellular Matrix and Derivatives  
Extracellular matrix-derived materials are generally comprised of structural proteins such as 
collagen, laminin, fibronectin, and vitronectin, as well as an array of glycosaminoglycans, and 
are specific to their tissue source. ECM is naturally bioactive, is important in cell signaling and 
in the case of cardiac ECM, plays an important role in the inflammation and remodeling process 
following MI. [89, 90] Because cells are naturally inclined to interact well with ECM it is often 
used as scaffolding for tissue engineering applications.[91] Degradation speed of these materials 
is determined by the cellular milieu in vivo and factors such as concentration and extent of cross-
linking. For example, gelatin, a denatured derivative of collagen, is much weaker and degrades 
quicker than its parent molecule.[92] The mechanical strength of injectable ECM derived 
materials is generally low. For example, the storage modulus, as determined by parallel plate 
rheometry, of injectable collagen is in the range of 20 to 80 Pa. Matrigel (Beckton & Dickenson), 
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an ECM gel generated by mouse sarcoma cells, is comprised primarily of collagen and has a 
modulus of 30 to 120 Pa.[93, 94]  
Gelatin has been injected into infarcted rat hearts but without improvement to function or 
histology after 4 weeks.[95] Gelatin was present in half the hearts after 2 weeks in vivo but was 
completely absent after 4 weeks of injection. Collagen has had slightly better results.[96] 
Injection of 100 μL of collagen at a single point in the infarct zone led to a higher EF than saline 
injection 6 weeks after treatment. Surprisingly the injected material did not allow for cell 
infiltration or angiogenesis, and thus seemed to behave similarly to the native collagen-rich 
infarcted tissue. The increased EF may have been a consequence of the increased wall thickness 
that was observed after injection. In contrast, Huang et al. were able to show improved 
myocardial angiogenesis and myofibroblast infiltration into injected collagen.[81] The reason for 
these disparate results could be related to the infarct model. No angiogenesis or cell infiltration 
was seen when injection occurred one week after infarction, whereas there was cell infiltration if 
injected after just 30 minutes of ischemia. This result may further indicate the difficulty in 
salvaging late-stage diseased tissue and reflect the importance of timing in therapeutic 
application. 
Injection of Matrigel was able to form a collagen-fiber network that ran parallel to that of 
the host myocardium and integrated with native collagen.[97, 98] For ischemic hearts Matrigel 
injection was able to improve FS and wall thickening 4 weeks after treatment. While the 
application of Matrigel clinically is questionable due to its tumor cell source, ECM from a 
variety of animal tissues are routinely applied in a variety of settings and are of interest in 
cardiac applications. For injection therapy, a mechanically ground digest of ECM from small 
intestinal submucosa was hydrated and injected into infarcted rat hearts.[99] The ECM material 
was able to improve function and decrease remodeling in the 6 week follow-up compared to 
infarct controls. As was hypothesized, the ECM material increased cell infiltration into the 
infarct zone. There was a significant increase in myofibroblasts, macrophages, and importantly, 
c-kit positive cells. ECM-injected hearts had substantially more stem cell factor and VEGF 
present. This study demonstrates a relatively high level of regeneration in the form of stem cell 
recruitment and muscle repair that can be elicited by biologically active ECM, and sets the stage 
for future work using similar materials.  
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Under the belief that ECM of a certain tissue type is going to best facilitate regeneration 
of that tissue, many groups are interested in using tissue-specific ECM materials for tissue 
engineering. In a pilot study, Singelyn et al. injected a hydrogel made of digested porcine cardiac 
ECM into healthy rat hearts.[100] Animals were sacrificed 11 days after injection to demonstrate 
that the ECM was still present and in morphology similar to intact decellularized cardiac ECM. 
Both in vivo and in vitro results showed that SMCs and endothelial cells migrate to and infiltrate 
the ECM biomaterial. The ability to use pericardial ECM for cell injection has also been recently 
demonstrated.[101] This tissue source is important as it may allow for injection of autologous 
ECM. Both human and porcine pericardial ECM gels supported arteriole formation within the 
injected material in healthy rat hearts and a few c-kit+ precursor cells to be recruited around the 
material. These studies demonstrate the potential that ECM materials may have for this 
application, although without results from injection into injured hearts, more detailed 
conclusions cannot be made.  
1.4.1.5 Comparative Studies 
Unfortunately, only a few studies have directly compared different types of materials for cardiac 
injection.[67, 81] In these studies the specific differences in material properties can be more 
directly linked to outcomes since all other study parameters are held constant. In one report, 
fibrin, collagen, and Matrigel were each injected 1 week after an ischemia-reperfusion injury into 
separate groups of rats. While lacking data on cardiac function, this study did show that for all 
three materials there was a similar increase in myofibroblast infiltration, capillary density, and 
arteriole density compared to saline injection. In another report, by comparing alginate to fibrin 
injection the importance of material residence time may be demonstrated.[67] Two days after 
injection both of these materials caused similar increases to wall thickening, decreased 
intraventricular diameters, and increased FS – Figure 8. After five weeks however, the fibrin-
injected hearts no longer maintained improved function despite largely preserving LV wall 
thickness. Alginate on the other hand improved FS, albeit at levels less than was shown at 2 
days. An obvious difference between groups was that the alginate was still present in substantial 
amounts after 5 weeks, whereas fibrin was completely resorbed. The continued presence of a 
material that may provide physical support in this case appears to be more advantageous.  
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Figure 8. Comparison between injection of fibrin or alginate into 5-week-old infarcts in 
rats. Two days after injection both materials demonstrated equivalent improvements to FS, 
(A) LV dimension (B) and wall thickness. (C) Five weeks after treatment the fibrin group 
lost much of the advantage seen at 2 days, whereas alginate retained a significant 
improvement (*p < 0.05). (From [67]). 
 
A recent study aimed to evaluate the how mechanical strength of the injected material can 
influence outcomes following cardiac injection.[102] Methacrylated hyaluronic acid with 30% 
(MeHA Low) and 60% (MeHA High) methacrylate substitution were injected into ovine infarcts 
and crosslinked in situ. While the two materials demonstrated similar degradation rate, cellular 
response, and tissue distribution the storage modulus of the MeHA High group was over 3 times 
higher than that of the MeHA Low group. In vivo, the stronger material allowed less infarct 
expansion and LV dilation compared to the weaker material. Functionally, MeHA High was 
associated with better EF than MeHA Low after 8 weeks, especially under cardiac stress testing. 
By evaluating the functional effects of manipulating a specific material property, in this case 
mechanical strength, this comparative study provides further guidance for future material 
development.  
1.4.2 Synthetic Materials 
As stated above, there are specific advantages to using synthetic materials that revolve around 
the engineer’s ability to control material properties to meet the desired specifications. The 
requirement for the material to be injectable can present a significant level of complexity to 
material design. Approaches that involve in situ polymerization or crosslinking are often 
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associated with high cytotoxicity making them unattractive for in vivo applictions. Because of 
this, self-assembling and temperature-responsive materials make up the majority of injectable 
synthetic materials used for cardiac application. Controlling the proclivity for self-assembly and 
the transition temperature of thermoresponsive materials becomes the main focus of material 
scientists in designing and implementing these materials. Further, controlling these parameters 
while simultaneously controlling properties such as mechanical strength and degradation rate, 
makes both the difficulty and the potential versatility of using these materials apparent.  
1.4.2.1 Self-Assembling Peptides 
Nature is replete with examples of materials that self-assemble to create larger structures. 
Materials ranging from lipids to proteins can form complex shapes with minimal outside 
influence so long as the appropriate complementarities exist between building blocks. Engineers 
have long sought to utilize self-assembling behavior to build materials on a small scale.[103, 
104] For example, peptides with specifically placed amino acid sequences can self-assemble into 
macroscopic materials that have been shown to support cell growth and have been considered as 
injectables for cardiac wall therapy.[105, 106]  
Peptides with the amino acid sequence AcN-RARADADARARADADA-CNH2 
(RAD16-II), which form a nano-fibrous 3D gel, have been studied extensively for cardiac 
injection to repair the myocardium after MI. Injection of 10 µL of this gel into a non-infarcted 
LV free wall showed significant host cell infiltration including endothelial cells and cells that 
exhibit some cardiac-specific markers even though the peptide sequence did not possess any cell 
recruitment signals.[107] However, injection of 80 µL of the same material into sham animals in 
a similar study showed a temporary decline in FS and LVESD before returning to normal levels 
after 2 months.[108] This indicates that while this material may be advantageous on a cellular 
scale, the addition of the non-contractile material in a healthy heart may have a transient negative 
effect on systolic function in healthy animals. For the more relevant infarction model, RAD16-II 
nanofiber injection into a rat heart immediately after coronary ligation has not been able to 
improve cardiac function, geometry, or histology compared to MI control groups.[108-110] The 
lack of improvement has not been investigated but may be the result of too little material being 
injected and a material that is not mechanically robust. These results led to significant 
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modifications of this material to act primarily as both a drug delivery and cell delivery vehicle 
with very promising results to be discussed later.  
1.4.2.2 Synthetic Hydrogels 
Because of their high water content and diffusivity, among other properties, hydrogels have been 
investigated as implantable biomaterials across a broad range of regenerative medicine 
applications.[111] One challenge for synthetic hydrogels for cardiac injection application is 
controlling the formation of hydrogel structure in situ following injection. While very weak 
hydrogels may be forced through a needle, the material strength may be inadequate for such a 
mechanically taxing environment as the myocardium, and mechanical modeling discussed earlier 
suggests that a more mechanically robust material may be beneficial. Several material design 
strategies may be employed to confront this issue: in situ cross-linking [112], photo-induced 
polymerization [113], self-assembly[114] and thermally responsive hydrogels[115]. 
A solution of α-cyclodextrin and methoxy polyethylene glycol–poly (caprolactone)-
(dodecanedioic acid)–poly(caprolactone)-methoxy polyethylene glycol (MPEG–PCL–MPEG) 
triblock polymer (α-cyclodextrin/MPEG–PCL–MPEG) has the ability to self-assemble into a 
hydrogel.[116] This gelation is posited to occur by two mechanisms. First, the MPEG-PCL-
MPEG polymer chain may be able to thread through the center of α-cyclodextrin rings to form 
microcrystal complexes. Second, micellization of the PCL blocks can further add physical cross 
links within the hydrogel network. This polymer solution can form a hydrogel within a few 
minutes at room temperature and then will degrade in accordance with PCL block hydrolysis. 
Injectability is obtained by separating the α-cyclodextrin solution from the MPEG-PCL-MPEG 
solution using a double barreled-syringe. Injection of this material into new or old infarcts in 
rabbits and rats has been able to show significant improvements in LVESD and LVEDD one 
month after infarction.[117, 118] FS was reported at 56% in the hydrogel injection group 
compared to only 37% in the saline injection group after 4 weeks in rabbits. Contrary to other 
studies, improvements in geometry and function were not present two days after injection but 
were so after one month. This indicates that presence of the material alone may not be the cause 
of enhancement. Rather, it appears the body’s longer-term reaction to this material generates the 
benefits. Indeed the LV wall thickness is increased after a month largely due to more collagen 
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deposition. Interestingly, functional improvements could not be linked to increased blood flow to 
the infarcted area as there was no difference in blood vessel density between hydrogel and saline 
injection groups.  
Because injected material acts as a mechanical support, it may be beneficial for the 
material to remain in situ indefinitely. To this end a non-degradable, in situ polymerized PEG 
hydrogel has been investigated for cardiac injection after MI.[119] Despite the often perceived 
inert nature of PEG hydrogels there was substantial macrophage response to the material 
throughout the 3 month follow-up. The benefits seen after injection – increased wall thickness 
and modestly attenuated dilation – only persisted during the first 4 weeks. By 3 months the 
hydrogel injection group had regressed to a cardiac geometry and function similar to the saline 
treated control group. In this case a long-remaining material did not provide long-term benefit, 
but rather appeared to only introduce a focal point for chronic inflammation. Indeed, hydrogel 
injection into sham operated hearts showed a significant reduction in FS at 3 months which may 
point to the damaging role that chronic inflammation can play. The authors also suggest that 
while PEG may be an adequate mechanical support initially, as the heart continues to dilate the 
wall stresses eventually become more than the PEG hydrogel can support and so remodeling 
continues unchecked.  
Thermoresponsive materials that transition from sol to gel near body temperature are 
frequently employed for tissue engineering and drug delivery applications because their 
transitional properties make them easy to deliver and manipulate.[120] N-isopropylacrylamide 
(NIPAAm) is one of the most studied thermoresponsive molecules. Poly-NIPAAm (pNIPAAm) 
chains can be dissolved in water below their transition temperature of 32°C, but precipitate to 
form a hydrogel upon warming to body temperature. Disadvantages to using pNIPAAm are 
related to its inability to degrade in vivo as well as its apparent structural similarity to toxic 
acrylamides. However, copolymerization of NIPAAm with degradable polymers can create a 
material that is thermoresponsive, biodegradable, and lacking observed cytotoxicity.[121, 122] It 
is also feasible to incorporate protein-reactive mers in NIPAAm-based copolymers to allow for 
covalent attachment of ECM components and growth factors [121, 123] and to incorporate 
enzymatically labile peptide cross-links [124] and adhesive peptide sequences [125]. 
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Fujimoto et al. developed a degradable, thermally responsive copolymer of NIPAAm, 
acrylic acid, and hydroxyl-ethyl methacrylate-poly(trimethylene carbonate) 
(HEMAPTMC).[126] The sol-gel transition of this polymer occurred around 33°C, forming a 
hydrogel with a mechanical stiffness of 20 kPa, and a degradation time greater than two months 
in vivo. The sol-gel transition of this material and subsequent elasticity is demonstrated in 
Figure 9. Using a chronic rat infarction model, injection of this material around the infarct 
prevented the progression of cardiac dilation and remodeling. In addition to cellular infiltration 
in the material, histological evaluation of the LV wall 8 weeks after injection also showed the 
formation of a layer of smooth muscle next to the remaining material. This muscle layer 
expressed proteins associated with a contractile phenotype, though the direct effect of the smooth 
muscle layer on overall LV contractility was not assessed. This phenomenon was similar to that 
found after alginate injection and may be the result of reduced ventricular wall stress altering the 
remodeling pathway away from a largely fibrotic result – Figure 10.  
 
Figure 9. Demonstration of the thermal properties of NIPAAm–co-AAc–co-HEMAPTMC 
hydrogel. (A) Aqueous polymer solution at 4 °C, (B) gel formation after 30 s incubation in a 
37 °C water bath, (C) after 10 min the gel continued to shrink and stiffen, leading to (D) a 
mechanically robust material with some elastic behavior. (From [126]). 
 
28 
 
A similar approach to the NIPAAm-based thermally responsive material above was 
investigated by Wu et al., who synthesized a hybrid biological-synthetic gel with PCL-grafted 
dextran chains that were subsequently copolymerized with NIPAAm monomer to form large 
branched copolymer chains.[127] Gel formation above 32°C led to a material with a storage 
modulus between 100 and 1500 Pa. Dextran cleavage in vivo led to breakdown and removal of 
the copolymer from the injection site within about 1 month. A volume of 200 μL of this material 
was injected into 4-day old infarcts in rabbits.[128] After 4 weeks, echocardiography showed 
that EF and LVEDD were significantly better in the material injection group compared to the 
saline injection group. While no material was evident in the histology at 4 weeks, the LV wall 
was substantially thicker. No analysis was done to determine if increased thickness was due to 
cell infiltration or more collagen deposition.  
 
 
Figure 10. Histological evaluation of myocardium following material injection. 
Intracoronary injection of alginate (A) led to substantial growth of myofibroblasts that 
stained positive for smooth muscle a-actin (brown) in the infarct. (B) Direct epicardial 
injection of a thermally responsive NIPAAm copolymer led to a smooth muscle layer (C) 
(blue arrows) beneath the material that stained positive for smooth muscle actin (D) (green 
stain). (Left panels from [72], scale bar 10 µm; right panels from [126], scale bar 100 µm). 
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Adaptation of an off-the-shelf material for use in cardiac injection was seen when 
Radiesse (Bioform Medical Inc) was injected into ovine infarcts.[129] Radiesse is a soft tissue 
filler made up of calcium hydroxyapatite microspheres suspended in a gel-like solution of water, 
carboxymethyl cellulose, and glycerin. This material is typically used in cosmetic procedures and 
has been shown to increase local collagen production after injection.[130] Injection of a total of 
1.3 ml of Radiesse at 20 uniformly distributed locations within the infarct area led to improved 
cardiac function within 15 minutes. The improvements were primarily the result of transforming 
the dyskinetic myocardium into akinetic tissue. Study of the ejection fraction in local regions of 
the myocardium demonstrated that apical and midventricular ejection fractions immediately 
improved after material injection contributing to the global improvement seen in EF. Four weeks 
after injection, improvements were seen compared to saline controls, although the benefits seen 
immediately after injection were attenuated and cardiac dilation continued.  
1.4.3 Injectable Materials Including Drug Delivery 
To build upon the results of material injections alone and to further encourage cardiac 
regeneration and functional improvements, many groups have sought to combine material 
injections with the controlled release of growth factors or other bioactive molecules. The injected 
material can serve as a depot for sustained biomolecule delivery, while also acting to protect 
these agents and thus extend their half-life in vivo.  
It has been shown that VEGF and platelet derived growth factor (PDGF) play important 
roles in vessel formation.[131] While VEGF is important in the early stages of angiogenesis, 
PDGF is crucial to stabilize and mature the new vascular network. Thus it has been shown that 
sequential delivery of VEGF followed by PDGF can cause larger, more mature vasculature to 
develop in an ischemic region.[132] The differing natural affinity of alginate to VEGF and 
PDGF can lead to a level of sequential dual delivery of these growth factors from this 
material.[68] In vitro, about 50% of the VEGF is released from alginate during the first day 
compared to only 10% of the PDGF, though both show about 80% release by 4 weeks. In the 
infarcted myocardium, this sequential dual growth factor delivery translated to increased 
capillary density and α-actin SMC positive vessels compared to delivery of either factor 
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individually. While EF and LVEDD were not changed after growth factor delivery, the 
researchers do show that the systolic velocity time integral – a measure of displacement of the 
myocardium during contraction – did improve significantly compared to saline injections and 
compared to single factor delivery.  
Because it has been shown that high local doses of angiogenic factors such as VEGF can 
have deleterious effects Christman et al. aimed to deliver a plasmid coding for pleiotrophin with 
the fibrin glue injected into an infarcted rat heart.[80] While no studies were performed to 
demonstrate transfection efficiency or overall levels of pleiotrophin production in the infarct 
zone, it was shown that hearts which received 250 μg of pleiotrophin with fibrin glue had an 
80% increase in arteriole density compared to those receiving pleiotrophin delivered in saline. 
Using a microbead perfusion assay it was shown that the neovasculature was functionally 
connected to the native vessel network. No data for cardiac function were presented in this study 
to determine if the increased vasculature translated to improved LV pumping capacity.  
Similarly, bFGF was delivered with gelatin injection into infarcted myocardium.[95] 
Delivery of 20 μg of bFGF either with saline or with gelatin lead to increases in arteriole density, 
capillary density, and fewer TUNEL-positive cells than injection of material without bFGF over 
4 weeks. However, bFGF in gelatin consistently suggested a stronger effect than bFGF in saline. 
The only functional improvement was an increase in FS transiently at two weeks in the bFGF 
with gelatin which reverted back to a level similar to the saline control by 4 weeks. This again 
demonstrates that improvements in cardiac function cannot necessarily be directly associated 
with improvements on a cellular level though it may be a necessary beginning.  
The hormone erythropoietin (EPO) has been found to inhibit cell apoptosis and increase 
neovasculature formation in ischemic tissue but may lead to increased risk of thromboembolic 
complications as well. Synthetic hydrogel α-cyclodextrin/MPEG-PCL-MPEG was used as 
delivery vehicle for EPO when injected into recent rat infarcts.[118] In vitro it had been shown 
that bioactive EPO is released from the biomaterial in a mostly linear fashion with 40% released 
after one week. In vivo, western blotting confirmed the presence of EPO both in and around the 
injected material after one week. There was a significant increase in the recruitment of CD 34+ 
cells and neovascularization, and decrease in apoptosis when EPO was delivered with the 
hydrogel compared to delivery of EPO with saline, injection of hydrogel alone, or injection of 
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saline. Importantly in this study the EPO-containing hydrogel group also showed improvements 
to cardiac geometry, FS and left ventricular end-systolic pressure that mirrored the histological 
improvements. 
The largest body of research related to protein delivery with a biomaterial for cardiac 
injection involves self-assembling peptides (SAPs). Insulin-like growth factor 1 (IGF1), PDGF, 
and SDF1 have all been incorporated into SAPs with promising results.[108-110, 133] PDGF has 
a natural affinity for SAPs at approximately 1 ng/μg material, leading to a steady in vivo release 
over 2 weeks. This is a large improvement over free PDGF in saline injections, which is all but 
removed by 3 days. Delivery of 8 ng of PDGF with nanofibers showed improved FS over 4 
months, decreased caspase-3 activation, and decreased apoptosis in the infarct region but did not 
increase myocardial cell proliferation, neovascularization, or regional blood flow.[108, 109] 
IGF1 within SAPs is also delivered over 2 weeks in vivo due to native peptide-growth factor 
affinity. However, in an attempt to increase the retention time of IGF1, nanofibers and IGF1 
were both biotinylated and tethered together by streptavidin – Figure 11.[133] This binding kept 
IGF1 present at the injection site for longer than 84 days. Because IGF1 was associated with the 
nanofibers it was not free to diffuse out of the material. Thus, only cells that infiltrated the 
boundaries of the material showed the Akt signaling activation that IGF1 elicits. While the IGF1 
was retained for a long duration and appeared to be bioactive it did nothing to improve FS, 
LVEDD, or wall thickness over a 3 week follow up period. 
Finally, specially designed SDF1 was produced that was resistant to MMP cleavage to 
improve its half-life in vivo.[110] Fusion proteins of the resistant SDF1 and the RAD16-II 
nanofiber sequence were synthesized, allowing direct SDF1 incorporation into the SAPs. Using a 
cleavage sequence for MMP-2 as the spacer sequence between SDF1 and RAD16-II allowed for 
release of SDF-I only in the presence of MMP-2, which is a method of stimuli-responsive drug 
release. SAPs containing SDF1 fusion proteins delivered to injured myocardium elicited 
significant improvements in EF and left ventricular end systolic volume 28 days after injection. 
Stem cell recruitment, capillary density and arteriole density were also significantly improved 
after delivery of fusion protein nanofibers compared to nanofibers alone or nanofibers with free 
SDF1.  
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Figure 11. Atomic force microscopy (A) of biotinylated peptide nanofibers (left), 
streptavidin (center) and streptavidin-bound biotinylated peptides (right) creating a beads-
on-a-string appearance. IGF1 was biotinylated and bound to biotinylated peptides through 
streptavidin (B). This attachment dramatically slows the release of IGF1 from the SAP 
environment compared to IGF1 that is not biotinylated or not tethered by streptavidin. 
(From [115], image copyright 2006 National Academy of Sciences, U.S.A.) 
 
Taken together, the results reported to date suggest that delivery of SAPs combined with 
growth factor delivery may have the ability to improve cardiac function. Furthermore, methods 
to increase drug retention time, such as using fusion proteins, appear to be worthwhile to 
improve therapeutic efficacy. It should also be noted that in all studies involving SAPs the 
material was injected within 1-2 minutes of coronary artery occlusion, which decreases the 
clinical relevance of the results. Further studies are necessary wherein more myocardial damage 
is allowed to occur before an intervention is performed as is generally the case in patients 
presenting with myocardial infarctions and ischemic cardiomyopathy.  
In reviewing the use of materials alone or as a delivery vehicle for drugs some notable 
general trends appear. First, injection of hydrogel materials can improve cardiac function and 
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histology over injection of saline. Second, injection of material provides similar or better results 
than injection of only growth factors in solution, when considering comparative studies. Third, 
combining material with growth factors often improves upon the benefits seen when material is 
injected alone. From a practical perspective, however, it may be that obtaining cardiac benefits 
by material delivery alone is the most attractive therapy for clinical translation because it avoids 
the regulatory burden associated with pharmaceutical-associated strategies. While the promise of 
adding appropriate drugs to a material is significant, ultimately the risk-benefit of adding this 
further complexity to intramyocardial biomaterial injections will need to be evaluated as these 
technologies advance.  
1.5 LIMITATIONS AND CHALLENGES 
In both patch and injection therapy, by reviewing the current literature it is difficult to determine 
which material properties and deployment techniques are most advantageous. For example, the 
volume of material injected into rat myocardium has varied between tens and hundreds of µL in 
different studies, which likely impacts the results regardless of material. Further, the number and 
location of these injections, whether a single injection directly in the middle of the infarct or 
multiple injections around the border zone, vary between studies. It is reasonable to assume, as 
was demonstrated in numerical modeling studies, that the volumes and locations will have an 
effect on outcomes.[53, 54] Delivery of material to the border zone may be better positioned to 
encourage regeneration from the healthier peripheral tissue than material injected in the center of 
the infarct. Looking at injection from another dimension, endocardial and epicardial injection 
approaches each have potential risks and benefits. The coupling of injection therapy with 
functional imaging is an area of promise, where the injection sites might be optimized and 
delivery of appropriate volumes achieved safely.  
Likewise, these same considerations relating to size, placement, and material properties 
of a cardiac patch may be important in understanding the successes and failures of that 
technique. Some synthetic materials are able to provide elastic mechanical strength to the heart 
and a support for engrafted cells which may be beneficial after injury, however these materials 
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may lack the biocompatibility desired for longer-term regeneration. The extent of remodeling is 
also influenced by the types and concentration of drugs and cells that are delivered with the 
materials, adding a significant layer of complexity when trying to understand the mechanisms of 
benefit. Different cell types have shown different capacities to survive and integrate in host 
tissue when delivered from a patch or by injection.  
Another major limitation to drawing general conclusions from data surrounding 
biomaterial treatments to heart disease involves the myriad infarction models employed. Many 
different scenarios are represented wherein hearts are treated between minutes to weeks after 
infarction. The ability to improve cardiac remodeling following deployment of a patch or 
injection of material is likely related to the duration between injury and treatment.  It is 
reasonable to assume that delivery of material immediately after injury, as is done in many of the 
animal models discussed above, would provide the most benefit as it has the highest likelihood 
of improving the damaging mechanical and cellular milieu that leads to negative remodeling. 
Early deployment, however, is clinically problematic as patients will never be available for 
immediate treatment at the onset of injury. Recent data also suggest that delivery of materials 
that are enzymatically degradable immediately after infarction may not be as beneficial as when 
delivered later.[134] Thus data on later stage infarction treatment are of particular value and 
relevance. In particular, treatment within one week after infarction may be the most clinically 
relevant as it follows the clinical flow often seen with patients. These patients often present to 
the hospital within a day of the onset of symptoms and are then stabilized and monitored until 
more advanced cardiac procedures are performed in the subsequent days.  Treatment during this 
intermediate stage may also bolster the injured tissue before significant and lasting geometric 
remodeling have occurred, thus providing more benefit than if the patch or injection therapy was 
administered at later times. As noted above, a number of patients undergo silent cardiac events 
and may present to the hospital long afterwards and so studying the delivery of material in the 
later stages of cardiac remodeling is also relevant. However, it may be more difficult to obtain 
positive results from later-stage material delivery due to the substantial damage that will have 
occurred by this time.    
The type of infarction, such as a sustained occlusion or an ischemia-reperfusion event, 
and the location and extent of the blockage may also influence recoverability. On top of this, 
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underlying co-morbities, which would be encountered in the patient population (e.g. diabetes, 
valvular disease) would further confound conclusions drawn from current animal models. A 
further important variable between studies is that the materials used often have different 
mechanical properties and degradation times, even if they are from similar starting molecules. It 
was suggested by several studies that residence time in the tissue may have a role in maintaining 
improvements. Finally, as few studies follow the outcomes for periods beyond a few months, the 
long-term benefits of these treatment approaches are not known. 
As the field involving biomaterials treatments for cardiovascular disease develops it will be 
necessary to conduct more comparative studies to elucidate which of the many material design 
variables provide functionally relevant cardiac improvements. It remains difficult to parse out 
what benefits are derived from changes exclusively in the mechanical environment of the LV and 
what benefits are a result of cardiac remodeling occurring concurrently, and likely dependently, 
in the ventricular wall. Furthermore, the potential positive and negative impact of the local 
inflammatory and phagocytic activity associated with material degradation is not clear. While 
there is evidence to suggest that ongoing inflammation from a non-degradable hydrogel injection 
is counter-productive [119], others have suggested that the inflammatory response may be 
beneficial, stimulating acute angiogenesis and potentially positively impacting the remodeling 
result [126, 135].  
1.6 FUNDAMENTALS OF DRUG DELIVERY 
As discussed above, the inclusion of important signaling molecules such as DNA, small peptides, 
and proteins can be important in the overall function of an implanted material. The presence of 
the biomaterial carrier is particularly important given that bolus injection of a drug free in 
solution leads to rapid clearance of the drug from the injection site, but extended periods of 
bioactivity over the tissue remodeling period in situ are desirable.[136] For example, It has been 
shown that when a solution of free bFGF is injected directly into the myocardium only 16% 
remains after one hour.[137] Contrariwise, the amount of bFGF remaining at the injection site 72 
h after injection was roughly 30% when the factor was incorporated into gelatin microspheres – a 
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15x increase compared to free bFGF injection at that time point. Because the rate of drug 
delivery from a biomaterial carrier may ultimately determine the success or failure of the 
implant, in vitro characterization of drug delivery systems is always warranted before being used 
in vivo. 
The complexities of drug delivery kinetics from a biomaterial carrier are significant and 
can vary depending on many system parameters such as material composition, material 
processing, carrier degradation rate, drug physicochemical properties, and drug loading – Table 
I (adapted from [138]).[139-142] The combination of these and other parameters leads to an 
overall release profile of drug that can be generally categorized into different types. Many 
systems demonstrate simple diffusion-controlled delivery characterized by a burst release of 
near-surface drug, a subsequent fast diffusion period, and ending with lower release rates as the 
agent is exhausted – Figure 12A. This is especially common for hydrogel systems due to their 
high water content, which provides drugs a relatively easy diffusion path out of the matrix. In the 
case of biodegradable materials a two-stage release profile can be observed. In this profile, after 
an initial burst a significant amount of drug remains trapped in the carrier until adequate 
degradation of the material occurs, at which point the remaining drug diffuses out quickly –
Figure 12B. For many applications the ideal release profile would be one of constant delivery at 
a defined rate that doesn’t change over time. This is referred to as a linear or zero-order release 
profile – Figure 12C. So long as the drug can be made to release from the matrix at a therapeutic 
rate, this type of carrier system could deliver drugs without the peaks and troughs in drug 
concentrations seen in other systems. However, the difficulty in developing this kind of system is 
often high and requires a fine balance of system properties.  
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Table I. Design Criteria from Hydrogels in Drug Delivery Formulations 
Design criteria Design variablesTransport properties Molecular weight and size of protein    Molecule diffusion Molecular weight of polymerCrosslinking densityPolymer-protein interactionsHydrogel degradation rateAdditional functionalitiesPhysical Properties Polymer/crosslinker/initiator concentrations    Gelling mechanisms Temperature, pH, ionic strength    Stimuli-responsiveness Concentration of responsive groups    Structural properties Molecular weight of polymer    Biodegradability Mechanical strengthConcentration of degradable groupsBiological Properties Cytotoxicity of the hydrogel    Biocompatibility Cytotoxicity of degradation productsCapsule formation  
 
 
 
Figure 12. Typical drug release profiles in controlled release formulations. Diffusion-
controlled systems show a large burst release early followed by slowing release until drug 
exhaustion (A), degradable materials can often provide levels of high release rate separated 
by a lag phase (B), and zero-order release is characterized by steady release rates 
throughout the release period (C).  
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Extensive mathematical modeling has been applied to various drug delivery systems in 
order to describe the release rates of a given drug from a given matrix. There are many excellent 
reviews which catalogue these various models.[138, 143-145] From an engineering standpoint 
these models are most useful if they can be linked directly to physical parameters of the drug 
delivery system which can be purposefully controlled. This allows the models to be more 
predictive than simply descriptive and thus guides system fabrication. For example, Guo et al 
have developed a model for polyurethane-coated stents incorporating variables for polymer 
degradation rate and polymer swelling rate. In this way, experimental data of degradation and 
swelling, when put into the model, are adequate to predict release without having to run the full 
release experiment.[146] Recently Rothstein et al have made significant improvements in this 
predictive modeling approach within the limits of certain bulk and surface degrading 
materials.[141, 147] Their model allows the user to specify what release profile is desired and 
then provides the necessary characteristics of the system - such as polymer molecular weight, 
matrix size, polymer degradation rate, including various processing methods - that will provide 
that profile. This promising area of research is the natural continuation to earlier work in drug 
delivery and is useful for newer systems that are increasingly complex and have stricter design 
requirements.  
There are additional considerations when studying drug delivery systems that need to be 
investigated. While many studies and models are good at quantifying and describing early stages 
of release behavior, most studies of drug release behavior from new materials do not extend 
beyond a few weeks, meaning that the complexities of the release kinetics may be left 
unobserved. The duration of release will also be influenced by the physiologic environment that 
the system will be used in. Changes in drug delivery rates may arise from the flow, mechanical 
forces, and biodegradation seen at the site of the implanted drug delivery system. Thus trying to 
duplicate the in vivo environment for controlled release experiments may be useful. For 
example, whereas enzymes have been routinely used to investigate polyurethane biodegradation, 
reports of the use of enzymes in the context of controlled release are scarce.[148, 149]  
Various therapeutic molecules have a relatively short half-life in vivo due to physiologic 
processes such as renal clearance, proteolysis, and non-specific binding.[150, 151] It is generally 
understood that drugs gain a level of protection from degradation when protected within a 
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carrier, thus increasing the effective half-life. However, the microenvironment of the carrier, and 
the processing necessary to load the drug, can also contribute to a loss of bioactivity of the drug. 
For example, protein denaturation can occur through mechanisms such as adsorption to the 
material surface or hydrolysis by acidic environments.[152, 153] Processing of drug-loaded 
materials may require the use of organic solvents, high temperatures, or reactive chemicals that 
may denature loaded proteins.[154] Many strategies have been employed to prevent denaturation 
of loaded proteins. Neutralizers can be used to prevent a buildup of acidic byproducts during 
material degradation, excipients such as BSA may help protect proteins from harsh 
microenvironments, and polymers such as poly(ethylene glycol) can be covalently attached to 
drugs to protect them.[155-157] Taken together the challenges in developing a drug delivery 
system to meet the end-user needs require a significant understanding and pairing of the 
principles of controlled release and biomaterial science.  
1.7 OBJECTIVES 
As has been discussed above, both cardiac patch and intramyocardial material injection are the 
most promising of biomaterials-based treatments for treating heart failure. The demonstrated 
ability of specific materials to encourage regeneration and improve function warrants their 
continued investigation. As has been shown previously, both implantation of a PEUU patch and 
injection of a NIPAAm-based hydrogel were able to halt detrimental dilation and wall thinning 
and encourage angiogenesis and tissue growth. PEUU has been used due to its strong and 
elastomeric mechanical properties that would be relevant to a cardiac environment.  NIPAAm-
based gels have been useful because of their rapid transition and the ability to tune their 
chemistry to provide relatively strong mechanical properties compared to other injectable 
hydrogels. In both cases their degradation rate appears to provide support for an extended period. 
In both cases the material was associated with positive responses in the absence of delivering any 
endogenous biosignaling molecules.  That previous work becomes the foundation upon which 
the current work is built. The literature in this field is full of examples where inclusion of a drug 
in the material was able to improve upon the results of the material alone. Thus, the main goal of 
this research was to build upon the results of patch or injection therapy from PEUU or NIPAAm-
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based gels by adding appropriate drugs and studying their release. Because controlled release 
properties can be dramatically different between different materials and different kinds of drugs, 
one primary aspect of this work was to study the release properties and control points for each 
drug/material system, all the while investigating drug activity and ultimate efficacy of the system 
as a whole.  
1.7.1 Objective #1: Spatial control of gene expression in a cardiac patch 
As discussed previously, PEUU that is processed into a porous structure by a thermally-induced 
phase separation technique has been shown to be beneficial as a cardiac patch following 
myocardial infarction. In the first specific aim of this research, PEUU was studied for its ability 
to release a small molecular weight gene-inducing molecule, rheoswitch ligand 1 (RSL1), in a 
controlled and spatially specific manner. We hypothesized that RSL1 could be released from 
PEUU in a bioactive manner.  The ability for cells grown on RSL1-loaded PEUU films or porous 
scaffolds, similar to what is used as a cardiac patch, to uptake the inducer and express a gene of 
interest was studied. By spatially patterning the location of RSL1 in the scaffold we aimed to 
cause cells grown on the surface of the scaffold to express the gene of interest in the 
corresponding patterned arrangement. Such a system would have the unique ability to 
independently control local cell behavior towards developing complex three dimensional tissues.  
1.7.2 Objective #2: Controlled growth factor delivery from PEUU patches 
Previous results of the application of a PEUU cardiac patch were acquired in the absence of any 
pharmacological agent in the material. It is likely that the inclusion of growth factors within the 
patch that are relevant to cardiac regeneration may be able to aid in the healing process and 
improve upon the previous results. Before future in vivo application, however, we aimed to study 
the delivery two growth factors that are relevant for cardiac repair – IGF1 and hepatocyte growth 
factor (HGF) – from PEUU patches in vitro. Due to the activity of inflammatory cells it is well 
understood that after implantation material degradation is increased compared to degradation of 
the material in saline. We first aimed to study the ability of the patch to release bioactive IGF1 
and HGF from porous PEUU scaffolds. After determining the protein delivery rates in the typical 
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saline environment, we aimed to better approximate the delivery rates of the proteins from the 
scaffolds in vivo by employing an esterase enzyme to our in vitro release media that would 
degrade the PEUU in a timeframe similar to what is seen in vivo. Characterizing the material 
during this degradation process was also studied to link the hypothesized in vivo drug delivery 
rates to the changes in material properties over time. This type of study, which encourages better 
understanding of the release behavior in the implant environment would be valuable in all 
controlled release applications.  
1.7.3 Objective #3: Controlling the drug delivery properties of an injectable gel 
We have previously shown that a thermally responsive injectable hydrogel based on N-
isopropylacrylamide can prevent cardiac remodeling and maintain cardiac function following 
injection into infarcted myocardium. As discussed above, reports suggest that concomitant 
delivery of growth factors can improve upon the benefits seen from materials alone. We 
developed a new thermoresponsive poly(NIPAAm)-based hydrogel material with stronger 
mechanical properties and slower degradation.  We aimed to determine how it can be loaded 
with model protein bovine serum albumin and how that protein is subsequently released. 
Specifically, the ability to control the delivery of this protein by modifications to the polymer 
composition or by incorporation of protein-loaded microparticles into the hydrogel was 
investigated. The ability to release two different protein populations at different rates was also 
explored in this system. This research provided a basis for moving to functional growth factor 
delivery to the myocardium.  
1.7.4 Objective #4: Characterization and in vivo application of a protein-loaded gel for 
cardiac repair 
After development of the hydrogel to release two different model proteins in a sequential 
manner, we sought to study how functional growth factors bFGF and IGF1 would be released 
from this system and if they would maintain their bioactivity upon release. The rationale was to 
provide a system wherein bFGF would be delivered primarily early after injection with IGF1 
release coming later as the microparticles degraded. Both the in vitro and in vivo release rates of 
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these proteins were investigated. The effect of intramyocardial injection of the new 
thermoresponsive hydrogel was investigated over a 16 week period. In addition to injection of 
the material alone, animals were divided into groups to receive injection of gel loaded with 
bFGF, IGF1-loaded PLGA microparticles, or both bFGF and IGF1-loaded microparticles. The 
ability of growth factors to improve upon results of unloaded gel were investigated by cardiac 
function, geometry, and histological milieu.  
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2.0  SPATIAL CONTROL OF GENE EXPRESSION BY LOCAL MOLECULE 
DELIVERY IN A PEUU DEGRADABLE SCAFFOLD 
2.1 INTRODUCTION 
(Note: This chapter was previously published as: Baraniak, P.R., D.M. Nelson, C.E. Leeson, 
A.K. Katakam, J.L. Friz, D.E. Cress, Y. Hong, J. Guan, W.R. Wagner. Spatial control of gene 
expression within a scaffold by localized inducer release. Biomaterials 2011;32(11):3062-71.) 
The inherent complexity associated with the structure of a tissue poses a major design challenge 
to engineering strategies for tissue repair and regeneration. Embryogenesis demonstrates the 
commitment of cells to multiple lineages in a well-regulated spatial and temporal manner, and 
differentiated cells must perform specific functions in synchrony to form a functional tissue or 
organ structure. Growth factor gradients and spatial patterning of gene expression not only direct 
cell differentiation, but also regulate processes such as vascularization and wound repair [158-
165]. Therefore, tissue engineered constructs capable of spatially and temporally controlling cell 
behavior may more closely mimic the natural tissue microenvironment, thereby resulting in more 
successful ex vivo development of functional tissues and in situ tissue repair and regeneration. 
Controlling the location and timing of biomolecule delivery from tissue engineering 
scaffolds has been the subject of many reports in the literature. Scaffolds have been used for the 
sustained delivery of numerous growth factors [68, 158, 166], and the spatial organization of 
growth factors on substrates has been achieved through a number of fabrication processes to 
modulate cell behavior including proliferation, differentiation, and migration in vitro [167-175]. 
In lieu of growth factor presentation, natural and synthetic polymers have also being used for 
controlled non-viral gene delivery [176-178]. Inducing cells to express a gene of interest can 
effectively alter local cell behavior and function leading to, for example, neovascularization 
following myocardial infarction or cell death in a tumor [80, 179]. Adsorption of DNA to 
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specific regions of a tissue engineered construct is also under investigation to encourage cells to 
express different genes depending on their location in the scaffold. Some of this work has been 
aimed at mimicking the organization of motor and sensory neurons in a spinal cord bridge 
following injury with promising results [180-182].  
Inducer molecules capable of regulating gene expression in specific cell populations have 
thus far proven effective in basic science and preclinical studies [183-186]. One such inducible 
gene expression system is based on a modified version of the ecdysone-responsive gene 
expression system which mimics the action of 20-hydroxyecdysone, a steroidal hormone which 
regulates genes necessary for metamorphosis in Drosophila melanogaster [187-189]. In this gene 
expression system, which uses a non-steroidal analog of 20-hydroxyecdysone as the inducer 
ligand, transcription is repressed in the absence of inducer, however, when the ligand is added to 
the system, it binds to the receptor and induces gene expression over a broad range of 
concentrations and in a dose-dependent manner. High induction potential coupled with very low 
basal expression makes this an attractive gene expression system. The use of such regulatable 
gene expression systems has many advantages relative to traditional DNA delivery approaches. 
First, because all cells used in these applications are stably transfected with the gene of interest 
prior to use, the problem of low transfection efficiency from delivering plasmid in situ is 
circumvented. Second, because the inducer molecules provide a direct method to regulate both 
the level and timing of gene expression, these systems offer the potential for greater control. 
Third, a well-designed inducer will have no effect on cells that lack the transfected plasmid, thus 
assuring a response only in the designated cells.  
The objective of this study was to combine the benefits of local controlled release with a 
gene expression system to provide spatial control of gene expression in a tissue engineered 
construct. To our knowledge, this approach has not been investigated previously, and is a 
potential step towards generating complex tissue architectures without the need for direct DNA 
delivery. To this end, the ability to achieve controlled release of an inducer ligand in an active 
form over extended periods of time was demonstrated from a biodegradable poly(urethane). 
Two-dimensional polymer films and three-dimensional porous scaffolds were fabricated with 
spatially-defined regions containing or omitting ligand. Cells stably transfected with a gene 
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under control of the inducer ligand were seeded onto biomaterials variably loaded with inducer, 
and spatial patterning of gene expression was achieved.  
2.2 MATERIALS AND METHODS  
2.2.1 Gene expression system  
 The inducible gene expression system (RheoSwitch, Intrexon Corp) was composed of an 
engineered nuclear receptor and a highly specific synthetic ligand inducer – Figure 13a. In 
Drosophila melanogaster 20-hydroxsyecdysone allows gene expression by binding to a nuclear 
receptor heterodimer consisting of an ecdysone receptor (EcR) and a retinoid X receptor (RXR). 
The RheoSwitch system uses a hybrid EcR (RheoReceptor-1, RR1), composed of the ligand 
binding domain of EcR fused to the yeast GAL4 binding domain. RR1 binds to RheoActivator 
(RA), which fuses the ligand binding domain of RXR with the activation domain of viral 
transactivator VP16. The RR1-RA bipartite holoreceptor has also been engineered to bind to the 
5X RE (contains 5 copies of the GAL4 response element) promoter and induce gene expression 
only in the presence of the non-hormonal, synthetic inducer ligand RheoSwitch Ligand 1 (RSL1, 
N-(2-ethyl-3-methoxybenzoyl)-N´-(3,5-dimethylbenzoyl)-N´-tert-butylhydrazine) (MW 382.5) – 
Figure 13b. Briefly, cells were stably transfected with both the pNEBR-R1 and pNEBR-X1 
plasmids (New England Biolabs), which constitute the RheoSwitch system. pNEBR-R1 
constitutively produces RA and RR1 under control of the ubiquitin B and ubiquitin C promoters, 
respectively. Once formed the holoreceptor regulates transcription of the gene of interest which 
was cloned into the pNEBR-X1 expression vector. For the selection and generation of stable cell 
lines pNEBR-R1 and pNEBR-X1 plasmids also provide neomycin and hygromycin resistance, 
respectively. In the absence of inducer ligand, the holoreceptor binds with negative regulatory 
cofactors to the 5X RE promoter, preventing transcription. However, when present, inducer 
tightly and selectively binds to the holoreceptor, changing the conformation of and activating the 
receptor protein so that it releases bound negative regulatory cofactors, resulting in a highly 
induced transcriptional state. The level of gene expression can be controlled by adjusting the 
concentration of inducer ligand present [189]. 
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Figure 13. Modified ecdysone-responsive gene expression (RheoSwitch) system (a) and 
chemical structure of the RSL1 inducer ligand (b). Plasmid pNEBR-R1 uses ubiquitin B 
(UbB) and ubiquitin C (UbC) promoters to constitutively express proteins RheoActivator 
(RA) and RheoReceptor-1 (RR1), respectively. RR1and RA form a bipartite holoreceptor 
that binds the 5X RE promoter sequence on plasmid pNEBR-X1, which contains the gene 
of interest (green fluorescent protein, GFP). When bound to inducer ligand RSL1, the 
holoreceptor exchanges bound negative regulatory cofactors for positive cofactors, allowing 
high transcription rates of GFP. 
 
A B16 murine melanoma cell line was obtained from Intrexon Corporation. These cells 
were stably transfected with both the pNEBR-R1 and pNEBR-X1 plasmids. pNEBR-X1 
plasmids were cloned to express a reporter gene, green fluorescent protein (GFP), in the presence 
of inducer ligand. Cells were maintained on tissue culture polystyrene (TCPS) in growth medium 
(RPMI-1640 supplemented with fetal bovine serum, gentamycin, G418 sulfate, non-essential 
amino acids, and beta-mercaptoethanol), and varying amounts of RSL1 ligand (1-5 µM final 
concentration) were added directly to growth medium in order to induce gene expression. After 
48 hrs, cells were fixed with 2% paraformaldehyde for 10 minutes, and nuclei were stained with 
Hoechst dye (1:100 in phosphate buffered saline [PBS]) or 4',6-diamidino-2-phenylindole 
(DAPI, 1:100 in PBS). Cell nuclei and GFP expression were visualized using fluorescent 
microscopy. 
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2.2.2 Polyurethane synthesis  
Poly(ester urethane) urea based on PCL diol (MW 2000, Aldrich), butane diisocyanate (BDI, 
Fluka), and putrescine (Aldrich) was synthesized in a two-step solution polymerization as 
previously reported – Figure 14. [190]. Briefly, PCL in dimethyl sulfoxide (DMSO) was stirred 
with BDI in DMSO. A catalyst, stannous octoate, (Aldrich) was added, and the reaction was 
allowed to continue at 80°C for 3 hrs. Putrescine in DMSO was then added to the pre-polymer 
solution, and the reaction was allowed to continue at room temperature for 12-18 hrs. The 
stoichiometry of the reaction was 2:1:1 BDI:PCL:putrescine. PEUU was precipitated in distilled 
water and immersed in alcohol to remove unreacted monomers. Finally, polymer was dried 
under vacuum at 50°C for 4-5 days in order to completely remove solvent. 
 
 
Figure 14. Synthesis of PEUU. Poly(caprolactone) diol reacts with 1,4 diisocyanatobutane 
to form the prepolymer. The final product is formed by chain extension of prepolymer with 
putrescine. 
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2.2.3 Preparation of RSL1-loaded PEUU films  
RSL1-loaded PEUU films were fabricated using a solvent casting method. PEUU was dissolved 
in DMSO at 80°C to obtain a 2 wt% polymer solution. Predetermined amounts of RSL1 
(reconstituted in DMSO) were added to polymer solutions (0-150 µM final ligand 
concentration), and 0.5 ml polymer solution was cast into each well of 24 well culture plates or 
glass vials for gene expression and ligand release studies, respectively. PEUU films were dried 
under vacuum at 50°C prior to the initiation of experimental protocols. 
2.2.4 RSL1 release kinetics  
RSL1-loaded PEUU films were incubated in vitro at 37°C in 1 ml release fluid (90% v/v PBS 
and 10% v/v acetonitrile) in order to determine ligand release kinetics. A solubility enhancer, in 
this case acetontrile, was required in the release fluid to encourage sink conditions for the 
hydrophobic RSL1 [140, 191]. Releasate was collected and stored at -20°C at pre-determined 
time points and was replaced with fresh release fluid. A ligand standard curve was obtained by 
adding known concentrations of RSL1 to releasate collected from polymer films that were not 
loaded with ligand and by assaying absorbance using UV spectrometry (Lambda 2, Perkin 
Elmer) at 250 nm. Absorbances at 250 nm for releasate collected from RSL1-loaded PEUU films 
(n=4) were compared to the ligand standard curve to determine the amounts of RSL1 released 
over time.  
2.2.5 Degradation of PEUU films 
Degradation of PEUU films was determined over time by measuring the intrinsic viscosity of 
polymer films dissolved in hexafluoroisopropanol (HFIP). Films were soaked in either PBS or a 
solution of 90% v/v PBS with 10% v/v acetonitrile. Degradation fluid was replaced weekly. At 
designated time points over one year, polymer films (n=3) soaked in each degradation fluid were 
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collected, dried, and dissolved in HFIP to a concentration of 1.5 mg/ml. Polymer solutions were 
put into a modified Ubbelohde viscometer (Ace Glass Inc.), and the time for solution to travel 
between markings was measured and compared to the time for pure HFIP solvent. These data 
were used to determine the intrinsic viscosity of polymer solutions using a single-point 
calculation as a representation of polymer chain degradation [192]. 
2.2.6 Bioactivity of released RSL1  
The bioactivity of released RSL1 was determined by the ability of the ligand to induce GFP 
expression in B16 cells plated on TCPS. For short-term bioactivity studies (3 week endpoint), 24 
well tissue culture plates containing PEUU films (n=4) loaded with 0-10 µM RSL1 were 
incubated in 1 ml B16 growth medium per well at 37°C. Growth medium was removed at pre-
determined time points from polymer films and transferred to B16 cells on 24 well tissue culture 
plates. For long-term (greater than 3 weeks) bioactivity studies, films (n=4) loaded with high 
RSL1 content (25, 75, 150 μM) were prepared. Releasate from polymer films was dried in a 
vacuum oven at 50°C overnight to remove acetonitrile and subsequently reconstituted in 4 ml 
B16 growth medium per sample prior to transfer to B16 cells on 24 well plates. In order to 
visualize cells and quantify gene expression, cell monolayers were fixed with 2% 
paraformaldehyde and stained with nuclear dye 48 hrs after treatment with released RSL1. Cells 
were visualized (at least 4 fields) for nuclear staining and GFP expression using fluorescent 
microscopy, and the percentage of GFP-positive cells was quantified. 
2.2.7 Gene expression on PEUU cell-seeded films 
Polymer films containing varying concentrations of RSL1 ligand (0-10 µM) were cast into 24 
well glass bottom plates (MatTek Corporation), and B16 cells (1000 cells/cm2) were plated 
directly onto PEUU films in 1 ml growth medium per well. Growth medium was exchanged 
every 3-4 days for a period of three weeks. At pre-determined time points, cells were fixed with 
2% paraformaldehyde and stained with a nuclear dye. Cells were visualized for nuclear stain and 
GFP expression using confocal fluorescent microscopy, and the percentage of GFP-positive cells 
was quantified. 
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2.2.8 Spatial control of gene expression on PEUU films 
A 2 wt% PEUU solution in DMSO was obtained as described. RSL1 ligand was added to half of 
the polymer solution to yield a 10 µM final ligand concentration. Droplets (20 µLs each) of 
PEUU with RSL1 and PEUU without RSL1 were pipetted onto glass microscope slides in a 
spatially-defined pattern and allowed to dry under vacuum at 50°C – Figure 20a. Once solvent 
was evaporated, another droplet was placed on top of the existing one. In total, five droplets of 
polymer solution (i.e. 5 x 20 µLs) were placed at each spot on each microscope slide. Various 
configurations of droplets were tested to optimize spatial control. Slides were incubated 
overnight in 10 ml PBS to remove surface-bound RSL1 and then sterilized under UV light for 20 
min. B16 cells were plated onto slides (1000 cells/cm2) and cultured in Petri dishes in 10 ml 
growth medium for up to 72 hrs with culture medium exchanged every 24 hrs. At pre-determined 
time points, slides were fixed with 2% paraformaldehyde and stained with a nuclear dye. Cells 
were visualized for nuclear stain and GFP expression using confocal fluorescent microscopy, and 
the percentage of GFP-positive cells was quantified. 
2.2.9 Fabrication of PEUU scaffolds with localized RSL1 loading 
A two-step salt-leaching processing method was used to obtain porous PEUU scaffolds. Polymer 
was dissolved in 1 ml HFIP (35% w/v PEUU) and 1000 µM RSL1, mixed with 5 g NaCl 
(particle size 75-100 µm), forming a paste-like material, and tightly packed into a small diameter 
(6 mm inner diameter) cylindrical glass mold. The newly formed scaffold was immediately 
pushed out of the glass mold and exposed to air overnight to allow solvent evaporation. The 
dried scaffold was then placed in the center of a larger cylindrical glass mold (inner diameter 13 
mm), and a polymer and salt mixture identical to that described above, but without RSL1, was 
packed around the small-diameter scaffold, creating a concentric scaffold with an RSL1-
containing core and an outer ring without RSL1. The concentric scaffold was removed from the 
mold, and solvent was again evaporated. The final scaffold was cut into disks (0.75 mm 
thickness, 13 mm diameter), and salt was leached from constructs by soaking in deionized water 
for 30 min immediately before seeding with cells. For comparison, porous scaffolds without any 
RSL1 or with RSL1 through the entire scaffold were also synthesized and seeded with B16 cells. 
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Scaffold disks were visualized using a JEOL 9335 field emission gun scanning electron 
microscope (JEOL, Peabody MA) to confirm porous structure and continuity between concentric 
scaffold regions. 
2.2.10 Spatial control of gene expression within PEUU scaffolds 
Stably transfected B16 cells were seeded onto porous PEUU disks with spatially defined RSL1 
loading in order to demonstrate the ability of the constructs to elicit spatially defined gene 
expression. Scaffolds were sterilized under UV light for 20 min, and cells were seeded onto 
scaffolds at a density of 2 x106 cells/scaffold using a filtration seeding method [193]. Cell-seeded 
scaffolds were then statically cultured in 6-well TCPS plates containing 8 mls/well B16 growth 
medium for up to 7 days with media exchanged every 3-4 days. Scaffolds were also cultured in a 
transmural perfusion system to reduce near-surface RSL1 in the fluid phase [194]. At days 3 and 
7, scaffolds were fixed with 2% paraformaldehyde, stained with nuclear dye, and mounted onto 
slides. For each scaffold (n=3), nuclear dye and GFP expression were visualized using 
fluorescent confocal microscopy, and 10 images were captured from each of the inner and outer 
regions. The percentage of cells expressing GFP was quantified for each image. One 
representative scaffold was selected to be imaged in its entirety in a mosaic fashion. 
Additionally, a Matlab computer program (Mathworks) was written to quantify the location-
dependent color intensity of the fluorescent images in order to obtain a quantitative measure of 
spatial control of gene expression. Specifically, the intensity of the green signal (GFP) was 
normalized to the intensity of the blue signal (nuclear dye) (G/B ratio) and averaged along a 4 
mm thick horizontal band across the center of the scaffold. 
2.2.11 Statistical methods 
Statistical analyses were performed by one-way ANOVA with Tukey post-hoc testing of 
differences at specific times of interest using SPSS software. Linear regression was used to 
describe the dose-dependent response of GFP expression to RSL1 loading dose in films or 
culture medium. Differences in GFP expression between inner and outer regions of concentric 
scaffolds were compared using a student’s t-test with p<0.05 considered significant.  
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2.3 RESULTS 
2.3.1 Gene expression by media manipulation  
Stably transfected B16 cells cultured in growth medium in the absence of RSL1 ligand did not 
express GFP. GFP expression, however, was evident in cells cultured in growth medium 
containing varying concentrations of ligand (1-5 uM) 48 hrs post-RSL1 administration – Figure 
15. The percentage of cells expressing GFP was 16.6 ± 4.4, 32.5 ± 3.0, 44.0 ± 15.0, and 63 ± 
7.0% for 1, 2, 3, and 5 µM RSL1, respectively (R2 = 0.981). 
 
Figure 15. Gene expression control by culture medium manipulation. At 48 hrs post-RSL1 
administration, cells in growth medium without ligand did not express GFP (a), while cells 
in growth medium containing 1, 2, 3, and 5 µM ligand (b-d, respectively) expressed GFP 
with increasing frequency in a linear fashion (f). Scale bar = 200 μm. 
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2.3.2 Sustained release of RSL1 from PEUU films 
Solvent casting of PEUU into 24 well TCPS plates yielded approximately 50 µm-thick polymer 
films. PEUU films loaded with 25, 75, or 150 µM RSL1 demonstrated a two-phase in vitro 
release profile with a small burst release of ligand accounting for less than 10% of loaded RSL1 
during the first week of incubation followed by near zero-order release kinetics over the next 10 
months. A total of 65-80% of loaded RSL1 was released after 10 months in vitro with 
approximately 1-3% of RSL1 steadily released per week regardless of the initial ligand loading 
dose – Figure 16. Degradation of PEUU films, as determined by the decrease in polymer 
viscosity over 1 year, was not different when films were soaked in PBS with 10% v/v acetonitrile 
compared to pure PBS. After just one week of soaking in each medium polymer intrinsic 
viscosity was 2.49 ± 0.03 and 2.51 ± 0.08 dL/g for films in PBS and in PBS with acetonitrile 
(p>0.1), respectively. These values decreased to 2.03 ± 0.14 and 1.91 ± 0.08 dL/g after 1 year 
(p>0.1). Additionally, RSL1 solubility in PBS/acetonitrile fluid far exceeded the total loading 
doses used in the films studied.  
 
Figure 16. Release of RSL1 from PEUU films in vitro. Films had initial loading 
concentrations of 25, 75, and 150 µM RSL1. 
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2.3.3 Bioactivity of released RSL1  
For short-term studies, cells cultured in releasate from all RSL1-loaded PEUU films expressed 
GFP 48 hrs post-treatment, while cells in releasate from PEUU films without ligand did not. 
Additionally, dose-dependent gene expression (R2=0.99) was evident in cells cultured in 
releasate collected over a three week period from polymer films containing as little as 0-5 µM 
RSL1 – Figure 17. For long-term studies, releasate collected from films loaded with high 
concentrations of RSL1 (>25 µM) was able to induce GFP expression in B16 cells for extended 
periods of time, with the duration of effective gene expression increasing with increasing RSL1 
loading concentration – Figure 18. Gene expression levels were similar between all three 
concentrations until 300 days, at which point differences in scaffold loading doses had a 
significant effect on the percentage of GFP expressing cells (p<.001 between each of the loading 
doses). By 300 days in vitro, releasate from 25 µM-loaded films appeared to lose the ability to 
effectively induce GFP expression in adherent cells, while releasate from 75 µM- and 150 µM-
loaded films maintained gene induction ability to at least 355 days, the longest timepoint studied. 
At this time, however, gene expression was reduced compared to earlier time points. 
 
Figure 17. Gene expression in cells treated with release medium from PEUU films containing 
(a) 0 µM, (b) 1 µM, (c) 2 µM, (d) 3 µM, (e) 4 µM, and (f) 5 µM RSL1. Scale bar = 500 μm. 
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Figure 18. Long-term bioactivity of released RSL1. Release fluid from films loaded with 25, 
75, or 150 μM RSL1 at designated time points was able to cause GFP expression in 
cultured B16 cells. * denotes p<.001 between each of the 3 concentrations. 
 
2.3.4 Gene expression from PEUU films  
B16 cells cultured directly on PEUU films containing 1-10 µM RSL1 expressed GFP for up to 
21 days in vitro, while cells cultured on films without ligand did not express GFP. Furthermore, 
cells cultured on films containing 0-5 µM RSL1 demonstrated dose-dependent GFP expression 
(R2=0.99) over this 3 week period, as evidenced by an increasing percentage of GFP-positive 
cells with increasing ligand loading concentration – Figure 19. While 75.2 ± 9.0% of cells on 
PEUU films loaded with 5 µM RSL1 expressed GFP, an increase in the GFP-positive cell 
fraction was not seen in cells cultured on PEUU films loaded with 7 µM (72.2 ± 7.8%) and 10 
µM (76.1 ± 8.3%) RSL1. 
2.3.5 Spatial control of gene expression on PEUU films 
All cells expressed GFP 24 hrs after being plated onto microscope slides containing distinct 
regions of polymer with and without RSL1, regardless of the configuration of PEUU droplets. At 
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48 and 72 hrs after cell seeding, however, cells in regions where polymer contained RSL1 ligand 
expressed GFP, whereas cells in regions where ligand was not added to the polymer did not 
express GFP – Figure 20b.  
 
Figure 19. Gene expression on PEUU films containing (a) 0 µM, (b) 1 µM, (c) 2 µM, (d) 3 
µM, (e) 4 µM, and (f) 5 µM RSL1. (g) Dose-dependent GFP expression is preserved when 
cells are maintained on polymer films. Scale bar = 500 μm. 
2.3.6 Spatial control of gene expression on PEUU scaffolds 
Porous scaffolds with or without RSL1 were successfully fabricated using the salt leaching 
technique. After 72 hrs of cell culture, cells were found on the surface and interior of PEUU 
scaffolds either with or without RSL1 ligand. Cells cultured in scaffolds without RSL1 did not 
express GFP, while cells cultured in scaffolds with ligand expressed GFP. Concentric porous 
scaffolds generated with an interior region containing RSL1 were successfully generated – 
Figure 21a. Electron microscopy revealed that the inner and outer regions were fused well at 
their interface (white arrows Figure 21b). Material continuity between the regions was further 
demonstrated by manual stretching of these scaffolds. The scaffold disks did not separate at the 
boundaries between inner and outer regions, but acted as a continuous material Figure 21c.  
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Figure 20. Spatial control of gene expression on PEUU films. (a) Typical slide layout for 2-
dimensional spatial control experiments. (b) Cells on all regions of slides containing PEUU 
without ligand (grey) did not express GFP (left), whereas cells on all regions of slides 
containing PEUU loaded with RSL1 (black) clearly expressed GFP (right), demonstrating 
spatial control of gene expression on 2-dimensional PEUU films. Scale bar = 500 μm 
 
Cells were evident throughout the concentric scaffolds after 72 hrs of static culture – 
Figure 22a-c. Cells in the center of the scaffold predominately expressed GFP; however, some 
GFP positive cells were evident in the non-RSL1 outer ring of the scaffold, radiating outward 
from the RSL1-containing core. The extent of high GFP expression in non-RSL1 regions varied 
by location around the scaffold core, in some areas being largely confined to the center and in 
other areas extending >1 mm away from the core. Additionally, the same level of spatial control 
over gene expression could be maintained up to seven days in static culture. The percentage of 
cells expressing GFP in the inner and outer regions of the scaffold after 3 days of culture was 87 
± 2.5% and 14 ± 2.6%, respectively (p<.001). The normalized G/B ratio of image intensity data 
across the center of the scaffold demonstrated the general localization of GFP expression to the 
middle of the scaffold, and GFP expression levels rapidly decreased the further cells were from 
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the RSL1-containing core – Figure 22d. Use of the transmural perfusion system led to fewer 
cells present on the scaffolds and markedly less GFP expression overall.  
 
Figure 21. Macroscopic and scanning electron micrograph of porous scaffold differentially 
loaded with RSL1. (a) RSL1 was added to a center core of the material whereas no RSL1 
was present in the outer ring, (b) Scanning electron micrograph of the boundary between 
RSL1-containing core and RSL1-free outer ring. White arrows delineate boundary 
between regions. (c) Mechanical stretching of the scaffold seen in (a) reveals continuity 
between concentric regions. Scale bar = 1 mm. 
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Figure 22. Spatial control of gene expression within 3D PEUU scaffolds. GFP expression 
was concentrated in the inner region of the scaffold where RSL1 inducer was present. (a) 
Blue - DAPI nuclear staining only, (b) green - GFP expression only, and (c) combined 
image showing localization of both cells and GFP expression. Dashed white circle 
represents boundary between inner and outer scaffold regions. Scale bar = 1 mm. (d) Ratio 
of green to blue (G/B) fluorescence signal with respect to location across center of scaffold, 
demonstrating spatial control of gene expression. 
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2.4 DISCUSSION 
Gene-regulating systems that utilize an inducer molecule to regulate the timing and level of gene 
expression have proven effective in various applications [183-186, 189, 195]. Not only do these 
systems eliminate the need for DNA delivery in situ, the inducer molecules are more stable than 
plasmids, lending themselves to easy incorporation into biomaterials with the potential for 
maintained bioactivity for extended release. The present study explored the potential for 
spatiotemporal regulation of gene expression through the use of a biodegradable, elastomeric 
polyurethane scaffold as a controlled-release system for the delivery of one such inducer 
molecule, RSL1.  
Biodegradable polyurethane scaffolds have been explored for a variety of soft tissue 
engineering applications including blood vessel, myocardial, cartilage, and abdominal wall 
reconstruction [43, 45, 196-200]. Linear thermoplastic elastomers are particularly advantageous 
because they can be easily blended and processed with biomolecules for controlled release 
applications [148, 201]. In the current report, scaffolds were synthesized using a salt-leaching 
technique since it provided a simple method to fabricate porous scaffolds containing RSL1 in a 
step-wise process with good continuity between neighboring regions. Further, this method did 
not require a liquid phase solvent extraction step which might allow premature release of 
incorporated ligand. 
The release characteristics of RSL1 from PEUU films were studied over an extended 
period in vitro. Release studies were performed under a solution consisting of 10% v/v 
acetonitrile to simulate sink conditions for the hydrophobic RLS1 inducer. This release medium 
also proved attractive because it did not influence polymer degradation and subsequently, release 
rates. The small burst release and subsequent linear release profile of ligand was likely due to the 
interaction of the hydrophobic RSL1 molecule with hydrophobic regions of the PEUU polymer. 
It is understood that such positive interactions between drug and carrier can influence drug 
release kinetics and has been demonstrated in other drug-delivery systems [140, 202]. 
Furthermore, the lack of porosity in PEUU films may lead to release rates slower than that which 
would be seen from porous scaffolds.  
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The diffusion of the RSL1 ligand seems to play an important role in the ability to 
spatially control gene expression. Varying the spatial patterning of droplets on microscope slides 
for 2D control had no effect on the spatially-defined gene expression. Rather, spatial control of 
gene expression in 2D films could be achieved only during the second phase of ligand release in 
static culture because the initial burst release from areas of film containing RSL1 sufficiently 
spread throughout the culture medium to cause GFP expression in cells on regions without 
RSL1. This limitation was less pronounced with three-dimensional scaffolds in static culture. 
Ligand from the center of the scaffold was not adequate to cause all cells on the scaffold to 
express GFP. However, the presence of some GFP-positive cells in the non-RSL1-containing 
region may have been due to the diffusion of the inducer molecule laterally from regions of high 
RSL1 content to regions of low RSL1 content. The functional consequence of high levels of GFP 
expression extending about 1 mm out from the scaffold core may be insignificant if larger 
scaffolds are involved. In contrast, dynamic culture of cell-seeded scaffolds, using a transmural 
perfusion system [194], did not achieve high levels of GFP expression regardless of cell location 
on the scaffold, and it is postulated that this was due to RSL1 being washed away from cells too 
rapidly (i.e. before they could take up ligand to initiate transcription). As such, while the use of 
static culture was limited in that it may have allowed RSL1 diffusion to trigger GFP expression 
in bordering non-RSL1 regions, its use led to higher GFP expression overall. Appropriate 
dynamic culture systems may be explored more fully for the potential to control molecule 
diffusion while allowing for RSL1 uptake into cells. Other material-based techniques may be 
employed to control ligand diffusion, for example forming a polymer film around the inner core 
to discourage lateral RSL1 diffusion or cell migration to the outer regions. Diffusion of ligand at 
a scaffold implant location in vivo may also vary depending on the local tissue environment. 
Areas with high mass transfer, for example on the luminal side of a blood vessel, may behave 
differently than other areas.  
It has been demonstrated that the activation of just a few genes of interest can cause both 
precursor and adult cells to differentiate to specific lineages [203-207]. While outside the scope 
of the current research, it is reasonable to postulate that if precursor cells are loaded with 
multiple genes which are under control of an inducer ligand, and which cause differentiation to a 
specific lineage, then those cells would differentiate automatically once in the location of a 
scaffold loaded with the inducer. For example, cardiac fibroblasts transfected with genes 
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GATA4, Mef2c, and Tbx5 under control of an inducer ligand may automatically reprogram to 
cardiomyocytes in the location of a scaffold containing the inducer ligand [203]. Additionally, it 
has been shown that spatiotemporal control of biochemical signals plays a role in influencing 
appropriate chondrogenesis [208, 209]. Particularly, articular cartilage has a complex three 
dimensional arrangement wherein the size and shape of chondrocytes, and the content and type 
of collagen and proteoglycans varies from the subchondral bone to the articulating surface. Using 
spatial gene expression through an inducer system may more closely generate this multifaceted 
by encouraging cellular differentiation or localized growth factor and extracellular matrix 
production.  
A similar approach may be useful in various cardiovascular applications. Blood vessels 
have a particular spatial arrangement of endothelial and smooth muscle cells, collagen, and 
elastin that is crucial to proper function. Currently, synthetic vascular grafts are being fabricated 
in a stepwise processes using thermally induced phase separation or electrospinning that could 
give distinct inner and outer layers of material that may be similar to what is seen in native 
vessels.[210] Loading each layer of the synthetic scaffold with specific inducers that could 
influence transfected cells, one could encourage growth of an endothelial layer in the inner 
region and a smooth muscle layer with high collagen production in the outer layer, for example. 
This is even more feasible when considering, in the case of electrospinning, that cells can be 
simultaneously electrosprayed during scaffold fabrication.[211] By applying both inducer-loaded 
materials and stably transfected cells, any layered geometry could be constructed with each layer 
being composed of the desired cells to respond to a desired inducer. In the realm of a cardiac 
patch, loading of channels through the patch material with inducer ligands in a geometry that 
resembles a vascular network may help to vascularize implantable scaffolds. Specifically, the 
inducer might encourage transfected cells that infiltrate the material to become the smooth 
muscle and endothelial cells necessary for blood vessels. Various molecules that are known to 
encourage cell differentiation for development of vascular networks could be employed.[212-
214] As a vascularized network would be critical in the generation of new myocardial tissue, an 
approach that guides such network development may be highly useful. The appreciation of such 
approaches is gaining momentum as shown by recent publication of research using other 
inducers, cell types, and materials.[215]  
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These types of complex architectures are found throughout the body including in the 
gastrointestinal tract, spinal column, and bone. Even more advanced scaffold systems may be 
envisioned wherein different cell types are loaded with different gene expression systems, the 
inducer ligands for which have been independently loaded into specific regions of a single 
scaffold. In this way both cell types could be cultured in the scaffold together, yet each will only 
perform a designated behavior in the location of release for their specific inducer ligand. Cells 
not in contact with their ligand would remain in their original state or subject to endogenous 
influences. Overall, such approaches may be promising for the development of a desired tissue 
type from precursor or adult cells in a three dimensional configuration which is patterned at the 
time of scaffold fabrication.  
While the in vitro data of this report demonstrate the potential for extended periods of 
controlled release of a bioactive inducer ligand, performing in vivo studies to evaluate the 
duration of the gene expression effect for extended periods is a logical next step. Polymer 
degradation will be accelerated in vivo and will be accompanied by local inflammatory 
phenomena. The inducer ligand release might be accelerated, or potentially the ligand bioactivity 
might be compromised at extended periods. Data from the in vivo administration of RSL1 does 
not suggest acute lability, however [216]. A more appropriate cell type would also likely be 
pursued for in vivo studies. B16 cells were utilized here for their ease of handling and expansion. 
Use of a cell whose functionality could be altered in a clinically relevant manner by the 
expression of a specific gene could be pursued. Furthermore, while B16 cell attachment and 
growth was qualitatively evident throughout the scaffolds and no reduction in cell numbers was 
noted over the culture period used in this study, the viability and proliferation of clinically-
relevant cell populations will need to be examined with further assessment of the therapeutic 
potential for this type of scaffold system. 
2.5 CONCLUSIONS 
A polymer scaffold system capable of spatially controlling gene expression in cells in vitro 
without local DNA delivery has been demonstrated. The biodegradable elastomeric polyurethane 
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employed released an inducer ligand over an extended period while maintaining ligand 
bioactivity. This scaffold system may ultimately provide a means to precisely control progenitor 
cell commitment in a spatially-defined manner in vivo for soft tissue repair and regeneration 
including in cardiac biomaterial therapies. 
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3.0 CONTROLLED RELEASE OF IGF1 AND HGF FROM A BIODEGRADABLE 
POLYURETHANE SCAFFOLD 
3.1 INTRODUCTION 
(Note: This chapter was previously published as: Nelson, D.M., P.R. Baraniak, Z. Ma, J. Guan, 
N.S. Mason, and W.R. Wagner. Controlled release of IGF-1 and HGF from a biodegradable 
polyurethane scaffold. Pharmaceutical Research 2011;28(6):1282-93.) 
The influence of substrate mechanical properties on cell proliferation, differentiation, and 
extracellular matrix production is increasingly appreciated.[217, 218] As such, more attention is 
being paid to the mechanical properties of candidate scaffolds for tissue engineering and 
regenerative medicine applications in an effort to improve functional outcomes. Historically, 
synthetic polymers used for cardiovascular replacement and repair have included non-degradable 
polymers such as poly(ethylene-terephthalate) and poly(tetrafluoroethylene) and tissue 
engineering approaches have frequently employed common polyesters such as poly(lactide), 
poly(glycolide), and their copolymers.[219] However, these polymers are relatively stiff and not 
mechanically similar to native cardiovascular tissue.  
Polyurethanes as a class of polymers are attractive for soft tissue applications because of 
their ability to exhibit elastic behavior generally similar to many soft tissues and to be able to do 
so through physical crosslinking. To this end, biodegradable, elastomeric polyurethanes have 
been developed using a variety of techniques to introduce lability [190, 220-222], and these 
materials have been investigated in several locations in vivo, including both vascular and 
myocardial applications.[43, 210] In the case of biomolecule delivery from polyurethane 
scaffolds, agents such as growth factors and adhesion molecules have been incorporated in order 
to enhance cellular infiltration into and survival within scaffolds and to direct the differentiation 
of endogenous and exogenous stem cell populations in situ.[201, 223-227] 
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Of particular interest for controlled release applications in myocardial tissue engineering 
is IGF1, which has been implicated in many physiological processes including tissue growth, 
protection and repair. Specifically, IGF1 has been linked to several pathways in skeletal muscle 
formation and regeneration [228] and is expressed during the early and middle stages of muscle 
repair.[229-231]. Following myocardial infarction, IGF1 has been shown to stimulate 
hypertrophy and prevent cardiomyocyte death, thereby attenuating ventricular dilation.[232] 
Another growth factor that plays both a protective and reparative role in cardiac muscle is 
HGF.[233-235] It has been shown to be antifibrotic, proangiogenic, and also recruit stem cells 
when delivered to the heart.[233, 236, 237] However, the therapeutic use of these growth factors 
is limited by their short half lives in vivo.[238, 239] Thus, the sustained delivery of IGF1 or HGF 
coupled with the attractive mechanical properties of a biodegradable, elastomeric polyurethane 
scaffold may prove more advantageous for myocardial or skeletal muscle repair and regeneration 
than the administration of growth factor or polymer matrix alone. 
The objective of the current study was to synthesize and process a biodegradable, elastomeric 
poly(ester urethane)urea material with the ability to incorporate and release bioactive IGF1 and 
HGF. Porous PEUU scaffolds were fabricated using a thermally induced phase separation 
technique, and growth factors were directly incorporated into scaffolds during preparation. The 
long-term in vitro release kinetics of IGF1 from scaffolds were investigated in PBS and in the 
presence of the enzyme lipase to simulate in vivo degradation. The bioactivity of released IGF1 
was confirmed with in vitro cell assays. HGF was also loaded into PEUU scaffolds, and while 
controlled release kinetics were not evaluated, it was also shown to maintain bioactivity upon 
release.  
3.2 MATERIALS AND METHODS 
3.2.1 Biodegradable poly(ester urethane)urea (PEUU) synthesis 
PEUU based on polycaprolactone diol (MW=2000, Aldrich), BDI (Aldrich), and putrescine 
(Aldrich) was synthesized in a two-step solution polymerization as previously reported – Figure 
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14.[190] In brief, a 15 wt% solution of PCL in DMSO was stirred with a 5 wt% solution of BDI 
in DMSO under argon gas. Stannous octoate, the catalyst, was added, and the reaction allowed to 
continue at 80°C for three hr with constant stirring. After this time, the prepolymer solution was 
removed from heat and allowed to cool to room temperature. Putrescine in DMSO was then 
added dropwise, with constant stirring, to the prepolymer solution, and the reaction allowed to 
continue at room temperature for 12-18 hr. The stoichiometry of the reaction was 2:1:1 
BDI:PCL:putrescine. The PEUU solution was precipitated in distilled water and immersed in 
isopropanol to remove unreacted monomers. Finally, the polymer was dried under vacuum at 
50°C. 
3.2.2 Fabrication of three-dimensional, growth factor-loaded PEUU scaffolds 
Three-dimensional, porous PEUU scaffolds were fabricated by a thermally induced phase 
separation (TIPS) method.[240] Following synthesis, PEUU was dissolved in DMSO at 80°C to 
make 5 or 8 wt% polymer solutions. Insoluble, cross-linked polymer was removed by 
centrifugation at 250xg, and PEUU solution was once again heated to 80°C. Hot polymer 
solution was injected into a cylindrical glass mold (inner diameter 10 mm) capped with rubber 
stoppers. The mold was immediately placed at -80°C for 3 hr. The cylinder end caps were then 
removed, and the mold was transferred to 200-proof ethanol for 3-7 days at 4°C for solvent 
extraction. Solvent extraction was considered complete once the polymer scaffold detached from 
the edges of the glass mold. Following DMSO removal, scaffolds were placed in water overnight 
to remove ethanol and reconstitute pore structure. Finally, the scaffolds were vacuum-dried for 
24 hr. Electron microscopy was used to verify porous scaffold morphology. 
To fabricate growth factor-loaded scaffolds, IGF1 and HGF (R&D Systems) were first 
reconstituted in PBS in an excess of bovine serum albumin (BSA) (1:100, wt:wt) to stabilize the 
protein. Solutions containing growth factor and BSA were then snap-frozen in liquid nitrogen 
and vacuum-dried for 48 hr. Dried proteins with salts were mixed with DMSO to make IGF1 and 
HGF stock solutions at a concentration of 25 µg/ml. Growth factor in DMSO was added to the 
polymer solution at 80°C under rapid stirring for 15 s to make protein homogenous in solution, 
after which the solution was injected into a cylindrical glass mold and immediately transferred to 
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-80°C. 125I-IGF1 was synthesized following previously published methods.[241] IGF1 and 125I-
IGF1-loaded scaffolds contained 2.5 mg of BSA and a final IGF1 concentration of 500 ng/ml in 
PEUU solution. HGF-loaded scaffolds contained 2.5 mg of BSA and a final HGF concentration 
of 250 ng/ml of PEUU solution. Scaffolds were also fabricated without growth factor, but with 
BSA.  
3.2.3 Mechanical testing of PEUU scaffolds 
Scaffolds with and without growth factor were snap frozen in liquid nitrogen and cut into 500 
µm-thick discs. In order to demonstrate similarity to scaffolds previously reported [201] , tensile 
properties were measured on an MTS TytronTM 250 MicroForce Testing Workstation (10 
mm/min crosshead speed) according to ASTM D638-98. Five samples were tested for each 
scaffold.  
3.2.4 Degradation of PEUU scaffolds 
BSA-loaded scaffold disks were weighed and then immersed in PBS with or without 2 μL lipase 
enzyme solution (Sigma Aldich, 100 units/ml final concentration) at 37°C. At specified time 
points, scaffolds (n=3) were collected, dried, and weighed. After collecting the data for each time 
point the studied scaffolds were discarded. The mass of dry scaffolds at each time point was 
compared to the starting dry mass of the sample. Release fluid was changed at regular intervals 
in order to maintain a constant pH and to keep an active concentration of enzyme present. 
Differential scanning calorimetry (DSC) of scaffold disks (n=3) at different stages of enzymatic 
degradation over 1 week, or without enzyme over 2 weeks, was completed using a Thermal 
Analyst 2000 (TA Instruments) DSC 2910 differential scanning calorimeter. Scaffold disks were 
heated from -100°C to 80°C at a heating rate of 10°C/min. 
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3.2.5 Quantification of growth factor release from PEUU scaffolds 
Release kinetics for PEUU scaffolds containing 125I-IGF1 were determined in vitro. Scaffold 
disks (750 µm thickness, 10 mm diameter) were placed in test tubes and incubated in release 
media consisting of either 2 ml PBS or 2 ml PBS + 100 U/ml lipase enzyme per well at 37°C. 
Releasate was collected at pre-determined time points and replaced with 2 ml of fresh release 
media. The calculation of pretin release at every time point was adjusted to account for the 
radioactive decay of I125 which is 59.6 days. These studies extended for up to a 440 day period. 
Growth factor release was determined by quantifying the radioactivity of the release fluid using a 
gamma counter (Auto Gamma II, Perkin Elmer).  
3.2.6 Verification of bioactivity of released growth factor 
The bioactivity of IGF1 released from scaffolds without lipase enzyme was measured by a cell 
mitogenicity assay, employing Balb/3T3 cells (a mouse embryonic fibroblast cell line, R&D 
Systems) and MG-63 cells (a human osteosarcoma cell line, R&D Systems). These cell types 
were selected due to their documented dose-dependent proliferation in response to IGF1 
treatment.[242, 243] Preliminary studies involving direct addition of IGF1 to these cells over a 
range from 0-200 ng/ml showed a maximum growth response for both cell types at 150 ng/ml 
IGF1. Thus, this concentration was used as the standard for comparison in bioactivity assays. 
The bioactivity of released HGF was measured by a cell motogenic assay, and human umbilical 
vein endothelial cells (HUVECs) were selected due to their documented motogenic response to 
HGF.[244] Scaffold disks (500 µm thickness, 10 mm diameter) with and without growth factor 
loading were placed into wells of 24 well tissue culture plates in cell basal media (Minimum 
Essential Medium (MEM) for MG-63 cells and DMEM for Balb/3T3 cells, both without fetal 
bovine serum). Basal medium from wells containing scaffolds was collected at pre-determined 
time points over three weeks, sterile-filtered, and kept frozen at -20°C until transfer to cells.  
Balb/3T3 and MG-63 cells were plated at 1 x 104 cells/cm2 in each well of 24 well TCPS 
plates in cell growth medium (MEM or DMEM supplemented with 10% fetal bovine serum and 
penicillin and streptomyocin). Prior to growth media exchange with polymer releasate (basal 
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medium), cells were treated overnight with 1 µl/ml colcemid (Sigma Aldrich) to synchronize cell 
cycle. Cells were then washed with PBS to remove traces of colcemid and fed with the 
appropriate polymer releasate. Four days following releasate treatment, cell numbers were 
indirectly quantified using a colorimetric assay for mitochondrial activity (MTT assay).[243] 
MTT results were qualitatively confirmed by visual cell inspection. Cell numbers for cells 
cultured in releasate were normalized to cells maintained in growth media. 
HUVECs were plated at 1 x 104 cells/cm2 in each well of 6 well TCPS plates in growth medium 
(Endothelial basal medium, Lonza Inc). An in vitro wound healing assay was used to confirm the 
motogenic effect of HGF on cells.[244] Briefly, once cells had grown to confluence, a cell 
scraper was used to create a wound down the center of each well of the 6 well plate. Cells were 
then washed with PBS to remove cell debris from the wound and treated with polymer releasate. 
A live-cell imaging system from Automated Cell Technology (ACT) was used to image cells at 
10 min intervals over a four day period. Cell motility was quantified in terms of cell velocity 
(using ACT software) and cell migration into the wound (using NIH ImageJ software). 
3.2.7 Statistical analyses 
Data are reported as mean ± standard deviation. All statistical analyses were performed using 
SPSS software. For cell proliferation, mass loss, and protein release studies t-tests were used for 
evaluation of differences between 2 sets of data. For cell motility studies, mechanical properties, 
and protein release data involving 3 or more data sets, data were analyzed by ANOVA with 
Tukey post-hoc testing for specific differences between various degradation solutions. 
Significance was defined as p < 0.05. 
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3.3 RESULTS 
3.3.1 Mechanical properties of PEUU scaffolds 
TIPS scaffolds fabricated without the addition of any biomolecules (BSA or growth factors) had 
tensile strengths of 0.61±0.15 MPa. Scaffolds containing BSA alone had tensile strengths of 
0.43±0.04 MPa, and scaffolds containing BSA and growth factor (IGF1 or HGF) had tensile 
strengths of 0.32±0.18 MPa (p>0.05). 
3.3.2 Degradation of PEUU Scaffolds 
Scaffolds incubated in PBS did not demonstrate significant mass loss over the time period 
studied – Figure 23. In the presence of lipase scaffold mass loss was substantially accelerated, 
with both polymer concentrations losing nearly half their mass over the first two days. With 
enzyme present 5 wt% scaffolds lost more mass over the first week compared to 8 wt% scaffolds 
with 38.9 ± 11.5% and 60.2 ± 2.5% mass remaining, respectively (p<0.05). Polymer degradation 
was nearly complete after 8 weeks. Morphologically, scaffolds maintained an organized pore 
Figure 23. The mass loss of PEUU scaffolds was determined over time for 5 and 8 wt% 
scaffolds soaked in PBS or with 100 units/ml lipase enzyme. * denotes p<0.05 between 
scaffold polymer concentrations. 
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structure, and after one week of incubation with lipase the polymer surfaces were noticeably 
broken apart – Figure 24.  
 
DSC confirmed the degradation of scaffolds in the presence of enzyme. The melting 
temperature (Tm) for original scaffolds was around 50°C for both 5 wt% and 8 wt% scaffolds – 
Figure 25 and Table II. During degradation a significantly lower second melting peak grew 
near 30°C as the primary peak weakened. By 7 days the original peak was gone in 5 wt% 
scaffolds though it continued to persist in 8 wt% scaffolds. Scaffolds in PBS did not show a 
significant change in Tm after 2 week. 
Figure 24. Electron micrographs of TIPS scaffolds (5wt% A and C, 8 wt% B and D) 
incubated in PBS (top panels) or lipase solution (bottom panels) for 1 week. Scaffolds 
maintained an organized pore structure after one week in PBS. After one week of 
incubation with lipase, scaffold surfaces were noticeably broken apart. Scale bar = 100 µm. 
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Figure 25. DSC heating curves of 5 wt % (A) and 8 wt% (B) scaffolds during degradation 
with lipase enzyme. In all situations the initial primary melting temperature near 50°C is 
lost as a new substantial peak near 30°C is formed. Scaffolds with 8 wt% PEUU maintain 
the first peak for 7 days (black arrow) suggesting a slower degradation than 5 wt% 
scaffolds which have lost that peak by 7 days. 
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Scaffold wt% Incubation Conditions
Primary 
Peak (°C)*
Secondary 
Peak (°C)*5 wt% Original 51.0 ± 1.3  - 2 days in lipase 51.3 ± 0.2 36.2 ± 2.2†7 days in lipase 34.4 ± 4.6†  - 14 days in PBS 54.1 ± 0.8  - 8 wt% Original 52.6 ± 1.3  - 2 days in lipase 53.1 ± 0.7 36.3 ± 2.4†7 days in lipase 35.3 ± 3.1† 53.8 ± 0.0214 days in PBS 54.8 ± 0.2  - *data presented as mean ± standard deviation
†p<0.05 compared to original Tm of same wt% scaffolds  
 
3.3.3 IGF1 Release from PEUU scaffolds 
Before samples were utilized in the release kinetics study, a substantial amount of IGF1 had 
already been lost from the cylindrical scaffolds during DMSO extraction in ethanol. In particular, 
8 wt% scaffolds lost 15% of loaded protein during this step compared to 50% for 5 wt% 
scaffolds. Thus, the starting mass of IGF1 in 8 wt% and 5 wt% scaffolds was 46.8 ± 7.5 and 22.5 
± 4.1 ng/scaffold, respectively. Once TIPS scaffold disks were immersed in PBS the initial burst 
release occurred over 48 hr, the extent of which was dependent on polymer concentration. 
Scaffolds with 8 wt% and 5 wt% polymer showed a burst release of 21.0 ± 1.0% and 10.3 ± 0.4 
%, respectively (p<0.001) – Figure 26A and Table III. Following the burst release, there was 
an extended period of slow, steady protein release from scaffolds, termed latent phase I, and the 
release rate in this phase was faster in 5 wt% scaffolds (0.80%/week) than 8 wt% (0.39%/week) 
scaffolds (p<0.001). Following latent phase I, a period of more rapid release occurred, labeled 
diffusion phase I, wherein 10-30% of protein was released. Observationally, the scaffolds 
showed distinct, moderate swelling at this point but maintained their shape. Upon handling, a 
qualitative reduction in modulus was noted. The initial burst, latent I, and diffusion I phases were 
followed by a second period of steady protein release (termed latent phase II) and then a second 
Table II. Melting Temperature of Polymer Scaffolds 
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stage of accelerated protein release (termed diffusion phase II) from the scaffolds. Protein release 
after this point was very low for both polymer concentrations (latent phase III). Neither scaffold 
released all incorporated protein during the study, but radioactivity measurements confirmed that 
residual incorporated protein still resided within the polymer scaffolds, both types of which 
remained in a single piece throughout the study.  
As is apparent in Figure 26A and Table III, the rate of protein release varied depending 
on the phase of the release profile and the initial polymer mass fraction. The rate of IGF1 release 
decreased for each subsequent latency phase. For example, during latent phase I in 5 wt% 
scaffolds, IGF1 released at 0.80%/week compared to 0.53%/week and 0.14%/week for the 
second and third latency periods, respectively (p<.001 between groups). The release rates in 8 
wt% scaffolds followed a similar pattern but were consistently lower than for the 5 wt% 
scaffolds during these same latent phases at 0.39, 0.35, and 0.08%/week respectively (p<.001 
between groups). The 8 wt% scaffolds consistently demonstrated longer latent periods. For 
example, the latent phase I lasted over 20 weeks compared to 10 weeks for 5 wt% scaffolds. 
Interestingly, diffusion I and diffusion II phases lasted similar amounts of time for both scaffold 
mass fractions. The diffusion I stage released more protein in 5 wt% scaffolds than 8 wt% 
scaffolds (30.3 ± 3.9% vs. 11.9 ± 2.1%, p<.001) but the diffusion II stage release was the 
opposite with less release from 5 wt% scaffolds (17.5 ± 2.9% vs. 32.6 ± 4.7%, p<.001) than the 8 
wt% counterparts.  
Scaffolds incubated with lipase enzyme released protein much faster than those without 
enzyme, with more than 90% of IGF1 being released after 9 weeks for both polymer 
concentrations – Figure 26B. The distinct release phases observed with scaffolds in PBS were 
not apparent when enzyme was present. However, a noticeable attenuation of release rate was 
demonstrated in 8 wt% scaffolds compared to 5 wt% scaffolds during specific early time points. 
Specifically, IGF1 release was slower in 8 versus 5 wt% scaffolds between days 1-2 (2.1 ± 0.8% 
vs. 7.5 ± 1.8% respectively, p<.05), days 2-4 (4.0 ± 1.6% vs. 10.4 ± 0.5%, p<.05), and days 4-7 
(7.6 ± 1.4%, vs. 13.1 ± 2.1%, p<.05).  
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Figure 26. A) Scaffolds in PBS demonstrated a tri-phasic release profile for IGF1 over the 
time period studied. Alternating periods of slow, steady protein release (latent phases) and 
more rapid release (diffusion phases) followed an initial burst release. B) Both scaffold 
types incubated with 100 units/ml lipase enzyme released IGF1 at a much faster rate than 
those without enzyme. 
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Release 
Phase
Phase Begin 
(Day)
Phase End 
(Day)
Phase 
Duration 
(Day)
Release 
Rate 
(%/week)*
Total IGF-1 
Release 
(%)*Burst 0 2 2  -- 10.3 ± 0.41Latent I 2 70 68 0.80 ± 0.04 7.8 ± 0.38Diffusion I 70 112 42  -- 30.3 ± 3.91Latent II 112 154 42 0.53 ± 0.03 3.2 ± 0.16Diffusion II 154 196 42  -- 17.5 ± 2.89Latent III 196  --  -- 0.14 ± 0.02  -- 
Release 
Phase
Phase Begin 
(Day)
Phase End 
(Day)
Phase 
Duration 
(Day)
Release 
Rate 
(%/week)*
Total IGF-1 
Release 
(%)*Burst 0 2 2  -- 21.0 ± 1.0Latent I 2 147 145 0.39 ± 0.01 8.1 ± 0.22Diffusion I 147 189 42  -- 11.9 ± 2.10Latent II 189 238 49 0.35 ± 0.02 2.4 ± 0.15Diffusion II 238 284 46  -- 32.6 ± 4.71Latent III 284  --  -- 0.08 ± 0.01  -- *data presented as mean ± standard deviation
8 wt% Scaffolds
5 wt% PEUU Scaffolds
 
 
3.3.4 Bioactivity of released IGF1 and HGF 
MG-63 and Balb/3T3 cells treated with releasate from IGF1 containing scaffolds collected 
between days 0-7 and days 7-14 exhibited a significant increase in proliferation compared to 
those treated with degradation solutions from scaffolds without growth factor (p<0.05) – Figure 
27. Cellular proliferation was comparable to that for cells treated with 150 ng/ml IGF1. 
Specifically, cells treated with day 0-7 releasate from scaffolds containing IGF1 exhibited a 2.0-
fold (MG-63) and 2.1-fold (Balb/3T3) increase in cell number compared to cells treated with 
releasate from scaffolds without growth factor. Cells treated with day 7-14 releasate from 
scaffolds containing IGF1 exhibited a 1.6-fold (MG-63) and 1.7-fold (Balb/3T3) increase over 
Table III. IGF1 Release Kinetics 
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cells in releasate from scaffolds without growth factor. No significant difference in cell 
proliferation was seen between cells treated with releasate collected between days 14-21 from 
either set of scaffolds. For HGF, following treatment with the day 0-7 and day 14-21 polymer 
releasate from scaffolds containing HGF, endothelial cells grew into and repopulated the wound 
area more extensively than those maintained in growth medium or in releasate from scaffolds 
without growth factor (p<0.05) – Figure 28. Day 7-14 releasate was not collected to evaluate. 
 
Figure 27. MG-63 (A) and Balb/3T3 (B) cells cultured in releasate from polymer containing 
IGF1 showed greater cell metabolic activity (as an index of cell number) compared to cells 
cultured in releasate from polymer without growth factor (*p<0.05). IGF1 added at 150 
ng/ml to releasate from polymer without growth factor served as a positive control. 
3.4 DISCUSSION 
The release profiles of drugs from biodegradable elastomers vary widely depending on material 
composition and processing. Biodegradable thermoset elastomers based on ε-caprolactone and 
D,L-lactide have been processed with solid drug particles to form an osmotically-driven drug 
delivery device that delivers drug in a zero-order fashion.[139, 245, 246] The release rates in this 
system can be altered by changing the molecular weight of the prepolymer or the amount of 
excipient included with the drug. In another report ascorbic acid was incorporated into the 
backbone of a thermoplastic polyurethane and released only after hydrolysis of ester bonds.[227] 
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This led to a slow release rate initially which increased substantially over time in a way that 
corresponded with bulk polymer degradation. Many other biodegradable elastomers release 
molecules in a diffusion-controlled manner characterized by high initial release rates that quickly 
taper off.[142, 224, 247] One such group, a family of injectable biodegradable polyurethanes, 
has been of particular interest due to their ability to crosslink in situ to form porous polymer 
scaffolds in a way that does not substantially decrease the bioactivity of incorporated drugs. 
These systems generally show a high initial release that plateaus after a few days with 50-90% of 
drug being released depending on the drug loading mechanism and type of drug being 
delivered.[223, 248] Despite the fact that some members of this family are relatively slowly 
degrading (~30% mass loss over 36 weeks), release studies do not extend beyond a few weeks. 
This prevents understanding the mechanisms involved over time in a slow-degrading 
polyurethane and how the remaining 10-50% of protein is released from the system. In studying 
the long-term release kinetics of protein from PEUU, as has been done here, more insight may be 
gained toward developing extended release approaches for polyurethane systems.  
Figure 28. HUVECs maintained in releasate from scaffolds containing HGF grew into 
and repopulated the artificial wound area more extensively than those maintained in 
growth medium or in releasate from scaffolds without growth factor (*p<0.05). HGF 
added at 100 ng/ml to releasate from polymer without growth factor served as a positive 
control. 
80 
 
IGF1 release from this biodegradable porous scaffold system demonstrated a multi-phasic 
release profile. There are a number of drug delivery systems that follow a biphasic drug release 
profile characterized by two separate stages of quick drug release separated by a latency 
phase.[138, 140, 249] The first phase of quick drug delivery occurs as drug is released that is 
either close to the surface or can easily diffuse out of the bulk of the material. Following this, 
delivery is slow in the latency phase until material degradation becomes adequate to loosen the 
scaffold and allow trapped drug to quickly diffuse out. The current report demonstrates a release 
profile wherein there are three distinct occurrences of rapid, diffusion-controlled release. 
Importantly, because the quantitative studies of IGF1 release used radiolabeled protein, the 
release kinetics observed may be different from what actually occurs when non-labeled IGF1 is 
released, as in the case of the bioactivity studies. As the scaffolds for both studies were made 
with identical protocols and loading concentrations, the protein released at each stage would 
likely be similar. However, variation may arise due to potential differences between IGF1 and 
125I-IGF1 and processing variability. 
While the exact mechanisms of the complex release mechanism are not clear and warrant 
further investigation, it is likely that the phase segregated nature of PEUU plays a role. First, 
both hard and soft segments may act independently in relation to degradation and drug release. 
Additionally, PCL is known to contribute significant crystallinity to polyurethanes, the gradual 
breakdown of which can be delayed even in the presence of enzyme.[220, 250] It is possible that 
degradation follows a multi-step process where amorphous soft segment, crystalline soft 
segment, and hard-segment degradation occur separately with each stage influencing drug 
delivery. This hypothesis is supported by the DSC data which show a change in Tm during 
degradation. The transition from a Tm near 50°C to one near 30°C in the presence of lipase 
shows that the crystal structure of the polymer is being altered, particularly to a Tm below body 
temperature. In the case of the lower Tm, crystal structures would largely be melted above 37°C 
which could loosen the polymer network and allow more protein to be released. It may be that 
one of the diffusion phases seen for protein release from scaffolds in PBS is the result of a 
transition from the higher Tm to the lower one. Additionally, the delayed loss of the initial 
melting peak for 8 wt% scaffolds agrees well with the slower mass loss and slower protein 
release that was demonstrated during enzymatic degradation of 8 wt% scaffolds compared to 5 
wt%. 
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The differences in protein release between 5 wt% and 8 wt% scaffolds illustrate the 
influence that polymer mass fraction had on drug release. First, 5 wt% scaffolds lost more 
protein in the solvent extraction step of scaffold processing, meaning these scaffolds had a lower 
loading efficiency. Second, the delivery rates of protein from 5 wt% scaffolds were consistently 
higher and occurred at earlier time points than for 8 wt% scaffolds. This phenomenon may be 
attributed to the smaller mass fraction of PEUU in the 5 wt% scaffold disks, which led to more 
free volume for molecular diffusion out of the scaffold and less material that required 
degradation. Both polymer mass fractions, however, exhibited slower release rates for IGF1 than 
had been shown previously when bFGF was released from similar scaffolds.[201] The reason for 
this difference is not clear but may be related to differences in the affinity of IGF1 and bFGF to 
the polymer or the slower polymer degradation that was present here compared to the previous 
study. While no significant mass loss was seen in the scaffolds in PBS over the time period 
studied, in the presence of enzyme, scaffolds with 8 wt% polymer had attenuated mass loss, 
particularly in the first week compared to those with 5 wt% polymer. This difference in 
enzymatic degradation between 5 and 8 wt% scaffolds was noticeable in the release profiles 
where the rate of IGF1 release was significantly lower between days 1 and 7 for the 8 wt% 
scaffolds.  
The biodegradation of polyurethanes is a complex process that has received significant 
attention in recent decades.[251] Hydrolytically labile bonds in the soft segment provide the 
most common mechanism of degradation. It has been shown that both oxidative and enzymatic 
processes encouraged by inflammatory cells may speed polymer breakdown in vivo.[252, 253] 
Two common esterase enzymes produced by macrophages that have been utilized in vitro to 
simulate in vivo soft-segment biodegradation mechanisms are cholesterol esterase and 
lipase.[149, 250, 252-254] The ability of cells and enzymes to degrade polyurethanes is 
dependent on many factors including hard and soft segment chemical composition, size, surface 
morphology and mechanical environment.[253, 255-257] These studies illustrate that numerous 
complex processes are involved in biomaterial degradation, which cannot be fully replicated in 
vitro.   
The enzyme concentration in this report was chosen for its ability to provide a 
degradation rate that corresponded to scaffold break down over approximately 8 weeks, similar 
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to what is histologically observed in vivo when a similar scaffold disk was implanted as a cardiac 
patch.[43] The release profile exhibited when scaffolds were incubated with lipase demonstrated 
that for in vivo environments where material degradation was accelerated, release rates were 
markedly different than in the PBS environments often used for in vitro controlled release 
studies. The rapid rate of polymer degradation in the presence of enzyme made for protein 
release kinetics that appeared more like the simple diffusion controlled systems discussed earlier, 
which was substantially different from the multiple phasic release profile seen in the PBS. 
Therefore, these data emphasize that researchers should consider the working environment when 
characterizing controlled release from biodegradable matrices, a practice not regularly seen in 
the literature.  
Linear thermoplastic elastomers have an advantage over thermoset elastomers in that 
drugs can be readily incorporated during processing and in a way that does not risk drug 
inactivation during polymer crosslinking. In the current research, protein bioactivity was studied 
over the first three weeks of drug delivery. It is unclear if the loss of measurable cellular 
response to IGF1 between day 14-21 was from a loss of bioactivity or simply due to the low 
protein release during that time period as seen in the release profile. The latter case would 
suggest that released protein was of insufficient concentration to influence cell behavior in the 
assay used, which might be corrected with a higher initial loading dose of protein. Additionally, 
it has been shown that growth factors incorporated into thermoset degradable elastomers can 
maintain bioactivity over at least 3 weeks [245], suggesting that longer-term maintenance of 
bioactivity is feasible.  
One limitation of the current research deals with understanding the maintenance of 
protein bioactivity during scaffold processing and throughout the release duration. To determine 
changes in bioactivity the amount of protein released from a scaffold needs to be quantified and 
then the functionality of that protein would be tested. However, in this report two distinct 
experiments were employed to study IGF1 release – quantitative release kinetics using 
radiolabeled protein and bioactivity of non-labeled released protein. Both were needed due to an 
inability to quantify non-labeled IGF1 using enzyme-linked immunosorbent assays (ELISA) and 
other spectrophotometric techniques. The inability to detect both IGF1 and HGF protein with 
these techniques may be related to the presence of polymer degradation products or 
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conformational changes to the protein which would prevent binding of the monoclonal antibody 
in the ELISA sandwich assay. In particular, the TIPS processing involved mixing protein in 
organic solvent and brief exposure to high temperatures – both factors that could damage the 
loaded protein. In order to preserve bioactivity, BSA was added in excess to protect the protein 
of interest as has been done previously.[157] Importantly, in spite of any presumed destruction of 
protein or changes to protein binding in the ELISA, enough protein remained bioactive over the 
three week studied to elicit the expected results on cell behavior in vitro. 
One basis of controlled release formulations is that while proteins generally have a short 
half-life in vivo, their sequestration in a polymeric scaffold can act to protect them in vivo to 
prevent rapid degradation. An important finding in this research is that maintaining protein 
bioactivity for long durations as would be necessary for in vitro release studies may be irrelevant 
given the much faster release seen in conditions that mimic the in vivo environment. In the 
experiments using lipase, protein delivery was nearly complete after only 9 week compared to 
nearly 15 months for studies without lipase.  
The ideal duration of IGF1 delivery that would be desired is dependent on the drug 
delivery application. For example, in the case of cardiac ischemia, rapid delivery of IGF1 in the 
days following injury has been shown to rescue injured myocardium.[133] However, in the case 
of slowly-progressing, chronic degenerative diseases such as inherited cerebellar ataxia [258] or 
diabetes [259], therapeutic options to treat severely debilitating symptoms are currently limited 
by the short in vivo life-span of peptide molecules and the need to administer drugs to patients 
on a daily basis. In such cases, controlled-release formulations leading to sustained 
improvements in patient symptoms and/or disease conditions allows for more convenient dosage 
and increased compliance with treatment. 
Scaffold processing was also noteworthy for its role in determining protein loading 
efficiency in PEUU scaffolds. The final step of scaffold synthesis using TIPS involved DMSO 
solvent extraction. This step required 3-7 days of soaking in ethanol during which time a 
substantial amount of protein was lost to the solvent. While this method was necessary to create 
the mechanically robust, porous scaffolds studied here, other techniques such as salt-leaching 
may be considered which do not have a lengthy liquid-phase solvent extraction step. The short 
duration required to remove salts from thin scaffold disks in water (<20 minutes) may lead to 
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less protein loss in solution initially, even in spite of the higher solubility of protein in water 
compared to ethanol. Regardless of processing technique it is important to have a uniform 
distribution of protein throughout the scaffold. In this report disks cut from locations throughout 
the initial cylindrical scaffold were used in the release experiments. The narrow standard 
deviation in the protein release kinetics among all disks suggests a homogeneous distribution of 
protein throughout the cylindrical scaffolds. 
Tissue engineering often seeks to combine appropriate scaffolding materials with important 
signaling molecules to encourage healthy tissue regeneration. It has been demonstrated that the 
controlled delivery of IGF1 and HGF from biomaterials in the context of ischemic myocardium 
has been influential in cardiac repair.[133, 260] These studies, however, utilize biomaterials that 
provide minimal mechanical support in a setting where such support may be advantageous. A 
mechanically robust, elastomeric scaffold similar to the one studied here was able to prevent 
further cardiac deterioration after its application as a surface patch following myocardial 
infarction.[43] Combining the benefit of this temporary mechanical support system with growth 
factor delivery might act to abrogate disease progression and encourage functional tissue repair 
in injured myocardium more effectively than either system independently. 
3.5 CONCLUSIONS 
A biodegradable elastomeric PEUU scaffold system was characterized for its ability to be loaded 
with and deliver growth factors (IGF1 and HGF) of clinical relevance. Cellular assays confirmed 
that the bioactivity of IGF1 and HGF was maintained during scaffold processing and for at least 
the early period of drug delivery. The kinetics of IGF1 release over a period up to 440 days 
demonstrated a complex triphasic profile. Much of this complexity was lost and replaced by a 
single phase release profile when enzyme was present to simulate in vivo scaffold degradation. 
The ease of processing associated with this thermoplastic biodegradable elastomer for both 
scaffold formation and drug loading makes this material an attractive option for soft tissue 
applications where both drug delivery and appropriate mechanical support are desired. 
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4.0 EXTENDED AND SEQUENTIAL DELIVERY OF PROTEIN FROM INJECTABLE 
THERMORESPONSIVE HYDROGELS 
4.1 INTRODUCTION 
(Note: This chapter was previously published as: Nelson, D.M., Z. Ma, C.E. Leeson, and W.R. 
Wagner. Extended and sequential delivery of protein from injectable thermoresponsive 
hydrogels. Journal of Biomedical Materials Research Part A 2012;100A(3):776-785.) 
The unique versatility of injectable biomaterials has led to their use in many biomedical 
applications including tissue engineering and drug delivery.[261, 262] One primary advantage of 
this class of materials is that material injection may avoid the morbidity associated with the large 
incisions required for implantation of a pre-formed material.[263] N-isopropylacrylamide 
(NIPAAm) has been incorporated into many biomaterials due to its favorable sol-gel 
behavior.[115, 121, 124, 125, 264-266] Below its lower critical solution temperature (LCST) of 
32°C, an aqueous solution of polyNIPAAm is liquid and can be injected through a small 
diameter needle. Upon reaching body temperature the polymer solution undergoes a sol-gel 
transition, thus forming a hydrogel in situ. Important functional properties such as mechanical 
strength, biodegradability, and cellular responsiveness have been imparted to NIPAAm-based 
injectable materials by copolymerization with specific monomers and peptides.[124, 125, 265-
268] These materials have been developed for many potential applications including cartilage, 
bone, spinal cord and cardiac repair, as well as for drug delivery. [123, 125, 126, 264, 269-271] 
Growth factor delivery has become an important tool in tissue engineering.[272] The 
delivery method is particularly important given that bolus solution injection leads to rapid 
removal of the growth factor from the injection site and extended periods of bioactivity over the 
tissue remodeling period in situ are desirable.[136] Hydrogels and microparticles are two 
delivery vehicles that have been widely studied for controlled drug release.[273, 274] Combining 
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both systems is a promising method under recent investigation to gain greater control over 
protein delivery rates. For example, it has been shown that putting drug-loaded microparticulates 
inside a hydrogel network can influence the rate of drug delivery from the 
microparticulates.[275-279] Additionally, combining microparticles of different compositions, 
where each particle type is loaded with a different growth factor, in the same hydrogel network is 
one way to allow for delivery of multiple drugs at rates independent of each other.[280] A 
variation on this theme, wherein one growth factor is loaded into microparticles that are inside 
the gel while another growth factor is dispersed in the gel phase, provides another means of 
controlling delivery rates.[280, 281] The value in delivering multiple versus individual growth 
factors on tissue response has been demonstrated in angiogenesis and bone growth.[64, 282] 
Further, independently controlling the rate at which each protein is delivered may allow for 
sequential delivery of factors, which has also been shown to be beneficial in some settings.[68, 
283, 284] In angiogenesis new blood vessels must sprout and then mature with appropriate 
cellular components. This process may be achieved by sequential delivery of biomolecules such 
as vascular endothelial growth factor followed by either platelet-derived growth factor or 
sphingosine 1-phosphate.[68, 136, 284] Simultaneous delivery of these protein combinations 
does not elicit the same level of regeneration.  
The objective of this study was to develop a thermoresponsive, biodegradable hydrogel 
system that would be capable of protein release from two distinct reservoirs – one where protein 
was attached to the hydrogel backbone, and one where protein was loaded into biodegradable 
polyester microparticles mixed into the hydrogel. A recently developed biodegradable and 
injectable NIPAAm-based biomaterial[265] was modified to allow direct protein conjugation. 
Poly(lactide-co-glycolide) microparticles generated by double emulsion processing were utilized 
to form the microparticulate protein carriers. The model protein bovine serum albumin (BSA) 
was delivered for extended periods from the modified thermoresponsive hydrogels, and distinct 
populations of labeled BSA were delivered from modified hydrogels embedded with 
microparticles to demonstrate sequential protein release. In addition, the effects of modifying the 
hydrogel to enable controlled release were examined in terms of thermoresponsive behavior. 
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4.2 MATERIALS AND METHODS 
4.2.1 Materials 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. NIPAAm was 
purified by recrystallization from hexane and vacuum-dried. HEMA was purified by vacuum 
distillation. Lactide was purified by recrystallization from ethyl acetate. Benzoyl peroxide 
(BPO), polylactide-co-glycolide (PLGA), sodium methoxide (NaOCH3), poly(vinyl alcohol) 
(PVA), acrylic acid (AAc), N-hydroxysuccinimide (NHS) and methacryloyl chloride were used 
as received. Iodinated bovine serum albumin (125I-BSA) (Perkin-Elmer) and fluorescein 
isothiocyanate or Texas Red labeled BSA (FITC-BSA and TexR-BSA, Molecular Probes) were 
used as received.  
4.2.2 Material synthesis 
4.2.2.1 Synthesis of methacryloxy N-hydroxysuccinimide (MANHS)  
MANHS was synthesized by dropping 20 g methacryloyl chloride into a solution of NHS (20 g) 
and triethylamine (22 g) in 350 ml dichloromethane under stirring at 0°C followed by reaction 
overnight at room temperature. After a filtration process to remove the precipitate, the solution 
was washed with water 3 times and the organic phase collected by centrifugation and dried over 
anhydrous MgSO4. Dichloromethane solvent was removed by rotary evaporation and the solid 
product was purified by flash chromatography to obtain a white solid, with a yield of 85%. 
Synthesis was verified by 1H NMR spectrum (in CDCl3): CH2=(6.43ppm, 1H, s), CH2=( 
5.90ppm, 1H,s) , -NCOCH2CH2CON-(2.88pm, 4H,s), -CH3(2.08ppm, 3H,s).  
4.2.2.2 Synthesis of methacrylate polylactide (MAPLA) 
MAPLA was synthesized as reported previously – Figure 29.[265] Polylactide-monomethyl 
ether (HOPLA-OCH3) was synthesized by ring opening polymerization by dissolving lactide in 
dichloromethane to which NaOCH3 initiator in methanol was added. After 2 h of reaction at 0°C, 
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the polymer solution was rinsed with 0.1 M HCl and deionized water, the organic phase was 
dried with MgSO4 and removed by rotary evaporation. MAPLA was formed by dropping 
methacryloyl chloride in an HOPLA-OCH3 solution in dichloromethane containing 
triethylamine, followed by reaction overnight at 0°C. Following reaction, precipitates were 
removed, the organic phase was dried and removed by rotary evaporation, leaving raw MAPLA 
product. MAPLA was purified by flash chromatography. NMR confirmed the synthesis of 
MAPLA with an average of 2.8 PLA units per MAPLA monomer. 
 
Figure 29. Synthesis scheme for methacrylate polylactide (MAPLA) 
 
4.2.2.3 Synthesis of poly(NIPAAm-co-HEMA-co-MAPLA)  
Poly(NIPAAm-co-HEMA-co-MAPLA) copolymers with or without MANHS were synthesized 
by free radical polymerization – Figure 30. Monomers, NIPAAm (6 g, 0.053 mol), HEMA, and 
MAPLA at a molar ratio of 80/10/10 were dissolved in 200 ml of 1,4-dioxane containing 160 mg 
BPO. The polymerization was carried out at 70°C for 24 h under argon atmosphere. The 
copolymer was precipitated in hexane and further purified by precipitation from tetrahydrofuran 
(THF) into diethyl ether and vacuum-dried. For inclusion of MANHS the molar feed ratio for 
NIPAAm, HEMA, MAPLA, and MANHS was 80/9/10/1, respectively. An additional copolymer 
was synthesized that incorporated 1 mol% AAc as a means to increase the degradation rate of the 
copolymer. The molar feed ratio for this copolymer was 80/8/10/1/1 
NIPAAm/HEMA/MAPLA/MANHS/AAc.  
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Figure 30. Synthesis scheme for a thermally responsive copolymer containing protein-
reactive MANHS. 
 
4.2.2.4 Synthesis of PLGA microspheres 
PLGA microspheres with a lactide:glycolide ratio of 75:25 (Mw 66-107 kD) were synthesized 
using a water-in-oil-in-water (W/O/W) double emulsion technique.[277] FITC-BSA or 125I-BSA 
was mixed with unlabeled BSA at a ratio of 1:10 and dissolved in 0.02x PBS to make a final 
total BSA concentration of 1 mg/ml . Initially, 200 mg of PLGA was dissolved in 4 ml 
dichloromethane. After all PLGA was dissolved, 200 µL of BSA solution was added to the 
dissolved PLGA and vortexed for 1 min. This primary emulsion was immediately added to 60 ml 
of 2% PVA that was stirring at 1000 rpm, to generate the W/O/W emulsion. After 5 min, the 
stirring speed was reduced to 600 rpm and an additional 80 ml of 1% PVA solution was added. 
After stirring for 6 h to allow dichloromethane evaporation, the microspheres were collected by 
centrifugation, rinsed with DI water and freeze-dried.  
4.2.3 Copolymer characterization 
Copolymer molecular weight was determined by gel permeation chromatography (Waters Breeze 
System). The copolymers were dissolved in tetrahydrofuran at 1 mg/ml and elution time was 
used to determine molecular weight by comparison to a poly(methyl methacrylate) standard. 
LCST values were determined by measuring the optical density of the material at 500 nm 
wavelength over a temperature range from 2 to 24°C. The LCST of the 80/9/10/1 copolymer 
without protein, with low protein content (BSA at 0.2 wt% of polymer), high protein content (20 
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wt%), and with microspheres (10 wt%) was determined (n=4 each group). The temperature at 
which the absorbance reached half of its maximum value was taken as the LCST, and was 
determined using a custom Matlab (MathWorks) program.  
Hydrogel degradation was studied by quantifying the mass loss of samples at 37°C in 
PBS over time. PBS was changed frequently to maintain a constant pH throughout degradation. 
Samples (n=3 each) were collected at specific time points and lyophilized. The mass remaining 
in each sample was compared against the initial dry mass to determine percent mass loss. 
Hydrogel and microsphere morphology was viewed with scanning electron microscopy. 
The change in mechanical properties of the hydrogels during sol-gel transition was characterized 
on a TA instrument rheometer (AR2000). Solutions of the 80/9/10/1 copolymer(16.7 wt % in 
PBS), with or without the inclusion of PLGA microparticles (10 wt%), were placed between two 
parallel plates and a temperature sweep from 5 to 35 °C (heating rate of 4 °C/min) was applied. 
The shear storage modulus G’ and the loss modulus G’’ were recorded as a function of 
temperature at a fixed strain of 2% and a frequency of 1 Hz. 
4.2.4 In vitro protein release studies 
4.2.4.1 Protein release from hydrogels 
Copolymer was dissolved in PBS at 4°C at a concentration of 16.7 wt% and loaded with protein 
at a concentration of 100 µg/ml. For the 80/9/10/1 copolymer, protein was present in the PBS to 
be available to react with MANHS groups as the polymer dissolved – Figure 31A. For the 
80/10/10 copolymer, protein was added to the solution after dissolving polymer. Gelation 
occurred by injecting 0.5 ml polymer solution into 1 ml of 37°C PBS. Samples (n≥4 for each gel 
type) were maintained in a water bath at 37°C and releasate was collected and replaced with 
fresh PBS at desired time points. 125I-BSA was used for these release studies and the amount of 
protein released was determined by a gamma counter (Auto Gamma II, Perkin Elmer). 
91 
 
 
Figure 31. Approaches to protein loading in thermally responsive hydrogels. A) Protein is 
mixed with reactive copolymer to form protein-polymer conjugates in solution before 
hydrogel formation. B) Protein-loaded microspheres are mixed with copolymer solution 
before heating. C) Combination of (A) and (B) where one protein population is reacted 
with the copolymer in solution to form protein-polymer conjugates followed by mixing with 
microparticles loaded with a second protein population prior to thermally induced gel 
formation.  
4.2.4.2 Stability of protein linkage to hydrogels 
To determine the stability of the protein-polymer linkage, hydrogels with and without MANHS 
were loaded with 125I-BSA and thermally cycled. Hydrogel solutions (n=4) were gelled at 37 °C 
for 3 h, released protein was collected, and gels were redissolved at 16.7 wt% at 4 °C. This 
process was repeated five times and released protein was measured after each cycle.  
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4.2.4.3 Protein release from microspheres 
For studies involving PLGA microspheres, microspheres were either free in PBS or were 
contained within the hydrogel network –Figure 31B. For inclusion inside the gel, microspheres 
were added to aqueous polymer solutions and mixed for 30 min until homogeneous, at which 
point the solution was heated to form the gel. For these studies 125I-BSA was encapsulated in the 
microspheres and release quantified by a gamma counter (n=4 for each group).  
4.2.4.4 Conformational stability of released protein  
The conformation of the released protein was assessed by circular dichroism (CD) spectroscopy 
as previously reported.[285, 286] FITC-BSA released from hydrogels without MANHS was 
collected after 3 h of gelation and concentrated using a centrifuge filter (Millipore) with a 50 kD 
molecular weight cutoff to remove interfering soluble polymer chains. FITC-BSA encapsulated 
in PLGA microparticles was collected using a method described previously.[285] Specifically, 
protein-loaded PLGA microparticles (75 mg) were dissolved in 1 ml dichloromethane to which 4 
ml of deionized water was added. The solution was sonicated for 90 min at 25 °C and 
centrifuged at 2000 x g for 10 min. The aqueous phase was decanted and the BSA was 
concentrated in a centrifuge filter. All protein solutions were measured using a Jasco J-810 
spectropolarimeter, and compared against stock FITC-BSA.  
4.2.4.5 Dual protein release from microspheres inside hydrogel 
Release of two distinct protein populations, FITC-BSA and TexR-BSA, was studied. TexR-BSA 
was allowed to react with the 80/9/10/1 copolymer in PBS to form a protein-polymer conjugate 
followed by addition of microspheres encapsulating FITC-BSA to the polymer solution. After 
mixing until microspheres were homogeneous, the solution (n=4) was heated to 37°C for 
gelation to occur – Figure 31C. Protein concentration in the releasate from the hydrogel was 
measured by a fluorescence microplate reader (SpectraMax M2, Molecular Devices) with 
excitation/emission wavelengths of 495/520 nm and 594/615 nm for FITC-BSA and TexR-BSA, 
respectively. In all experiments measured levels of radioactivity or fluorescence were compared 
against standard curves to determine concentration.  
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4.2.5 Statistics 
Protein release rates during specific phases in the release profile were compared between 
polymer types using unpaired t-tests. Where three or more groups were being compared, one-
way ANOVA was used. To determine differences between hydrogel compositions during 
thermal cycling two-way ANOVA was applied. Tukey’s post hoc test was used in conjunction 
with each ANOVA. Statistical significance was defined as p<0.05.  
4.3 RESULTS 
4.3.1 Characterization of thermoresponsive copolymers 
Thermoresponsive hydrogels were successfully synthesized with yields >75%. The 80/10/10 
copolymer had a Mn of 22K with a polydispersity index (PDI) of 1.6. The Mn and PDI of the 
80/9/10/1 copolymer was 26K and 1.5, respectively. All copolymers were able to form bulk gels 
upon heating to 37°C. Representative thermal transition profiles are shown in Figure 32 with 
quantification of the LCST values in Table IV. Although altering the LCST as much as 5°C, the 
presence of protein or PLGA microspheres did not interfere with the polymer’s ability to form a 
gel below body temperature. The presence of microparticles increased the turbidity of the 
polymer solution leading to a smaller relative change in optical density upon heating, but the 
final gel appeared similar to those without microparticles. Likewise, the addition of 
microparticles did not have an effect on the mechanical properties of the hydrogel above or 
below the LCST. The maximum of the shear storage and loss moduli for the hydrogel without 
microparticles was 10290 Pa and 21940 Pa, respectively. Similarly, the maxima of these same 
parameters for the hydrogel with microparticles was 10720 Pa and 22620 Pa, respectively – 
Figure 33. 
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Figure 32. Representative optical absorption curves of hydrogel solutions with various 
protein and microparticle additives as solutions are heated. 
 
 
Table IV. LCST of Hydrogels 
Hydrogel Additive
Transition 
Temperature 
(°C ± SD)
80/9/10/1 None 11.0 ± 0.1
0.2 wt% BSA 10.5 ± 0.1
20 wt% BSA 5.4 ± 0.3
10 wt% PLGA microspheres 9.2 ± 0.6
80/10/10 none 12.4 ± 0.4  
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Figure 33. Shear mechanical properties during heating of the 80/9/10/1 hydrogel with or 
without the inclusion of microparticles in the gel network. The presence of microparticles 
did not alter the mechanical properties of the hydrogel. 
 
The degradation of the copolymer, which occurs as hydrolysable MAPLA side chains are 
cleaved leaving a more hydrophilic polymer chain that becomes soluble at 37°C, is complete 
after approximately 4 to 6 months. The inclusion of 1 mol% MANHS increased the degradation 
rate of the copolymer as shown in Figure 34. However, the degradation profile remained similar 
to the 80/10/10 copolymer wherein mass loss was slow in the first few months of gel formation 
followed by a rapid loss of mass as MAPLA side chains were cleaved to increase hydrophilicity 
and allow solubilization at 37°C.[265] 
4.3.2 Protein release from hydrogels 
The BSA release profile for 80/10/10 (no MANHS, protein mixed), 80/9/10/1 (1% MANHS, 
protein reactive), and 80/8/10/1/1 (1% MANHS and 1% AAc, protein reactive) copolymers are 
shown together in Figure 35. For ease of comparison, release profiles were separated into 
distinct phases and rates were quantified using previously reported methods – Table V.[280] The 
loading efficiency was here defined as the amount of protein remaining after the 3 h necessary 
for the complete stabilization of hydrogel size and water content.[265] Protein release was 
relatively quick during the burst release phase from 3 to 24 h. Following the burst there was a 
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period of continued high diffusion rates (phase I, days 1 to 7) followed by slower release (phase 
II, weeks 1 to 6). Hydrogel degradation became more prominent as time progressed leading to 
higher release rates in phase III (week 6 until 98% of protein was released).  
 
 
Figure 34. Mass loss curves for hydrogels with and without the MANHS linker. 
Incorporation of 1 mol% MANHS increased the polymer degradation rate. Data for 
80/10/10 hydrogel reproduced from [265]. 
 
The loading efficiency increased from 22.0 ± 2.1% in the 80/10/10 hydrogel up to 44.6 ± 
6.9% when 1 mol% of MANHS was present (p<0.05). The 80/9/10/1 hydrogel showed 
significantly higher release rates in phases I, II, and III compared to the 80/10/10 hydrogel 
(p<0.05 each phase) and demonstrated a more linear release profile. The presence of hydrophilic 
AAc sped polymer degradation and displayed near zero order release kinetics such that the 
release rates in phases I, II, and III were not significantly different from each other (p>0.05), 
although in all phases they were higher than the 80/10/10 copolymer (p<0.05 each phase). In 
hydrogels without AAc, BSA continued to be released for over 3 months in vitro, whereas the 
duration of release was shortened to 2 months in the copolymer with hydrophilic AAc. After the 
burst phase the copolymer without MANHS released protein at a slow rate until polymer 
degradation became more substantial after 60 days.  
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Figure 35. In vitro BSA release from hydrogels with different compositions. Polymers with 
protein-reactive MANHS showed higher loading efficiency and more constant release rates 
than copolymers without. Addition of hydrophilic AAc increased the rate of protein 
delivery. 
 
Table V. In Vitro BSA Release Kinetics from Hydrogels 
Hydrogel
Loading 
Efficiency 
(%)
Burst       
(%)
Phase I 
(%/wk)
Phase II 
(%/wk)  
Phase III 
(%/wk)
80/10/10 22.0 ± 2.1 10.9 ± 1.6 1.61 ± 0.32 0.37 ± 0.05 0.82 ± 0.04
80/9/10/1 44.6 ± 6.9* 11.7 ± 6.3 5.81 ± 0.73* 1.88 ± 0.29* 2.77 ± 0.32*
80/8/10/1/1 38.3 ± 3.9* 4.8 ± 1.3* 4.05 ± 1.18* 4.14 ± 0.32* 4.86 ± 1.33*
* Denotes p<.05 compared to 80/10/10 hydrogel during same phase  
The influence of MANHS on protein retention within the hydrogel is demonstrated in 
Figure 36. More protein remained after each thermal cycle in hydrogels with MANHS compared 
to those without (p<0.05). The percent of protein lost from the preceding thermal cycle is 
presented in Table VI. Hydrogels without MANHS lost a significantly greater percentage of 
their remaining protein at each subsequent cycle compared to hydrogels with the MANHS linker 
(p<0.05). 
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Figure 36. Protein remaining in hydrogels during repeated thermal cycling. Hydrogels 
incorporating the MANHS linker retained more protein after each cycle than hydrogels 
without linker. 
 
Table VI. BSA Lost After Each Thermal Cycle 
Cycle Number
Not Linked    
(% ± SD)
Linked               
(% ± SD)*
Cycle 1 85.4 ± 1.7 77.1 ± 2.8
Cycle 2 57.8 ± 5.6 46.4 ± 5.3
Cycle 3 30.9 ± 5.3 14.0 ± 1.4 
Cycle 4 36.6 ± 2.7 16.7 ± 2.5
Cycle 5 46.0 ± 14.0 10.9 ± 2.8
* denotes p<0.05 for all  cycles compared to not l inked  
4.3.3 Protein release from PLGA microspheres 
BSA-loaded PLGA microspheres were synthesized with an average diameter of 34 ± 30 µm and 
could be easily incorporated into the hydrogel networks – Figure 37. Microspheres free in PBS 
demonstrated a substantial early-stage protein release – Figure 38 and Table VII. The burst 
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release, which included all release during the first 24 h, for microspheres in PBS was 17.4 ± 
5.4% compared to 6.6 ± 1.0% when microspheres were entrapped in hydrogel (p<0.05). During 
the remainder of the first week (phase I) release rates were 16.9 ± 2.5% and 6.6 ± 1.2%, 
respectively (p<0.05). The release rate of BSA from microspheres inside the hydrogel was higher 
than the PBS counterparts only during phase III as polymer degradation became more 
substantial.  
 
 
Figure 37. Scanning electron micrographs showing dehydrated structure of A) PLGA 
microparticle (scale bar = 5 µm) and B) PLGA microparticles embedded in the hydrogel 
polymer network (scale bar = 20 µm). 
 
CD spectroscopy of protein encapsulated in PLGA microparticles and protein released 
from the hydrogels is shown in Figure 39. The spectra of both BSA released from hydrogels and 
BSA encapsulated in microparticles are similar to native FITC-BSA. Each has minima near 208 
and 222 nm and increased ellipticity below 200 nm, characteristic of the largely alpha-helical 
BSA.[286]  
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Figure 38. BSA release from microspheres in PBS and mixed into hydrogel network. 
Protein release was delayed when microspheres were entrapped in the hydrogel. 
 
Table VII. In Vitro BSA Release Kinetics from Microspheres 
Microsphere 
Environment
Burst            
(%)
Phase I 
(%/wk)
Phase II 
(%/wk)
Phase III 
(%/wk)
Microspheres 
in PBS
17.4 ± 5.4 16.9 ± 2.5 2.99 ± 0.31 1.13 ± 0.05
Microspheres 
in 80/10/10 gel
6.6 ± 1.0* 6.6 ± 1.2* 2.33 ± 0.58 2.27 ± 0.18*
* denotes p<0.05 compared to microspheres in PBS during same phase
 
4.3.4 Sequential protein release from microspheres embedded within the hydrogel 
The release of two differently labeled BSA proteins (FITC-BSA and TexR-BSA) from the same 
hydrogel samples using the MANHS-containing polymer with microspheres together showed 
sequential protein release – Figure 40. TexR-BSA, which was in the gel phase, showed a large 
release initially, whereas during the same early time points FITC-BSA release from entrapped 
PLGA microspheres was relatively slow. Specifically, in the first 3 week 54.2 ± 3.1% of TexR-
BSA was released compared to 17.9 ± 5.4% of FITC-BSA. Over the next 10 week TexR-BSA 
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release averaged 1.6%/week whereas FITC-BSA release gradually accelerated from an average 
of 1.4%/week up to a high of 3.7%/week.  
 
 
Figure 40. Sequential release of distinct BSA protein populations. A majority of TexR-
BSA was released from the reactive polymer system during the first three weeks 
compared to the delayed release of FITC-BSA from microspheres inside the hydrogel. 
 
Figure 39. CD spectroscopy of native BSA compared to BSA encapsulated in PLGA 
microparticles and BSA released from hydrogels without MANHS. Spectra demonstrate 
that protein conformation is not altered by this polymeric drug delivery system. 
102 
 
4.4 DISCUSSION 
Of the many applications of injectable materials in tissue engineering, one of recent focus in the 
literature is that of material injection into the myocardium following ischemic injury.[287] An 
appropriate biomaterial, upon injection into the heart wall, may act as a bulking agent to 
mechanically support the weakened myocardium or as a focal point for tissue remodeling and 
angiogenesis. These benefits have been shown using a number of injectable synthetic and 
biological materials. It has been reported that intramyocardial injection of a NIPAAm-based 
material with similar design features as the one presented in the current report was able to halt 
deleterious cardiac remodeling following ischemic injury.[126] Use of the current injectable 
material in this same application would also be feasible. Another treatment for cardiac disease of 
clinical interest has been therapeutic angiogenesis, which aims to increase collateral blood flow 
and attenuate ischemic damage by delivering pro-angiogenic proteins to ischemic myocardium. 
Of the clinical trials that have investigated cardiac therapeutic angiogenesis, the longest and most 
substantial benefit was seen when basic fibroblast growth factor was delivered to the heart in 
sustained release capsules compared to direct intracoronary infusion.[48, 288] Studies using 
animal models have also confirmed the potential for improved cardiac function when pro-
angiogenic factors are released in a controlled fashion in the heart wall.[68, 95, 289] In this 
report we have sought to combine these two beneficial effects by developing an injectable, 
biodegradable material capable of serving as a bulking agent with controlled release capabilities.  
The developed thermoresponsive polymer system was amenable to molecular design 
changes that resulted in predictable effects on protein delivery. For example, addition of just 1 
mol% MANHS consistently improved the loading efficiency of this system and allowed more 
protein to be delivered over an extended duration in a more linear fashion. Additionally, 
inclusion of 1 mol% AAc predictably increased the degradation rate of the polymer allowing the 
protein to be delivered over a shorter duration and in a near zero order fashion. These features 
may allow for a more specific release profile to be engineered depending on the hypothesized 
drug delivery needs of the target biological environment.  
The addition of microspheres to the system provided another means to control the timing 
of protein delivery and allow for multi-factor release in a sequential manner. PLGA was chosen 
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for microsphere synthesis because of a hypothesized affinity of the hydrophobic PLGA to 
associate with the hydrophobic MAPLA and NIPAAm residues of the copolymer. This 
interaction appeared to exist as the microparticles were not excluded from the hydrogel during 
phase transition. Likewise, the fact that the mechanical properties were not altered by the 
inclusion of microparticles in the gel network may be a manifestation of a favorable interaction 
between these two moieties. Release profiles from protein-loaded microspheres suggested that 
only about 60% of the loaded protein was released. However, measurements of the sample tubes 
at the end of the experiments demonstrated that 100% of protein was released, but the remaining 
40% of the protein was adsorbed onto the inner surface of the polypropylene tubes, making it 
unavailable for measurement in the collected fluid samples.  
 It was apparent that the initial release of protein was delayed when the microspheres 
were entrapped in the hydrogel versus being free in PBS. While releasing some protein in the 
first few weeks, acceleration of the delivery rate did not occur until after 6 week. The extent of 
the delay may be related to the degradation rate of PLGA used, which would constitute another 
control point in this delivery system. For example, PLGA with lower molecular weight or higher 
PLA content would lead to faster degradation and potentially quicker release. Additionally, the 
W/O/W fabrication technique used in this study produces a dense inner structure and porous 
surface on the microparticles, which also plays a role in the release profile. Particle morphology 
is influenced by many different processing parameters and has been shown to influence drug 
delivery rates.[290-292] In particular, surface porosity will lead to a larger burst release than 
would be seen from a nonporous surface. The high polymer volume fraction of the dense internal 
structure provides a more tortuous diffusional path that would favor a more extended release 
compared to hollow particles, which lose all encapsulated drug once the outer shell is breached. 
Thus, processing of the microparticles may provide yet another control mechanism for drug 
release.  
It is clear that the sequential nature of the current drug delivery system does not follow a 
strict on-off mechanism wherein all of one protein is delivered before all of another. Indeed, in 
both the hydrogel and the microparticle system there is continued release throughout the duration 
of the study. However, a strict sequential delivery may not be necessary to see desired biological 
effects. Previous studies have shown a beneficial biological outcome when growth factors are 
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delivered in a sequential manner similar to the one shown in the current report.[68, 283, 293] For 
example, Ruvinov et al. demonstrated different rates of IGF1 and HGF release from an alginate 
gel.[293] Similar to the current report, the growth factors were both continuously released from 
the gel but with one releasing faster than the other. Nevertheless, the sequential nature was 
adequate to elicit an improved biological response. One advantage of the current system is that 
the release profile of each of the two components – hydrogel and microsphere – could be 
independently manipulated, allowing each drug to be released in a desired profile to meet the 
perceived biological need. 
The thermoresponsive hydrogels reported were able to deliver protein, with or without 
protein-reactive moieties in the backbone, for a period in excess of 3 months. This contrasts with 
many hydrogel systems which, because of their high water content, are associated with quick 
molecular diffusion.[138] Previous studies have shown that the equilibrium water content of the 
80/10/10 hydrogel is near 45%.[265] This relatively low water content was associated with a 
more collapsed gel structure with smaller pore sizes and thus likely lower aqueous convection 
rates for protein release. In conjunction with this, the large size of the model protein BSA (MW 
66 kD) may inhibit its quick release from the gel. This size effect has been shown in 
polyNIPAAm hydrogel systems previously.[294, 295]  
The presence of MANHS in the 80/9/10/1 hydrogels consistently improved loading 
efficiency compared to 80/10/10 hydrogels – an effect attributed to the putative linkage of the 
protein to the polymer backbone. The occurrence of this linkage is also supported by the protein 
loss data during hydrogel thermal cycling. Presumably protein that is not bound to the hydrogel 
will be lost more quickly as the gel solubilizes and reforms, with the collapse of the gel pushing 
unbound protein out. Accordingly, hydrogels undergoing thermal cycling retained protein to a 
greater extent when MANHS was present compared to those without the linker. Because more 
protein remains in the gel after formation there is subsequently more protein to be released over 
time, and it appears to be released in a more linear fashion.  
Protein bioactivity is a primary concern for any drug delivery system. Synthesis of the 
PLGA microparticles involved a W/O/W emulsion technique that includes the possibility of 
protein denaturation by various mechanisms.[152] CD spectroscopy confirmed that BSA 
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encapsulated in microparticles maintained its native confirmation following synthesis, as 
compared to the changes in ellipticity that would occur following denaturation.[286] Likewise, 
BSA released after 3 h from 80/10/10 hydrogels did not exhibit a conformational change. One 
potential concern associated with the protein-reactive hydrogel approach would be the effect that 
polymer-protein conjugation could have on protein bioactivity. Covalent attachment of polymers, 
specifically poly(ethylene glycol), to protein therapeutics is an established method being used 
clinically to improve protein half-life in vivo for better pharmacokinetics.[155] However, it has 
been shown that uncontrolled conjugation can lead to a decrease in activity of the therapeutic if 
the polymer chain blocks protein active sites or influences protein conformation.[296] Each 
protein that would be conjugated to this polymer would require a bioactivity assessment to define 
the impact of conjugation. Should conjugation prove detrimental, a more careful linking strategy 
could be pursued by different conjugation chemistries, analogous to the approaches used for 
pharmaceutical PEGylation.  
4.5 CONCLUSIONS 
Injectable, biodegradable polymers with thermoresponsive properties were synthesized and 
characterized as a drug delivery system. These hydrogels were able to release model protein 
BSA in a controlled manner extending 3 months. Modification of the polymer backbone, 
specifically inclusion of a protein-reactive MANHS group, led to higher protein loading in the 
gel during thermal transition. Further, addition of hydrophilic AAc to the polymer increased the 
drug delivery rate as predicted. The presence of both MANHS and AAc led to a more linear 
protein release profile than from hydrogels without these monomers. Protein-loaded 
microspheres entrapped in the hydrogel network during gel formation released protein in a 
delayed fashion relative to microspheres in saline. Neither protein conjugation nor microsphere 
presence interrupted the ability of the copolymer to transition from sol to gel when warmed to 
body temperature, thus maintaining the injectability of this system. Combining both systems 
provided a sequential release of two distinct protein populations where the majority of protein 
associated with the gel phase was released before protein loaded into microparticles. Thus, this 
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composite material combines the advantages of injectability, degradability, extended release, and 
sequential release into a single delivery system. 
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5.0 INVESTIGATION OF A STRONG, BIODEGRADABLE HYDROGEL WITH 
CONTROLLED PROTEIN DELIVERY FOR INTRAMYOCARDIAL INJECTION  
5.1 INTRODUCTION 
 
Intramyocardial biomaterial injection therapy continues to be an area of significant research 
involving materials of both biological and synthetic origins, generally with promising 
results.[287, 297] It has been noted previously that the material properties may play a role in the 
overall benefit seen following injection. These properties include material degradation rate, 
bioactivity, and mechanical strength.[53, 119, 298-300] It has been demonstrated, for example, 
that materials that degrade too quickly (<6 week) and those that are non-degradable both lead to 
decreased function similar to saline control groups at study end points. Likewise, theoretical 
models and empirical data suggest that stronger materials may have a greater benefit than weaker 
materials, though the upper limits on mechanical strength have not been investigated. It has also 
been postulated that appropriate cell infiltration into the injected material may be important in 
eliciting sustainable improvements to cardiac function. While studying the effects of these 
material properties it is important to provide adequate follow-up time after injection to see the 
lasting effects of the therapy. Few published studies extend beyond 2 months, making long-term 
efficacy difficult to assess.  
Another area that has shown promise to improve material injection therapy is the 
inclusion of appropriate growth factors with the material for controlled release at the injection 
site. Growth factors that have received the most focus to-date are those with known 
proangiogenic properties such as bFGF, VEGF, PDGF and HGF.[136, 237, 301-305] IGF1 has 
also been used due to its known benefits in the myocardium including influencing cell size and 
metabolism, decreasing apoptosis, improving contractility, and encouraging cardiac stem cell 
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proliferation.[236, 306, 307] It has recently been demonstrated that controlled release of two or 
more growth factors, in some cases in a sequential manner, can have benefits beyond what is 
seen from single factor delivery.[68, 293, 308] For example, the delivery of complementary 
proteins sequentially has been shown to be more beneficial in angiogenesis than simultaneous 
delivery, presumably because it mimics the body’s own regenerative healing mechanisms.[284, 
309] Finally, in an approach that delivers the myriad growth factors and cytokines that are 
released from activated platelets, a gel made of 10% v/v plasma, after injection into rats 
immediately after infarction, reduced the damage of infarction compared to controls.[308] 
As discussed previously we have reported on the benefits of injecting a N-
isopropylacrylamide (NIPAAm)-based thermally responsive hydrogel in infarcted rat hearts and 
have subsequently developed a stronger material with a slower degradation time which may be 
more beneficial in cardiac injection therapy.[126, 265] We reported on the drug delivery 
properties of this new material by studying the release of model protein BSA. Specifically, this 
system allowed for two proteins to be delivered in a sequential fashion. The aim of that research 
was to develop and understand a system that could be used with functional growth factors for 
cardiac regeneration. We hypothesize that primary bFGF delivery to the heart may be able to 
encourage early angiogenesis, thus establishing a healthier microenvironment in the damaged 
muscle. Following this, delivered IGF1 may be able to encourage cardiac stem cell and 
cardiomyocyte proliferation at the newly-vascularized injection site. 
This report shows the effects of intramyocardial injection of a biodegradable material 
with higher mechanical strength and a longer degradation time than has been published 
previously. After presenting the in vitro characterization of growth factor delivery from this gel, 
we further test the effect that delivery of bFGF, IGF1 or both from the hydrogel has on cardiac 
function and histology. In all cases the follow-up after injection continues for 16 weeks to 
determine longer-term effects of this therapy.  
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5.2 MATERIALS AND METHODS 
5.2.1 Materials 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. NIPAAm was 
purified by recrystallization from hexane and vacuum-dried. 2-Hydroxyethyl methacrylate 
(HEMA) was purified by vacuum distillation. Benzoyl peroxide (BPO), lactide, poly(lactide-co-
glyoclide), sodium methoxide (NaOCH3), poly(vinyl alcohol), and methacryloyl chloride were 
used as received. IGF1 and bFGF (Peprotech) and 125I-bFGF (Perkin Elmer) were reconstituted 
according to manufacturer instructions. Protein extraction buffer (Bioo Scientific) and ELISA 
assays (R&D Systems) were used as received.  
5.2.2 Material Synthesis 
5.2.2.1 Synthesis of methacrylate polylactide (MAPLA) 
MAPLA was synthesized as reported above – Figure 29.[265] After dissolving lactide in 
dichloromethane to which NaOCH3 initiator in methanol was added, polylactide-monomethyl 
ether (HOPLA-OCH3) was synthesized by ring opening polymerization. The reaction persisted 
for 2 hr at 0°C, after which the polymer solution was rinsed with 0.1 M HCl and deionized water. 
The organic phase was next dried with MgSO4 and then removed by rotary evaporation. 
HOPLA-OCH3 was dissolved again in dichloromethane with added triethylamine. MAPLA was 
formed by dropping methacryloyl chloride into this solution and allowing reaction overnight at 
0°C. Following reaction, precipitates were removed, the organic phase was dried and removed by 
rotary evaporation, leaving raw MAPLA product. MAPLA was purified by flash 
chromatography. NMR confirmed the synthesis of MAPLA with an average of 2.9 PLA units per 
MAPLA monomer. 
5.2.2.2 Synthesis of poly(NIPAAm-co-HEMA-co-MAPLA)  
Poly(NIPAAm-co-HEMA-co-MAPLA) copolymer was synthesized by free radical 
polymerization – Figure 41. Monomers, NIPAAm (6 g, 0.053 mol), HEMA, and MAPLA at a 
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molar ratio of 80/10/10 were dissolved in 200 ml of 1,4-dioxane containing 220 mg BPO. The 
polymerization was carried out at 70°C for 24 hr under an argon atmosphere. The copolymer was 
purified by repeated precipitations in hexane, diethyl ether, and warm DI water. The final 
product was freeze-dried before being dissolved in cold PBS at 15 wt% for use in all studies.  
 
Figure 41. Schematic of poly(NIPAAm-co-HEMA-co-MAPLA) copolymer synthesis (from 
[288]) 
 
5.2.2.3 Synthesis of PLGA microspheres 
PLGA microspheres with a lactide:glycolide ratio of 75:25 (Mw 66-107 kD) were synthesized 
using a water-in-oil-in-water (W/O/W) double emulsion technique.[277] IGF1 was mixed with 
unlabeled BSA at a ratio of 1:10 and dissolved in 0.02x PBS to make a final total BSA 
concentration of 1 mg/ml. Initially, 200 mg of PLGA was dissolved in 4 ml dichloromethane. 
After all PLGA was dissolved, 200 µL of IGF1 solution was added to the dissolved PLGA and 
vortexed for 1 min. This primary emulsion was immediately added to 60 ml of 2% PVA that was 
stirring at 1000 rpm, to generate the W/O/W emulsion. After 5 min, the stirring speed was 
reduced to 600 rpm and an additional 80 ml of 1% PVA solution was added. After stirring for 6 h 
to allow dichloromethane evaporation, the microspheres were collected by centrifugation, rinsed 
with DI water and freeze-dried. The IGF1 content of the PVA and DI water supernatants was 
determined by ELISA to calculate loading efficiency of IGF1 in the particles. 
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5.2.3 Copolymer characterization 
Copolymer molecular weight was determined by gel permeation chromatography (Waters Breeze 
System). The copolymer was dissolved in tetrahydrofuran at 1 mg/ml and elution time was used 
to determine molecular weight by comparison to a poly(methyl methacrylate) standard. LCST 
values were determined by measuring the optical density of the material at 500 nm wavelength 
over a temperature range from 2 to 24°C. The temperature at which the absorbance reached half 
of its maximum value was taken as the LCST, and was determined using a custom Matlab 
(MathWorks) program.  
5.2.4 In vitro growth factor release studies 
5.2.4.1 In vitro quantification of growth factor release 
For quantification of the bFGF release rate from hydrogels, 125I-bFGF was loaded into 15 wt% 
gel solutions alone, or after being premixed with either BSA (1:350 bFGF:BSA molar ratio) or 
BSA and heparin (1:350 BSA, 1:1000 bFGF:heparin). These samples were gelled in PBS at 37 
°C and releasate was periodically collected and measured with a gamma counter (Auto Gamma 
II, Perkin Elmer) to determine the amount of bFGF released at each time point. For 
quantification by ELISA and to determine growth factor bioactivity, hydrogel solutions loaded 
with 16 ug/ml bFGF or 1 ug/ml IGF1 in loaded microparticles were injected in 0.25 ml aliquots 
into 24 well plates containing 37 °C basal media (EMEM, Lonza). At designated time points the 
media was removed and replaced. A portion of the removed supernatant was used for 
determination of released growth factor concentration with ELISA (R&D Systems). The 
remaining media was stored at -80 °C until being used for bioactivity studies. 
5.2.4.2 In vitro growth factor bioactivity 
Rat smooth muscle cells were cultured at 5 x 103 cells per well in a 96 well plate in culture 
medium (DMEM, 5% fetal bovine serum, penicillin and streptomycin). After 24 hr the cell 
culture media was removed and replaced with serum-free supernatant from the growth factor 
release studies. Cells were cultured with the supernatant for 48 hrs, at which point a 
mitochondrial assay (CellTiter 96 Aqueous One, MTS, Promega) was used to determine cell 
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number. Visual inspection qualitatively confirmed the results from the MTS assay. Results from 
the assay were compared against cells grown in basal media without serum.  
5.2.5 In vivo hydrogel injection studies 
5.2.5.1 Chronic rat infarction model 
Adult female Lewis rats (Harlan Sprague Dawley) weighing 200–250 g were used. The protocol 
followed National Institutes of Health guidelines for animal care and was approved by the 
University of Pittsburgh’s Institutional Animal Care and Use Committee. Anesthesia was 
induced with 3.0% isoflurane inhalation followed by intubation and respiratory support with a 
rodent volume-controlled mechanical ventilator. Electrocardiogram and tail cuff blood pressure 
measurements were used to monitor vital signs in all animals. A left thoracotomy was performed 
to expose the heart after which the proximal left anterior descending coronary artery was ligated 
with a 7–0 polypropylene suture. The creation of myocardial ischemia was verified by regional 
cyanosis and ST segment elevation and the incision was closed in layers with 4–0 continuous 
silk sutures. 
5.2.5.2 Poly(NIPAAm-co-HEMA-co-MAPLA) hydrogel injection 
Two weeks after induction of myocardial infarction, the rats were anesthetized and evaluated 
with echocardiography to measure infarct size in terms of the percentage of scar area (akinetic or 
dyskinetic regions) compared to the LV free wall area. Rats with infarcts greater than 25% of the 
LV free wall were randomly divided into 5 groups: those that would receive plain hydrogel 
injections (hydrogel group, n=8 for all groups), control PBS injections (PBS group), hydrogel 
with 25 ug/ml bFGF (gel+bFGF group), hydrogel with 1 ug/ml IGF1 in PLGA microparticles 
(gel+IGF1 group), and hydrogel with 25 ug/ml bFGF and 1 ug/ml IGF1 in PLGA microparticles 
(gel+bFGF/IGF1 group). The infarcted anterior surface of the rat heart was exposed through a 
left thoracotomy. For rats receiving hydrogel injection a total volume of 400 ul of hydrogel 
solution in PBS was injected into the apical, proximal, lateral, and septal wall regions bordering 
the infarct as well as into the center of the infarct (5 injections, 80 µL per region). For a rat in the 
PBS group, 400 µL PBS was injected into the same locations with the same volumes. The 
incision was closed in layers with 4–0 silk continuous sutures for both groups. 
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5.2.5.3 Echocardiography 
Echocardiography was performed immediately before injection (pre-injection time point – 2 
weeks post-infarction), as well as 4, 8, 12 and 16 weeks after injection. To perform the 
procedure, rats were anesthetized with isoflurane inhalation. Standard transthoracic 
echocardiography was performed using the Acuson Sequoia C256 system with a 13-MHz linear 
ultrasonic transducer (Acuson Corporation) in a phased array format. The LV short axis view 
was studied using B-mode measurements. The end-systolic (ESA) and end-diastolic (EDA) inner 
LV areas were measured by outlining the endocardial surface. LV FAC was calculated as, FAC 
= [(LVEDA - LVESA)/LVEDA] x 100%. All measurements were taken using Scion Image 
software (Scion Image). 
5.2.5.4 In vivo growth factor retention 
To test the residence time of bFGF and IGF1 in the heart, animals for each treatment group 
above were injected two weeks following MI as described. At 5 minutes, 2 days, and 2 weeks 
after injection 3 animals from each group were euthanized and their complete hearts were 
immediately extracted and snap frozen in liquid nitrogen. The LV free wall of each heart was 
excised and digested using a tissue homogenizer and protein extraction solution followed by 
gentle mixing for 2 hr at 4 °C. Samples were centrifuged for 10 minutes and the supernatant was 
decanted. Growth factor concentration in the supernatants was determined by ELISA. Healthy 
hearts and PBS-injected hearts were similarly digested and tested for use as controls.  
5.2.5.5 Histology 
Rats were sacrificed for detailed histological analysis of the hearts 16 weeks after injection. 
Animals were anesthetized, and the heart was exposed and arrested by injection into the apex of 
2 ml of a hypothermic arresting solution including 10 U/ml of heparin. The excised hearts were 
fixed in 2% paraformaldehyde for 2 hr before being embedded in optimal cutting temperature 
compound (Tissue-Tek) and frozen at -80° C. LV tissues were serially sectioned to a thickness of 
8 mm in the LV transverse direction. Hematoxylin and eosin (H&E) staining and 
immunohistochemical staining were performed with antibodies against alpha-smooth muscle 
actin (a-SMA, Sigma), CD 68 (Serotec), and CD 163 (Serotec). Nuclei were stained with DAPI 
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(Sigma). For quantification of the immunohistochemical staining, each LV from 5 different 
animals was photographed at 10 different microscopic fields at 200x magnification.  
5.2.6 Statistical Analysis 
Where three or more groups were being compared, one-way ANOVA was employed. To 
determine if changes in LV variables over time varied among the experimental groups, a two-
way repeated-measures ANOVA was used which determined the effects of treatment, time, and 
treatment-by-time interaction. The REGWQ post hoc test was used when the necessary 
assumptions were met. When there were unequal sample sizes or lack of homogeneity of 
variance Gabriel’s test and the Games-Howell test were used, respectively. Statistical 
significance was defined as p < 0.05. 
5.3 RESULTS  
5.3.1 Material characterization 
Poly(NIPAAm-co-HEMA-co-MAPLA) was successfully synthesized with properties similar to 
what has been reported previously.[265] Specifically, the Mn was 34.1 kD, Mw was 67.1 kD, 
and PDI was 1.96, with a transition temperature of 13 °C. 
5.3.2 In vitro growth factor release 
Quantification by ELISA of bFGF and IGF1 release in vitro was unsuccessful as no appreciable 
amount of growth factor was detected. However, the release rate of 125I-bFGF from the hydrogels 
is shown in – Figure 42. During the initial gelation, which lasts approximately 3 hr, there was 
significant release of bFGF from the gels. The extent of that initial loss was influenced by the 
presence of excipient with the protein. The release at 3 hr for plain bFGF was nearly identical to 
the release when BSA was also present, with 41.5 ± 1.1% and 40.9 ±1.2% released, respectively. 
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When heparin was also combined with BSA and bFGF the amount released after 3 hr nearly 
doubled to 80.0 ± 2.8% (p<0.05). Release profiles from the hydrogel after this early release was 
similar and characterized by a slow, steady release over many weeks.  
The cellular assays showed that the bFGF and IGF1 released from gels retained 
bioactivity over many weeks as demonstrated by increased rat SMC proliferation – Figure 43. 
Cell proliferation data show a peak of bFGF bioactivity during the first 2 weeks of release with 
little effect beyond 6 week. The effect of IGF1 was seen from the first time points to a period 
extending beyond 3 months. The peak effect observed for IGF1 bioactivity came after 4 weeks. 
These data demonstrate both the bioactivity of released growth factors as well as the difference 
in release rate of these two proteins from their respective carriers.  
5.3.3 In vivo growth factor retention 
The ability of growth factor to be retained at the cardiac injection site in vivo is shown in Figure 
44 and Table VIII. Hearts injected with the bFGF-loaded gel demonstrated a 590-fold, 10-fold 
and 2-fold increase of bFGF content 5 min, 2 days and 2 weeks after injection, respectively, 
compared to injection of gel without growth factor at the same time points.  Similarly, there was 
a 7-fold, 3-fold and 4-fold increase in detected IGF1 for hearts receiving hydrogel mixed with 
IGF1-loaded microparticles. There was no difference in detectable bFGF or IGF1 between 
infarct control and plain hydrogel injection. 
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Table VIII. Retention of Injected Growth Factors in Myocardium 
Injection Fluid
5 min 2 day 2 wk
Healthy 2.03 ± 0.77
Saline 5.26 ± 0.74 3.39 ± 0.40 6.15 ± 2.80
MAPLA only 4.04 ± 1.57 5.30 ± 0.32 5.51 ± 1.24
MAPLA with bFGF 2378 ± 404* 50.4 ± 13.1* 12.5 ± 4.32*
MAPLA with IGF1-
loaded microparticles
4.14 ± 1.20 4.52 ± 1.31 6.35 ± 1.26
Injection Fluid
5 min 2 day 2 wk
Healthy 0.32 ± 0.14
Saline 0.19 ±0.09 0.23 ± 0.02 0.27 ± 0.12
MAPLA only 0.34 ± 0.22 0.30 ± 0.06 0.13 ± 0.10
MAPLA with bFGF 0.40 ± 0.14 0.28 ± 0.05 0.41 ± 0.02
MAPLA with IGF1-
loaded microparticles
2.28 ± 0.46* 0.80 ± 0.08* 0.55 ± 0.06*
LV  bFGF content (ng)
LV  IGF1 content (ng)
*p<0.05 vs  gel  injection at same time point  
 
5.3.4 In vivo injection results  
5.3.4.1 Effects of cardiac injection on cardiac function  
Compared to pre-injection, FAC was significantly reduced in hearts injected with PBS after 16 
weeks – Figure 45. By contrast, there was no significant decrease in FAC for any hearts 
receiving hydrogel injection. The presence of growth factors did not improve upon results seen 
from injection of the plain hydrogel. Overall there was a significant difference in FAC between 
all gel and PBS injection groups at 16 weeks.  
Cardiac dilation was markedly improved after gel injection compared to saline controls – 
Figure 46. The ESA and EDA of hearts receiving plain hydrogel was 0.42 ± 0.15 and 0.62 ± 
0.13, respectively, compared to 0.70 ± 0.10 and 0.88 ± 0.11 for hearts injected with saline 
(p<0.05). There was no difference in dilation when the hydrogel was loaded with growth factors 
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compared to hydrogel without these factors. In all cases the dilation was statistically larger at 16 
weeks for all experimental groups than at baseline (p<0.05). In the case of gel-injected groups, 
the majority of the change occurred in the first 4 weeks, and subsequently there was no 
significant difference for either of these parameters over time from 4 to 16 weeks. In 
comparison, following saline injection the area at end systole and diastole continued to increase 
at each time point.  
 
 
Figure 42. Release profiles of 125I-bFGF from poly(NIPAAm-co-HEMA-co-MAPLA) 
hydrogels. The presence of heparin allowed more bFGF to be released during gel 
formation. 
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Figure 43. Proliferation of rat smooth muscle cells in response to bFGF released from the 
hydrogel (A) or IGF1 released from microparticles inside the hydrogel (B). bFGF release 
caused proliferation in the first few weeks of release whereas IGF1 caused proliferation 
over a longer time with a peak after four weeks. 
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Figure 44. Total content of bFGF (A) and IGF1 (B) in the left ventricular free wall of rat 
hearts injected with either bFGF-loaded hydrogel or hydrogel loaded with microparticles 
encasulating IGF1, respectively. Increased levels for both growth factors are shown up to 
2 weeks after injection. *denotes significance compared to injection of plain gel. 
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Figure 46. Measurements of dilation in hearts receiving injection of hydrogels with or 
without growth factors. *denotes a significant change from pre-injection, † denotes 
differences between groups over time. 
Figure 45. Effect of gel injection on fractional area change 16 week after treatment. Gel 
injection prevented the worsened function observed in hearts receiving saline injection. 
Addition of growth factors did not improve upon the results of the plain hydrogel. *denotes 
a significant change from pre-injection, † denotes differences between groups over time. 
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Figure 47. Histological view of cardiac cross-section 16 weeks after injection of plain 
material (A), or material loaded with bFGF (B), IGF1-loaded microparticles (C), or both 
(D). Arrows point to residual hydrogel infiltrated with cells. Scale bars = 500 µm 
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Figure 48. Representative images of αSMA (green), macrophage (red) and DNA (blue) 
staining from hearts receiving injection of hydrogel with and without growth factors. 
There is marked infiltration of macrophages and presence of smooth muscle cells, 
especially in the mid-wall. Scale bar = 100 µm 
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Table IX. Quantification of Immunohistochemical Staining of Infarct Zones in Hearts 
Nuclei αSMA CD68 CD163 Vessels Arterioles
(per HPF) (x10,000 pixels 
per HPF)
(x10,000 pixels 
per HPF)
(x10,000 pixels 
per HPF)
(per HPF) (per HPF)
Plain gel 126 ± 34 3.6 ± 1.8 3.4 ± 0.6 2.0 ± 0.5 4.1 ± 0.9 0.3 ± 0.1
Gel + bFGF 136 ± 28 6.0 ± 3.0 5.1 ± 2.7 3.5 ± 1.2 3.8 ± 0.7 0.7 ± 0.4
Gel + IGF1 216 ± 79 4.0 ± 1.2 3.9 ± 1.7 3.5 ± 1.4 3.1 ± 0.8 0.5 ± 0.4
Gel + bFGF + IGF1 157 ± 55 3.9 ± 1.6 3.6 ± 2.5 2.8 ± 1.7 5.1 ± 2.0 0.7 ± 0.4
Hydrogel Type
HPF = high-power field  
5.3.4.2 Effect of injection on cardiac histology 
Representative cross-sections of hearts explanted after 16 weeks showed regions where the 
material was still present and infiltrated with cells – Figure 47. Immunohistochemical evaluation 
of the LV walls at 16 weeks showed that all hearts injected with hydrogel showed a large number 
of αSMA-positive cells in the injected material and neighboring infarct regions, and both vessel 
and arteriole formation – Figure 48. Even at this late endpoint the material was clearly infiltrated 
by macrophages including those of an M2 phenotype. There was no significant difference in the 
amount of angiogenesis or cell infiltration at 16 weeks following injection of hydrogels with or 
without different growth factors – Table IX.  
5.4 DISCUSSION 
The continued development of intramyocardial biomaterial injection therapy requires that the 
mechanisms by which benefits are obtained following injection be further elucidated. Many 
parameters may contribute to successful treatment, including timing and location of injections, 
distribution of material in the heart wall, and physical and biological properties of the injected 
material. Moreover, the long-term benefits of this treatment will need further investigation before 
it can become a clinical reality. This report discusses application of a material that has been 
designed specifically for the cardiac environment as seen by its increased mechanical strength, 
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relatively slow degradation time, and the ability to delivery growth factors in a controlled way. 
The effects of treatment with this material have been observed for 4 months after injection.  
Quantification of the growth factor released in vitro could not be completed by ELISA 
due to an inability to detect the released protein. Instead, using 125I-bFGF it was shown that the 
release profile was similar to what has been previously shown with BSA from this material, 
particularly the significant release during the first 3 hrs of gel formation followed by slow release 
afterwards. It was interesting to note that when growth factor was loaded into the gel in the 
presence of BSA it released at the same rate as when it is loaded by itself, however when heparin 
is mixed into the solution nearly twice as much protein is released during gelation. This suggests 
that there may be a significant interaction of the protein with the polymer chains in the gel that is 
disrupted once heparin, which can bind bFGF, is added. A strong interaction between the 
polymer and the growth factors may partially explain why ELISA is unsuccessful at detecting the 
proteins. The polymer-protein interaction may cause conformational changes that prevent 
binding in the sandwich assay but yet still allow it to maintain a level of bioactivity as seen by its 
ability to affect in vitro cell proliferation. This observation highlights the vulnerability that 
sensitive growth factors may have to biomaterial carriers and the need to consider appropriate 
protective excipients with the protein.  
 Injection of the plain poly(NIPAAm-co-HEMA-co-MAPLA) in 2 week-old infarcts is 
remarkable for the ability to maintain cardiac function for at least 16 weeks after injection. 
During this time the material demonstrated significant cellular infiltration and growth of αSMA-
positive cells throughout the infarct zone. The presence of these smooth muscle-like cells was 
likewise observed following injection of a similar thermoresponsive gel which also had relatively 
strong mechanical properties and degraded over a few months in vivo.[126] Interesting research 
into the biological response following application of a strong and elastomeric degradable 
epicardial patch has also shown a similar αSMA-positive zone near the implant. That muscular 
zone was shown to be similar to the myocardium during fetal growth and differentiation and may 
be a sign that the observed cells are on a pathway of tissue regeneration. The exact mechanisms 
that are involved in the growth and survival of these muscle cells near the injected material are 
unknown but may be related to a combination of appropriate cellular infiltration, material 
degradation, and mechanical support.  
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An interesting observation in this study was the lack of additional benefit to either cardiac 
function or cellular environment when either or both growth factors were included in the 
material. The amounts of growth factor that were delivered were similar to amounts that have 
shown benefits in other intramyocardial injection studies.[133, 293, 303, 304] It was observed 
that the tissue had elevated levels of both bFGF and IGF1 for at least two weeks following 
injection, which demonstrates that growth factor was being locally released at the site of injury. 
In vitro, the bioactivity of growth factors released from the gel was demonstrated by cellular 
proliferation assays. Because the in vivo environment will likely cause a faster rate of drug 
delivery than in vitro studies, the exact rates of delivery and the profile of the sequential release 
of bFGF and IGF1 cannot be determined. While the increase in IGF1 in the digested LV tissue 
was mostly gone by 2 weeks it is likely that more IGF1, which may not have been removed from 
the particles during tissue digestion, remained loaded in the microparticles to be released slowly 
over a longer term. 
These results may provide important information about the mechanisms by which 
benefits are observed following injection. It is well known that a myriad of inflammatory 
processes are at work following injection of a material, especially a synthetic one, into the 
body.[310, 311] One aspect of that response is the recruitment of macrophages to the site of 
injury, which are known to excrete many cytokines and growth factors that aid in new ECM 
formation and angiogenesis.[312] We demonstrated that macrophage infiltration to the site of 
injury was pronounced, even 16 weeks after injection. Many of these cells stained positively as 
those of a M2 phenotype which encourages tissue regeneration as opposed to scar 
formation.[311, 313] It may be that a continued release of angiogenic and pro-healing factors 
from these cells at the implant site is adequate to provide robust angiogenesis that is not further 
augmented by endogenous delivery of these factors from the material.  
The degradation rate of the material is also a likely contributor to the overall success of 
this material, especially as it relates to the cellular environment at the injection site. It has been 
shown previously that the benefits of material injection seen soon after delivery can be altogether 
lost if the material degrades too quickly.[67] On the other hand, non-degradable materials, 
whether they are infiltrated with cells or not, do not provide any long-term benefits.[119, 300] 
The material used in this research is one that degrades in vivo over approximately 4-5 months. 
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This time frame will be intimately tied to the cellular response. Because the material is not 
permanent it does not undergo fibrous encapsulation and chronic inflammation. However, it does 
remain long enough to maintain cell recruitment to the injection site where the cells may provide 
continued positive tissue remodeling as described above. While the exact timing of degradation 
in the cardiac environment remains to be determined there is evidence that a duration beyond 2 
months should be considered if the material is also providing mechanical support.[299] The 
support provided during that time, and the slow shifting of load-bearing responsibilities to the 
newly formed tissue may also play a role in the overall health and function of the cellular 
environment.  
The inability of growth factor delivery to improve the functional results with hydrogel 
delivery is not unprecedented. Whereas in many cases intramyocardial delivery of a growth 
factor with a biomaterial has shown functional improvements, in other reports the benefits are 
seen only histologically in terms of cellular milieu and vascularization. For example, Shao et al 
demonstrated that delivery of a bFGF gelatin showed a higher EF than injection of material alone 
2 weeks after treatment but the increase was not maintained to 4 weeks despite higher vascular 
density, decreased infarct expansion and fewer TUNEL-positive cells throughout the study.[95] 
Likewise delivery of IGF1 tethered to self-assembling peptides demonstrated bioactivity in the 
form of cellular Akt signaling, but was unable to improve functional or geometric cardiac 
parameters.[133] There have also been studies that identify the positive histological effect seen 
after injection of extracellular matrix materials – known to contain growth factor signaling 
molecules.[100, 101, 314] However, benefits to cardiac function remain to be proven in these 
studies. Again, these results point to the complexity in understanding exactly how benefit is 
achieved in intramyocardial biomaterial injection. 
5.5 CONCLUSIONS 
A strong, slowly-degrading hydrogel was injected into infarcted rat hearts. The material was able 
to prevent worsened cardiac function for a period of at least 16 weeks. The injected material 
exhibited marked infiltration of macrophages and was associated with angiogenesis in the infarct 
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zone. Cells staining positive for αSMA were found throughout the infarct region near the 
injected material. Growth factors bFGF and IGF1 were successfully loaded into the gel directly 
or in polyester microparticles. Despite demonstration that injected growth factor was present at 
elevated levels in the LV for at least two weeks after injection, and that released growth factor 
was bioactive in vitro, there was no effect on cardiac function or histology following injection of 
growth factor-loaded gels compared to the gel without growth factor. These results suggest that 
the mechanisms by which benefit is achieved may involve a multitude of factors, the 
investigation of which is of critical importance to see the successful development of 
intramyocardial biomaterial injection therapy.  
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6.0 CONTINUED RESEARCH AND FUTURE DIRECTIONS 
The data and results presented in the previous sections provide useful information that adds to 
the scientific knowledge of controlled release, especially for cardiovascular applications. It also 
lays the groundwork for more and exciting research that will continue to advance the field. Such 
work that continues beyond the specific aims of this dissertation will be shown presently. This 
work deals with controlled release systems, intramyocardial injection therapy, and the 
development of related biomaterials for cardiovascular and other applications.  
6.1 OTHER APPROACHES TO GROWTH FACTOR DELIVERY  
6.1.1 Introduction 
When considering the results following growth factor loaded hydrogel injection into infarcted rat 
hearts, the lack of functional benefits is noteworthy and deserves further investigation. As has 
been discussed above there may be numerous mechanisms to describe these data. It is important 
to keep in mind that the ELISA assays were unable to detect the protein that was released from 
the gel. Additionally, the large change in the amount of protein released in vitro after 3 hr when 
bFGF was delivered alone compared to when bFGF was mixed with heparin, suggests a possible 
interaction between bFGF and the polymer chains that may be influencing protein conformation. 
While it was noted that the bioactivity is retained to a degree sufficient to elicit a cellular 
proliferation response, it is possible that some protein is no longer functional. What specifically 
may be happening at the molecular level is unknown but it is possible that other proteins do not 
have this same susceptibility to conformational change or loss of activity.  
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 VEGF is a growth factor with similar proangiogenic effects as bFGF. This protein has 
been shown to play a prominent role in angiogenesis during embryogenesis and its controlled 
delivery can help preserve damaged ischemic tissue in adults.[50, 315, 316] The delivery of 
plasmid DNA coding for VEGF or delivery of the endogenous protein have both been shown to 
aid in angiogenesis following myocardial infarction.[305, 317] We tested the ability to quantify 
VEGF released from the gel using ELISA and measure its bioactivity. We did this as a potential 
replacement for bFGF for future studies. Preliminary results suggest that VEGF may be more 
compatible with this hydrogel system.  
6.1.2 Methods 
Similar to the methods reported above, VEGF was loaded into 15 wt% poly(NIPAAm-co-
HEMA-co-MAPLA) gel solutions at a concentration of 1 ug/ml and allowed to gel at 37 °C in 
basal cell culture media (EGM-2, Lonza) with low serum content (0.5% v/v). The releasate was 
collected at predetermined time points and split into portions for ELISA measurement of growth 
factor content and for use in cellular proliferation assays. Human umbilical vein endothelial cells 
(HUVECs) were plated in full serum media in a 96 well plate at 5,000 cells per well. After one 
day of growth the media was replaced with releasate from gels loaded with VEGF or from 
control gels with no growth factor. After 3 days of growth in this media the cell number was 
counted with a hemocytometer. 
6.1.3 Results and discussion 
VEGF release was successfully quantified by ELISA measurements – Figure 49A. The release 
profile demonstrated a diffusion-controlled system characterized by high amounts of release 
early and decreasing release at later times. The released VEGF increased proliferation of 
HUVEC cells similar to what was seen by direct loading of VEGF into culture media – Figure 
49B. The releasate collected for at least 4 weeks was able to increase proliferation. 
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These results show that VEGF can be released from poly(NIPAAm-co-HEMA-co-
MAPLA) hydrogels in a way that is detectable with the ELISA sandwich assay and retains 
protein bioactivity. While the mechanisms by which bFGF was not detectable and VEGF was 
detectable has not been explored, these results show that the individual components of a drug 
delivery system can be important. This data suggest a potential path forward when considering 
the release of proangiogenic growth factors from the hydrogel. Simple in vivo tests may be 
appropriate to confirm the functionality of this drug delivery system before moving to future 
cardiac studies. For example, subcutaneous injection of the VEGF-loaded gel in rats may provide 
a more certain guarantee of bioactivity than in vitro tests and could be used as a reference in the 
event that growth factor-loaded gel injection to the heart was again unable to change the 
biological response.[318] 
Figure 49. VEGF release from poly(NIPAAm-co-HEMA-co-MAPLA hydrogel. Released 
VEGF was detected by ELISA (A) and was bioactive as demonstrated by increased 
proliferation of HUVECs when grown in releasate (B). 
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In conjunction with testing different signaling molecules, other delivery mechanisms may 
be worth exploring. Here we use direct-loading and microparticle encapsulation methods to 
deliver the growth factors. The number and properties of microparticle systems that have been 
used are many, and it may be that those using different materials or fabrication methods can do 
more to protect loaded proteins.[153, 273] If the growth factors are in greater need of protection 
then other techniques such as PEGylation, which has been reviewed elsewhere, could be 
explored.[155, 296, 319] Likewise other types of drugs may be appropriate in the cardiovascular 
application. For example, plasmid DNA either free or housed in a viral or synthetic vector could 
be explored.[320] 
6.2 LARGE ANIMAL HYDROGEL INJECTION 
6.2.1 Introduction 
The use of injectable materials to treat heart disease has mostly been focused on small animal 
models to-date. Moving to larger animals is advantageous not only because of the increased 
relevance to final human application, but also because some of the technical difficulties 
associated with trying to inject into a small muscle mass is reduced. For example, the thickness 
of an infarcted rat LV wall can be less than 1 mm, and injecting a material into that space 
without puncturing through the wall is technically challenging. The complications that are likely 
to be associated with misplaced material are serious and can include embolic stroke and death. 
The pig LV wall is at least 1 cm thick which makes breaching the LV cavity unlikely during 
injection. The greater tissue space will also allow for more control on locations and 
configurations of the injected material, which may eventually inform patient specific injection 
regimens.  
Larger animals also provide more options for the method of delivering the material. One 
particular device, the HeartLander, has been developed as an epicardial, semi-autonomous robot 
that can scale the surface of the heart and make injections at designated locations.[321, 322] This 
approach is obviously not possible in the small animal model due to size limitations, but in a 
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large animal such as the pig further development of this robotic system becomes feasible. Other 
approaches of delivery which rely on endovascular access to the heart are also not feasible in 
small animals. Pilot studies that involve injection of an alginate material into the lumen of the 
coronary arteries, or injection of material from an endocardial approach are recently being 
explored.[72, 314] Injection that does not require open-chest surgery has significant potential for 
human applications because it should decrease patient morbidity and recovery time. Potential 
problems with endovascular delivery such as accidental embolization of the material in the blood 
stream still need to be addressed. By this it becomes obvious that research on large animals will 
provide the necessary foundation to develop technologies that will ultimately make injection 
therapy more effective for human patients.  
We have conducted a pilot study of the use of the poly(NIPAAm-co-HEMA-co-MAPLA) 
material, without growth factors, into infarcted porcine hearts for short-term follow-up. The pilot 
study has been aimed at determining the proper surgical protocols and injection methods to 
ultimately direct the next stage of long-term porcine injection experiments.  
6.2.2 Materials and Methods 
6.2.2.1 Materials 
The thermoresponsive poly(NIPAAm-co-HEMA-co-MAPLA) material was prepared as 
described above – Figure 41. Dry polymer was dissolved in sterile PBS and mixed with a 
solution of gadoteridol (ProHance, Company) MRI contrast agent to a final polymer 
concentration of 15 wt% with 25 mg/ml gadoteridol. The material was sterilized by UV radiation 
for 30 minutes and loaded into sterile 1 ml syringes to a volume of 200 µl per syringe.  
6.2.2.2 Infarction and injection procedures 
A posterior wall myocardial infarction was created in female Yorkshire pigs by 60 min balloon 
occlusion of the second branch of the left circumflex artery (LCx). Animals were sedated with 
isoflurane inhalation and intubated. Animals were monitored by oximetry and ECG and 
maintained on continuous infusion of amiodarone throughout the procedure. Successful 
occlusion was determined by angiography. Four animals in total were infarcted and injected. 
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Animals were returned to the operating room 6 days after myocardial infarction and again 
sedated and monitored. Injections of Pigs #1, #2, and #3 were completed without preoperative 
echocardiography to determine the location of infarction, but rather the infarct was assumed to 
be around the coronary artery that had been occluded. Echocardiographic viewing preoperatively 
was added for Pig #4. A left thoracotomy was performed to expose the heart. The gel solution 
was injected at 20 sites in a grid configuration over the infarct and border zones (200 
µl/injection) using a 25 g needle. All syringes were kept on ice until used for injection. Blood 
pressure and ECG monitoring were used to track the hemodynamic stability of the animal during 
injection.  
6.2.2.3 Assessment of injection 
Within one week after material injection (1 day for Pig #2 and #3, 7 days for Pig #4) the animals 
were again sedated for MRI imaging using a full body 1.5T scanner. The heart was imaged using 
a modified look-locker inversion recovery (MOLLI) method before and after contrast injection. 
After MRI, the animals were sacrificed and hearts harvested for visual and histological 
evaluation.  
6.2.3 Results and discussion 
Occlusion of the LCx in all animals was successfully completed as shown by 
angiography and ECG – Figure 50. All animals survived the infarction and underwent injection 
of the thermoresponsive gel – Figure 51. No arrhythmias were noted in any of the animals 
during or following material injection. The first three pigs received material injection into the 
anterolateral LV wall, and Pig #4 was injected in the posterolateral LV free wall. After the chest 
was closed following material injection in Pig #1 the animal went into cardiac arrest and expired. 
Upon removal and sectioning of the heart it was observed that the gel had been properly injected 
and there were no obvious signs of having injected material into the ventricular lumen. It is 
believed this animal expired due to complications surrounding anesthesia in the presence of 
decompensated cardiac function.  
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Pigs #2 and #3 survived material injection and MRI imaging one day later. In these, as 
well as all other animals in this pilot study, the infarction zone could not be determined by visual 
inspection of the epicardium. The material was injected into the anteriolateral region of the LV 
where, based upon fluoroscopy films from the infarct procedure, it was believed the infarction 
was located. In both of these animals MRI analysis and the cross section of the LV after explant 
demonstrated that the material was not injected into the infarcted tissue – Figure 52. The actual 
infarct region was found to be in the posterior LV free wall.  
 
Figure 50. Radiographic images of the swine heart before (a) and during (b) 60 min 
occlusion of the LCx. Black and red arrows indicate the LCx, and occlusion balloon, 
respectively. Electrocardiographs pre-occlusion of the LCx (c) and post-occlusion (d) are 
shown. Elevated S-T segments were seen in lead I after occlusion. 
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Figure 51. The hydrogel injection procedure (a) for Pig #2 and view of the heart after 
injection (b) show successful delivery of the material. Black arrows show the occluded 
coronary artery. The dotted circle outlines the region where hydrogel was injected. LAA 
denotes left atrial appendage. 
 
 
Figure 52. MRI images of the heart from Pig #2 before (a) and after (b) the MOLLI MRI 
imaging sequence. White arrows indicate the posterior wall infarction. Yellow arrows 
indicate presence of the hydrogel loaded with contrast agent. The high signal from the 
hydrogel is not enhanced in the post-MOLLI images as was seen in the infarct zone. 
Sectioning of the excised heart (c) confirms that hydrogel was not injected into the infarct 
zone, and agrees with the MRI images.  
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For Pig #4 echocardiography was performed prior to the injection procedure. This 
successfully confirmed location of the infarct zone to be in the posterolateral LV wall as was 
seen in the previous animals, and thus material delivery was focused on this region. Injection 
into the posterior wall proved more technically difficult as it required greater manipulation of the 
heart. While injection was still carried out successfully, it was necessary to take periodic breaks 
in between injections to allow the heart to rest and the heart rate to stabilize. In all cases the 
material was observed in the ventricular wall using MRI, and the MRI images agreed with what 
was observed upon sectioning the heart after explant – Figure 53. The presence of the contrast 
agent in the gel allowed visualization of the material location even when the MRI was done 1 
week after injection as was the case for Pig #4.  
 
 
This pilot study injecting poly(NIPAAM-co-HEMA-co-MAPLA) into infarcted pig 
hearts demonstrates the early safety of this approach to treat heart disease. Of note is that the first 
animal did expire shortly after material injection. While there was no obvious evidence that the 
material was the cause, a more detailed autopsy would have been needed to completely rule out 
such a possibility. However, a surgical mortality of approximately 20% has been reported due to 
Figure 53. MRI images of the heart from Pig #4 before (a) and after (b) the MOLLI 
imaging sequence. White arrows indicate the posterior wall infarction. Yellow arrows 
suggest the presence of the hydrogel loaded with contrast agent. The high signal from 
the hydrogel does not change in the post-MOLLI images though it does in the 
surrounding infarcted tissue, indicating the material was accurately delivered into the 
infarcted myocardium. Autopsy confirmed that the material was successfully delivered 
to the posterior infarcted wall (c). RV = right ventricle, LV = left ventricle. 
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the damaging and invasive nature of these procedures.[323] In all cases the material injection 
itself was without incident.  
The ability to use imaging to improve the efficacy of this procedure is important. The 
material was observable in the MRI imaging, likely due to the presence of gadoteridol in the gel. 
The amount of this contrast agent that remains in the gel 24 hr after injection when the MRI 
imaging was done is not known, though based on previous drug delivery studies from this 
material it is likely that much of the agent was gone. Nonetheless, enough remained to provide a 
difference in appearance compared to the surrounding tissue under magnetic relaxation. This 
provides a useful way to see where the material has deposited relative to the infarct zone in 
living animals. It is unlikely, however, that this approach would be useful for long-term follow-
up as the contrast agent will have been completely released from the gel and new tissue ingrowth 
into the material will change the magnetic appearance of that area of heart tissue. To address the 
inability to see the infarct zone visually during the injection procedure, echocardiography was 
introduced. This confirmed the presence of an infarct and guided the location of gel injection. 
This method of imaging each heart before injection provides a powerful means with which to 
personalize the treatment for each patient. A physician could map the infarct zone and provide 
material injection exactly to the regions that would benefit from it most.  
This pilot study has provided the necessary information needed to inform long-term 
studies in pigs. The procedures on these first four animals have provided valuable information on 
the clinical flow of the pigs, the locations and methods of injection, and the necessity of imaging 
both before and after the procedure. The future group of animals, which will involve doing the 
same infarction and injection procedures, will be followed for eight weeks after injection to 
study longer-term effects of material injection.  
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6.3 THERMORESPONSIVE GELS FOR SHORT TERM THERAPEUTIC DELIVERY 
6.3.1 Introduction 
Much of the research described above is aimed at studying the delivery of drugs from an 
injectable hydrogel of poly(NIPAAm-co-HEMA-co-MAPLA). It was found that due to the 
thermal transition of the material, and in particular the large volume change from solution to 
solid gel, much of the incorporated drug is released during the first 3 hr of gelation. The extent of 
the initial release was shown to be dependent on the protein and the chemical composition of the 
material. The subsequent release also followed a general profile of slow release until material 
degradation became significant after many weeks. The reason for the slow, long-term release is 
likely due to the low water content of 45% and the collapsed polymer network following 
transition as shown in Figure 54.[265] There are many cardiovascular and other applications that 
may require the delivery of drugs on a faster scale or where material collapse may not be 
advantageous.  
 
Figure 54. Scanning electron micrographs of poly(NIPAAm-co-HEMA-co-MAPLA) 
hydrogels 30s and 1d after transition at 37 °C demonstrating loss of porosity during 
thermal transition. From [265]. 
 
It is well known that infection of implantable devices is a tremendous clinical problem. 
Because infected devices account for nearly half of all nosocomial infections, substantial 
research is ongoing to develop material and controlled release systems for implantables that will 
be resistant to bacterial adhesion or survival.[324-326] Because of their life-sustaining nature, 
infection of cardiovascular implants such as vascular grafts, pacemakers, and ventricular assist 
139 
 
devices (VADs) has particularly dangerous repercussions. Studies show that the frequency of 
infected devices can reach as high as 40% in VADs and 4% in the other cardiovascular 
implants.[327] Given that about 450,000 vascular grafts are implanted every year in the United 
States leading to 16,000 infected devices, and that the estimated cost of treatment per infected 
device is $40,000, it is apparent that preventing and treating infected devices is of significant 
concern. These types of infections can be particularly difficult to treat through administration of 
intravenous antibiotics because they may reside on the outside of the device – for example in 
pacemaker and VAD pockets – where blood does not readily contact. Treatments for these 
infections generally require difficult surgical intervention involving irrigation and debridement 
and even placement of a muscle or omental flap over the infected device to increase vascular 
access to the infected device.[328-330] In some cases polymethylmethacrylate beads that were 
designed for orthopedic applications and are impregnated with antibiotic have been implanted 
into infected device pockets for local antibiotic delivery.[331, 332] However, studies show only 
a small portion of loaded antibiotic is delivered and adequate inhibitory concentrations do not 
extend beyond a few days.[333] The ability to deliver a material to the outside of such infected 
implants that would provide controlled release of antibiotic for longer periods would be 
beneficial. Thermoresponsive materials inherently have the ability to be delivered through 
injection where a fluid material could coat a device and fill infected cavities, thus making the 
procedure less invasive.  
Short-term drug delivery has many other applications in the cardiovascular system, 
especially for the release of proteins or other signaling molecules to aid in regeneration. If the 
primary purpose of the therapy is drug delivery, the release behavior of the material would be 
more beneficial than a material with robust mechanical properties. Shorter drug delivery 
durations may be particularly useful in the early period following infarction where a host of 
processes cause necrosis, apoptosis, and fibrosis in the myocardium. There are many different 
chemical cues that can help rescue the myocardium if given during the first few weeks, when 
most of the tissue damage occurs. Examples of such signals that have been useful during this 
stage include heat shock proteins, p38 MAP kinase inhibitor, antioxidants, and IGF1, among 
others.[278, 306, 334-336] After myocardial rescue is complete, prolonged release of some of 
these agents may no longer be needed and so degradation of the injected carrier would be 
worthwhile.  
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 We aimed to develop a material based on the poly(NIPAAM-co-HEMA-co-MAPLA) 
that is used for cardiac applications but that would show minimal network collapse while 
maintaining its thermoresponsiveness. The material should be better able to deliver drug and 
degrade over a shorter duration. To this end we used atom transfer radical polymerization 
(ATRP) to make a block copolymer that incorporated a balance of hydrophilic and hydrophobic 
moieties and studied the material and drug delivery characteristics of this material.  
6.3.2 Materials and Methods 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. NIPAAm was 
purified by recrystallization from hexane and vacuum-dried. 2-Hydroxyethyl methacrylate 
(HEMA) was purified by vacuum distillation. Vancomycin, sodium methoxide (NaOCH3), 
poly(vinyl alcohol), methacryloyl chloride, copper (II) bromide, 2-bromoisobutyryl bromide, 
triethylamine, linear chain poly(ethylene glycol) (PEG, Mn 3,400), and 4-arm star polymer PEG 
(Mn 10,000, PEGworks) were used as received. 125I-BSA (Perkin Elmer) was reconstituted 
according to manufacturer instructions. 
6.3.2.1 Synthesis of methacrylate polylactide (MAPLA)  
MAPLA was synthesized as reported above – Figure 29.[265] Polylactide-monomethyl ether 
(HOPLA-OCH3) was synthesized by ring opening polymerization by dissolving lactide in 
dichloromethane to which NaOCH3 initiator in methanol was added. After 2 h of reaction at 0°C, 
the polymer solution was rinsed with 0.1 M HCl and deionized water, the organic phase was 
dried with MgSO4 and removed by rotary evaporation. MAPLA was formed by dropping 
methacryloyl chloride in an HOPLA-OCH3 solution in dichloromethane containing 
triethylamine, followed by reaction overnight at 0°C. Following reaction, precipitates were 
removed, the organic phase was dried and removed by rotary evaporation, leaving raw MAPLA 
product. MAPLA was purified by flash chromatography. NMR confirmed the synthesis of 
MAPLA with an average of 2.8 PLA units per MAPLA monomer. 
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6.3.2.2 Synthesis of ATRP macroinitiators 
Linear or 4-arm PEG were activated with 2-bromoisobutyryl bromide to make the ATRP 
macroinitiator – Figure 55. Briefly, PEG was dissolved in dichloromethane to which 
triethylamine and then 2-bromoisobutyryl bromide were added under vigorous stirring at room 
temperature. After 48 hr, precipitates were removed from the sample by filtration, the sample 
was washed once each with 0.2 M Na2CO3, 0.1 M HCl and deionized water, the organic phase 
was dried with MgSO4 and removed by rotary evaporation. Finally, the sample went through 
repeated steps of dissolving in warm ethanol, precipitating the polymer when cooled to 4 °C, and 
then centrifuging while cooled to collect and discard the supernatant. This was completed until 
the product was a white color and the supernatant was clear. The sample was then dried 
overnight in a vacuum oven before use. 
  
Figure 55. Macroinitiators for ATRP chemistry. Linear PEG (MW=3.4k) and 4-arm star 
PEG (MW=10k) were activated with bromoisobutyrl bromide to form PEG-BBr2 (A) and 
(PEG-BBr)4 (B).  
  
6.3.2.3 ATRP of thermoresponsive block copolymers 
A dry, hot schlenk flask was prepared by repeated applications of argon and vacuum. In 40 ml of 
methanol were added 0.0001 mole PEG macroinitiator, the ligand 1,8-dimethyl-1,4,8,11-
tetraazacyclotetradecane, NIPAAm, HEMA, and MAPLA – Figure 56. The molar ratio of 1,8-
dimethyl-1,4,8,11-tetraazacyclotetradecane to the –Br end groups of the macroinitiator was 6:1. 
Using 2g of NIPAAm, the HEMA and MAPLA were added to have a molar ratio of 
NIPAAM:HEMA:MAPLA of 80:10:10 as before. The solution went through repeated freeze-
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pump-thaw cycles to remove oxygen and was maintained under an argon atmosphere. After 
degassing, the copper (II) bromide catalyst was added and the reaction proceeded at 45 °C for 48 
hrs. After reaction, the methanol was removed by rotary evaporation and the product was 
dissolved in DCM. Aluminum oxide beads were repeatedly mixed into the solution to bind 
impurities and copper, and removed by centrifugation until the solution became colorless. Rotary 
evaporation removed the dichloromethane to form a solid product which was twice dissolved in 
THF and precipitated once in hexane and once in diethyl ether and then dried. The final product 
was a hydrophilic block flanked by hydrophobic moieties as shown in Figure 57. Before use the 
polymer was dissolved in PBS at 15-20 wt%.  
 
Figure 56. Scheme of ATRP synthesis of the linear block copolymer. 
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6.3.2.4 Material characterization 
The molecular weight of samples was determined using gas permeation chromatography. The 
gelation properties were assessed using parallel plate rheometry. Water content was determined 
by freeze drying gelled samples, where the weights of the sample before and after drying were 
used to determine original water content. Sample degradation was conducted in PBS at 37 °C. 
6.3.2.5 Bacterial culture 
Methicillin-resistant stapholococcus aureus was cultured in trypticase soy broth under agitation 
overnight. The bacterial solution was diluted by a factor of 50 and allowed to return to the 
growth phase for 2 more hr. This culture was diluted to a 1:10 working dilution for bacterial 
studies. The actual number of cells present in the working dilution was determined by plating 
serial dilutions of the working solution on trypticase soy agar plates and counting colony forming 
units after overnight growth.  
6.3.2.6 Drug delivery studies 
Vancomycin or 125I-BSA was dissolved into block copolymer solutions or poly(NIPAAM-co-
HEMA-co-MAPLA) at concentrations of 20 mg/ml and 0.5 mg/ml, respectively. 0.5 ml samples 
were allowed to gel at 37 °C and then were maintained in warm PBS. Releasate was collected at 
designated time points and the amount of released drug was measured by UV spectroscopy at 
Figure 57. Representation of the linear (A) and star-shaped (B) block copolymers where 
the hydrophilic block, B=PEG is flanked by the hydrophobic blocks, A=poly(NIPAAm-co-
HEMA-co-MAPLA). 
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280 nm or by gamma counter for vancomycin and 125I-BSA, respectively. For activity of released 
vancomycin, releasates were diluted to 2.5 ug/ml (just above the mean inhibitory concentration 
[MIC] of vancomycin for MRSA which was determined to be 2 ug/ml) and were mixed with 
MRSA solutions for 6 hr at 37 °C. After incubation the number of MRSA cells present was 
determined using a luminescence assay (BacTiter Glo, Promega). The luminometer readings 
were verified by correlation to the number of colony forming units that grew from solutions of 
known bacterial load.  
6.3.3 Results and discussion 
The block copolymer hydrogels were able to form a gel under 37 °C and did not demonstrate 
significant collapse of the network upon thermal transition. The general properties of the 
materials are shown in Table X. The onset of gel transition was at 25 °C and 30 °C for the linear 
and star copolymers, respectively. 
 
Table X. Material Properties of Block Copolymers 
BA2 PEG (3.4k) 24,000 White color, 84% 2 weeks
BA4 4-arm PEG (10k) 48,000 White color, 84% 3 weeks
Block copolymer 
type B Block
Molecular 
weight (Da)
Full dissolution 
(PBS at 37oC)
Gel property and 
water content at 
37 °C
 
 
The release of 125I-BSA from these two materials is shown in Figure 58. The amount of 
protein released during the first 3 hr after gel transition was 11.1 ± 1.0 % and 17.7 ± 2.0 % for 
the linear and star-shaped block copolymers, respectively, compared to 78.0 ± 2.1% for the 
previous poly(NIPAAM-co-HEMA-co-MAPLA) hydrogel used for cardiac injection. The 
release profile demonstrated a diffusion-controlled system characterized by a gradual decrease in 
release at each subsequent time point until exhaustion of the loaded protein.  
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Release of vancomycin from these block copolymer gels also showed a diffusion-
controlled system that delivered antibiotic over 1 to 2 weeks – Figure 59. In comparison the 
release of vancomycin from poly(NIPAAm-co-HEMA-co-MAPLA) gels is also shown. The 
initial release at 3 hr was 33.1 ± 5.1% and 15.7 ± 0.8% for the linear and star-shaped block 
copolymers, respectively, compared to 46.2 ± 2.8% for the cardiac gel. Following the initial 
release, the concentration of antibiotic in the releasate at each time point in the block copolymers 
was higher than the MIC for MRSA. In contrast, after gel formation very little vancomycin was 
released from the poly(NIPAAm-co-HEMA-co-MAPLA) gel during the subsequent 2 week. The 
antibiotic that was released from the star copolymer was bioactive as demonstrated by its ability 
to inhibit MRSA survival in solution when diluted to just above the MIC – Figure 60. Releasate 
from control gels without loaded antibiotic had no ability to inhibit MRSA growth.  
Figure 58. Release profiles of BSA from linear and star-shaped copolymers compared to 
the poly(NIPAAm-co-HEMA-co-MAPLA) gel without PEG. The initial release of protein 
is significantly reduced when a PEG block is incorporated into the copolymer. 
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Figure 59. Release of vancomycin from block copolymer gels and the poly(NIPAAm-co-
HEMA-co-MAPLA) gel that did not have a PEG block. After an initial release the non-
PEG gel releases very little antibiotic.  
 
 
 
 
Figure 60. Inhibition of methicillin-resistant staphylococcus aureus by releasate from 4-
arm star copolymers loaded with vancomycin.  
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A relatively short duration of drug delivery from cardiovascular biomaterials may be 
appropriate or even advantageous in some situations. A material that will deliver its payload and 
degrade within a few weeks may have higher clinical efficacy and a reduced risk of chronic 
inflammation. The newly developed block copolymers using ATRP chemistry are one example 
where a substantial adaptation of the material previously used for intramyocardial injection may 
prove to be useful for shorter term drug delivery needs in applications where strong mechanical 
properties are of lesser importance. These applications may include therapeutic angiogenesis, 
myocardial rescue, or even cell delivery.  
 The material developed using hydrophilic PEG blocks between the thermoresponsive 
blocks consisting of NIPAAm, HEMA, and MAPLA was able to form a gel below body 
temperature without substantial collapse. The fine balance between affinity for water and 
repulsion of it allows the material to maintain its volume without either collapsing or requiring a 
transition temperature higher than 37 °C. The ultimate effect of this balance in these materials is 
a gel network with increased water content which allows for simple diffusion of drug from the 
matrix. In contrast to the cardiac gels, these materials did not exhibit the substantial drug losses 
seen just after gel transition. Not only did the initial release decrease, but the amount of drug 
released at each time point over the next several days was more substantial, presumably due to 
the higher water flux through the open gel network. 
One area of promise in the field of injectable materials is their ability to co-deliver a cell 
of interest to an injection site. It has been widely observed that cells injected into a tissue, 
especially one as mechanically active as the heart, do not remain, survive, or engraft at the 
injection site in significant numbers.[337-339] In cases where cells have been simultaneously 
delivered with material to act as an in situ scaffold the cell survival and engraftment has 
increased substantially.[78, 79, 87] The requirements for a scaffolding material would be to 
allow a favorable cell environment with adequate mass transfer for nutrient supply to cells 
throughout the material. These block copolymers may be useful candidates for a material to 
deliver cells to the heart due to their high water content. While lacking mechanical strength 
relative to its poly(NIPAAm-co-HEMA-co-MAPLA) precursor, because the primary purpose of 
this material would be for cell delivery, trading some mechanical strength for greater porosity 
may be reasonable.  
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 In determining the potential benefit of these new gels, the clinical applications of the 
material need to be investigated. As mentioned previously, infected cardiovascular implants are a 
significant problem in clinical practice. To further investigate the ability of this material to treat 
infected cardiovascular devices, a reasonable experiment may involve coating materials used for 
vascular grafts with this antibiotic-loaded gel in vitro as either prophylaxis against bacterial 
innoculation or as treatment once a bacterial biofilm has already deposited. Prophylactic delivery 
of such a material at the implant site during cardiovascular surgery may prove to be a more 
effective means of preventing implant related infections than systemic delivery of antibiotic in 
the post-operative period.  
 Where short term delivery of protein is needed this material may be loaded with protein 
to be delivered to the infarct zone soon after infarction. One relevant protein for this type of 
approach may be IGF1 which could act as a cell survival cue to salvage myocardium in the days 
to weeks following injury, when cell death is most prevalent. The sol-gel nature of this material 
means that systems could be devised to deliver it through non-invasive techniques such as 
endovascular catheterization. This may reasonably be done at the time of balloon angioplasty or 
stent placement which is often performed early after a heart attack.  
There are many ways in this these newly developed block copolymers could be used and 
adapted. As relating to controlled release, functionalization of the polymer to include peptide 
sequences, conjugating moieties, or particle systems may be applied to change the rates at which 
drugs are released. The full field of modifications to hydrogel systems that has been reported 
over several decades is at the engineer’s disposal when considering directions to pursue. 
Additional applications of this material beyond the cardiac environment may also be pursued. 
For example, antibiotic delivery in other wound environments or protein delivery for various 
regenerative medicine applications could be investigated.   
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7.0 FINAL SUMMARY 
As heart disease remains a significant problem throughout the world, finding new and 
better ways to treat it is always of value. Biomaterials-based approaches have been gaining 
recognition in recent years for their ability to ameliorate the effects seen after MI. The research 
presented above discusses new developments in two of those biomaterial approaches: 
implantation of a cardiac patch and intramyocardial biomaterial injection. Both approaches have 
shown success in animal models. Historically, results are generally improved when appropriate 
signaling molecules are loaded into the materials for controlled release after implantation. The 
delivery rates for these drugs can have an influence on their effectiveness. Especially in the case 
of more advanced systems involving spatial or temporal control, it is important to understand and 
adjust the controlled release system before implantation.  
Inherent with either a patch or injection technique are certain benefits and disadvantages. 
For example, using a cardiac patch allows for a greater variety of materials and processing 
methods to be used. In the case of material injection, the material is limited by its ability to be 
injectable through a small gauge needle and form a stable implant in situ. In contrast, materials 
used as a patch can be formed before implantation to provide specific architectures, porous 
networks, and mechanical properties. The synthesis and processing can involve harmful 
chemicals that would not be possible in vivo, so long as they are removed before implantation. 
Formed patches can also be treated in vitro before implantation, for example with cells or 
proteins, to increase their functionality. This provides numerous control points to the engineer 
and allows many specific design parameters to be specified. Another advantage to a patch 
method is that large areas of the heart can be patched continuously. Injected material has been 
shown to have a local effect on myocardial wall stress around the injection sites. This makes 
choosing the injection locations and layout important. In the case of a large patch there is likely 
to be a more widespread benefit throughout the ventricular wall.   
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The injection of material into the heart wall directly has some distinct advantages over a 
patch approach. One major benefit can be found in the method of delivery. Whereas patch 
implantation will generally require an open-chest procedure to have enough access to the 
epicardial surface for material deployment, intramyocardial injection may be done less 
invasively through a keyhole incision or endovascular approach. Because major surgery is highly 
demanding on a weakened heart and infection risk is increased with larger incisions, this could 
make the delivery safer as well as decrease the morbidity and recovery time following injection. 
Another advantage to an injection approach is that the material may interact more freely with the 
native tissue which allows for better cellular infiltration and communication between the material 
and the host. It has been shown with patch implantation, for example, that host cells may have 
difficulty in penetrating or surviving in epicardial patches presumably due to the decreased 
nutrient access. Injectable materials, which tend to be gel-like, are also generally porous with 
high water content to allow for better nutrient transfer for cellular ingrowth or to support cells 
loaded into the material before injection.  
Poly(ester urethane) urea has been shown to be a valuable patch material. The 
elastomeric properties and degradation profile make it useful in cardiovascular and other 
applications. We showed that when loaded with a gene-inducing molecule, RSL1, this material 
provides long-term drug delivery from polymer films. The released inducer is bioactive as 
determined by its ability to cause expression of GFP in cells stably transfected with the 
corresponding gene induction system. Cells grown on RSL1-loaded films expressed GFP 
proportional to the amount of RSL1 loaded. When films and porous scaffolds were differentially 
loaded with regions of high RSL1 content and regions without the inducer, the expression of 
GFP in cells cultured on the material generally mirrored the RSL1 loading pattern. Delivery of 
gene inducing molecules in 3D patterns has important applications in tissue engineering as it can 
allow the formation of tissue substitutes with complex cellular architectures. Tissues such as 
cardiac muscle and blood vessels, which are formed by specific organizations of cells and 
proteins, may be fabricated by combining appropriately transfected cells and scaffolds that 
present the inducer in specific spatial patterns as described in this research. Furthermore, cells 
grown on inducer-loaded scaffolds would continue to receive their directions for gene expression 
whether being cultured in vitro or after implantation in vivo. This approach is novel because it 
allows the scaffold, once appropriately loaded with inducer, to independently direct cell fate or 
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behavior in the absence of any additional cues to the system.  This approach has not been 
investigated before and may lead to a new paradigm for both in vitro and in vivo tissue 
engineering. 
A more common approach to aiding in tissue regeneration after patch implantation would 
be the controlled release of growth factors from the material. We show that growth factors IGF1 
and HGF can be loaded into the patch and are released in a bioactive form as shown by in vitro 
cellular response to releasates. It was interesting to observe that the proteins were released over a 
long time period with multiple phases of fast and slow release. This complex profile has not been 
observed previously and may be related to the segmented nature of the polyurethane. An 
important observation was that the release rates were much different when scaffolds were soaked 
in solutions that contained the enzyme lipase. This enzyme degrades the material in a way that 
helps mimic the in vivo environment that would be seen following patch implantation. In this 
case it was shown that while polymer mass fraction in the scaffold did influence the delivery 
rates as had been shown with scaffolds in PBS, the effect was much smaller in the presence of 
enzyme. Most studies of drug delivery from biomaterials use a saline environment to simulate 
sink conditions that would be experienced in vivo. However, sink conditions are only part of the 
complex milieu experienced by implanted materials. This research clearly shows that 
information gained from in vitro testing of drug delivery systems may not accurately describe 
what the devices will ultimately experience upon implantation, especially in the case of 
degradable materials.  The lessons learned from this research, while useful for the dynamic 
cardiac environment discussed here, has broad applications for drug delivery studies throughout 
the field of controlled release.  
Another important biomaterials-based therapy for heart disease, delivering material into 
the wall of an infarcted ventricle, has been under considerable investigation in recent years. The 
properties of the materials used are increasingly appreciated as a necessary component to the 
success or failure of a material in this application. We developed a strong, thermoresponsive 
material that can be injected into the heart and degrades over at least 5 months. The ability to 
release growth factors from this material may be able to augment the regeneration and benefit 
that is seen upon injection of material alone. We showed that the significant volume collapse of 
the material during thermal transition leads to loss of much of the loaded model protein BSA 
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during the first few hours. By adjusting the chemistry and providing a means of binding the 
protein to the polymer we are able to better encapsulate the growth factors so they can be 
released more steadily over time. We were also able to load degradable microparticles that 
encapsulate protein into the gel network to provide a second depot of drug delivery. When 
particles are loaded into the hydrogel their burst release diminishes significantly, leading to later-
stage release of drugs. Combining the gel with the microparticles allows one protein to be 
directly loaded into the gel and be released mostly during the early period following gelation 
while proteins loaded into microparticles inside the gel are released later – forming a sequential 
release profile. It is important to note that the system described here has multiple control points 
and allows for independent adjustment of both of the drug delivery reservoirs: gel or 
microparticles.  This system thus becomes a useful foundation for multifaceted systems where 
more drugs and various delivery rates are desired. These types of complex release systems may 
be especially useful for aiding regeneration in target tissues where the complexity of signaling 
molecule delivery is increasingly appreciated.  
After using model protein we demonstrate the ability of this gel-microparticle drug 
delivery system to release important growth factors bFGF and IGF1 in a sequential manner. We 
hypothesize that earlier bFGF delivery from the gel phase will be able to encourage angiogenesis 
in infarcted tissue and thus create a healthier microenvironment to which cardiac stem cells can 
survive, proliferate, and differentiate due to the signals of subsequent IGF1 release from loaded 
microparticles in the gel. We demonstrated that a sequential release profile can be obtained from 
this system and that the released protein retains its bioactivity in vitro. When growth factor-
loaded gels are injected into infarcted myocardium it was seen that the tissue growth factor levels 
are elevated for at least two weeks. After intramyocardial injection of the new thermoresponsive 
gel without any growth factors we show the material alone is able maintain cardiac function for 
at least 16 weeks and significantly reduce negative remodeling of the heart seen during that time. 
Histological evaluation showed that many macrophages, smooth muscle cells, and blood vessels 
were present in the infarct zone at the study endpoint. The presence of growth factors loaded into 
the gel was not able to improve upon any of the functional, geometric, or histological properties 
seen from injection of plain gel. This points to a primary role of the material to improve cardiac 
function and cellular environment where added growth factors are insufficient to provide further 
benefits. More drug delivery strategies may need to be employed to see increased effect in this 
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system. Additionally, continued research into the mechanisms by which appropriate biomaterials 
elicit improvements in tissue environments is justified by the results we have shown here.  
The lessons learned from the research just described have led to more improvements and 
investigation. For example, as the release of bFGF was unable to cause additional angiogenesis 
in vivo after release from the injectable gel, a different growth factor, VEGF, is being 
considered. Early evidence suggests it may be released with less suspected damage than was 
bFGF. The positive results seen from injection of the thermoresponsive material into infarcted rat 
hearts has led to its application in the large animal swine model of infarction. A pilot study has 
been completed that shows the infarcts can be created, material injected, and the cardiac anatomy 
imaged successfully. Chronic studies that will show efficacy relevant to future human 
applications will begin shortly. Finally, we showed previously that most growth factor is released 
from the injectable gel during the first few hours due to significant gel collapse. To ameliorate 
this concern we have developed a new material that uses the previous polymer as one block 
within a block copolymer structure. The applications for this material include intramyocardial 
injection, primarily as a depot for drug delivery, or as a means to treat infection in cardiovascular 
implants. The ability to release active antibiotic in a clinically relevant time frame from this 
material was demonstrated.  
Regular clinical application of these therapies has not been fully realized and will require 
more research and optimization to make common human use a reality. While there have been 
few instances of patch materials being used in humans, material injection therapy is only 
beginning in the clinical environment. The research explained above illuminates some of the 
technical challenges that must be addressed to move through the necessary regulatory processes. 
The governing body for medical devices in the United States, the Food and Drug Administration 
(FDA), is responsible for guaranteeing that both safety and efficacy are demonstrated before 
device approval. While the safety of patch application has largely been confirmed, the safety of 
intramyocardial material injection remains to be fully proven. For example, approval will require 
a demonstration that a material can be injected without embolization in the blood stream, can be 
localized to the desired tissue, and does not migrate over time. When considering the growing 
number of materials used for patch and injection therapy there is specific safety testing of in vivo 
biocompatibility according to international standards that must be completed for FDA approval.  
154 
 
As the FDA does not approve a material, but rather applications, the soundness of the selected 
materials must also be proven in the context of cardiac failure. It is no surprise that common 
implanted materials such as collagen were among the first used in these applications as their 
previous approval in other devices may lead to a quicker regulatory approval in the context of 
patch and injection therapy.  
The efficacy of the treatments must also be proved in a way that demonstrates 
improvement over current treatment options.  In animal models this benefit has been 
demonstrated with some material systems but often large animal models have not been 
investigated.  Acquiring more data in large animals will be necessary to move this work to the 
clinic.  Many patch and injectable materials are useful as drug or cell carriers.  As has been 
discussed here, the inclusion of these moieties can improve efficacy, however they do add 
complexity to the device and the regulatory pathway. As the changes in drug delivery properties 
have been shown to be influenced heavily by in vivo degradation, appropriate pre-clinical 
characterization becomes even more difficult. When drugs or cells are included in a treatment 
that is primarily a materials-based therapy the product becomes a “combination device” for 
regulatory approval.  This requires approval of the device not only from a materials perspective 
but also from a biological or pharmaceutical perspective.  The way in which with FDA handles 
such combination products is evolving but currently involves significant additional testing and 
time. As the FDA works to streamline the regulatory process the final clinical application of 
these products will become more common.  
The benefits of application of biomaterials for cardiovascular disease have been shown in 
the settings of both cardiac patch and intramyocardial biomaterial injection. The complexities of 
drug delivery from both material types have been shown using large and small proteins and a 
small molecule. In each case described above we find a system with completely different release 
properties than the others – whether it be very long release times, cycling periods of fast and 
slow release, or sequential delivery of multiple factors. The overall theme is that each system 
requires independent testing and understanding of what dictates the release kinetics before in 
vivo use. It cannot necessarily be taken for granted that simple changes of drug types or material 
properties within a controlled release system will result in substantially similar results. As the 
field of implantable biomaterials continues to expand with better materials, the need for a drug 
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delivery component to the material in each application should be considered and the properties of 
controlled release will require investigation in order to have a successful product.  
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